{"647c19a813cc099cda0bfa5d23a62cceeab9ad00": [["Media outlets and online forums are continuing to document the upsurge of verbal and physical assaults against Asian Americans, with polls showing that about one third of Americans have witnessed someone blaming Asian people for the coronavirus epidemic 1 .", [["verbal and physical assaults", "DISEASE", 74, 102], ["coronavirus", "DISEASE", 233, 244], ["Americans", "ORGANISM", 171, 180], ["someone", "ORGANISM", 196, 203], ["people", "ORGANISM", 218, 224], ["people", "SPECIES", 218, 224], ["coronavirus", "SPECIES", 233, 244], ["the coronavirus epidemic", "PROBLEM", 229, 253]]], ["Community advocates, legislators, and public health professionals have called for swift measures to protect Asian Americans.", [["swift measures", "TREATMENT", 82, 96]]]], "42532524b4747190511aa3e2ef86cd7702e21b90": [["IntroductionHumans have coexisted with viral pathogens for tens of thousands of years, influencing both their emergence and evolution.", [["IntroductionHumans", "TREATMENT", 0, 18], ["viral pathogens", "PROBLEM", 39, 54], ["viral pathogens", "OBSERVATION", 39, 54]]], ["However, the pervasiveness of the Western diet and disparities in food access and security have altered how we as hosts interact with our viral pathogens.", [["our viral pathogens", "PROBLEM", 134, 153]]], ["Malnutrition, the state of having insufficient, excess, or imbalanced sources of energy, is well known to attenuate immune responses.", [["Malnutrition", "DISEASE", 0, 12], ["Malnutrition", "PROBLEM", 0, 12]]], ["Malnourishment is a global, intersectional issue, and it may soon force a revision of our understanding of how viruses evolve within their hosts (Fig 1) [1] .Why do RNA viruses form quasispecies?First theorized over 4 decades ago [2] , a quasispecies population structure has been documented in plant, animal, and human pathogens [3] [4] [5] .", [["Malnourishment", "DISEASE", 0, 14], ["human", "ORGANISM", 314, 319], ["[3] [4] [5]", "SIMPLE_CHEMICAL", 330, 341], ["human", "SPECIES", 314, 319], ["human", "SPECIES", 314, 319], ["Malnourishment", "PROBLEM", 0, 14], ["a revision", "TREATMENT", 72, 82], ["RNA viruses form quasispecies", "PROBLEM", 165, 194], ["a quasispecies population structure", "PROBLEM", 236, 271], ["global", "OBSERVATION_MODIFIER", 20, 26]]], ["A viral quasispecies describes the mutant but related genomes that collectively infect, replicate, and spread among hosts.", [["A viral quasispecies", "PROBLEM", 0, 20], ["the mutant", "PROBLEM", 31, 41], ["viral quasispecies", "OBSERVATION", 2, 20]]], ["Traditionally, the theory has been applied to RNA viruses.", [["RNA viruses", "PROBLEM", 46, 57], ["RNA viruses", "OBSERVATION", 46, 57]]], ["Because of their short generation times, small genomes, and the inherent lack of proofreading in most RNA replication, single nucleotide variants (SNVs) emerge at a rate of roughly 10 3 to 10 7 more mutations per nucleotide copied compared with DNA viruses [6] .Why do RNA viruses form quasispecies?Nonsynonymous SNVs are continuously accrued and purged from the viral genome.", [["nucleotide", "CHEMICAL", 213, 223], ["nucleotide", "CHEMICAL", 213, 223], ["DNA", "CELLULAR_COMPONENT", 245, 248], ["viral genome", "DNA", 363, 375], ["their short generation times", "PROBLEM", 11, 39], ["small genomes", "PROBLEM", 41, 54], ["single nucleotide variants (SNVs)", "PROBLEM", 119, 152], ["a rate", "TEST", 163, 169], ["DNA viruses", "PROBLEM", 245, 256], ["RNA viruses form quasispecies", "PROBLEM", 269, 298], ["Nonsynonymous SNVs", "PROBLEM", 299, 317], ["small", "OBSERVATION_MODIFIER", 41, 46], ["genomes", "OBSERVATION", 47, 54], ["viral genome", "OBSERVATION", 363, 375]]], ["This flux generates a related \"swarm\" of viruses, which have little effect on the consensus sequence but may show phenotypic differences.", [["consensus sequence", "DNA", 82, 100], ["This flux", "PROBLEM", 0, 9], ["a related \"swarm\" of viruses", "PROBLEM", 20, 48], ["the consensus sequence", "TEST", 78, 100], ["phenotypic differences", "PROBLEM", 114, 136], ["swarm", "OBSERVATION_MODIFIER", 31, 36], ["viruses", "OBSERVATION", 41, 48], ["little", "OBSERVATION_MODIFIER", 61, 67], ["effect", "OBSERVATION_MODIFIER", 68, 74], ["phenotypic", "OBSERVATION", 114, 124]]], ["Mutations with phenotypic consequences are generally deleterious; very few mutations have any fitness benefit.", [["Mutations with phenotypic consequences", "PROBLEM", 0, 38], ["generally deleterious", "PROBLEM", 43, 64]]], ["However, if beneficial mutations arise, they may relate to host range, drug resistance or vaccine escape, and replicative capacity [7, 8] .", [["beneficial mutations", "PROBLEM", 12, 32], ["drug resistance", "PROBLEM", 71, 86], ["vaccine escape", "PROBLEM", 90, 104]]], ["Both beneficial and the common deleterious mutations balance the structure of the viral swarm through complementation, interference, and cooperation [9] [10] [11] .", [["the common deleterious mutations", "PROBLEM", 20, 52], ["viral swarm", "OBSERVATION", 82, 93]]], ["Within a single host, tissue-specific subpopulations may vary in virulence without affecting consensus sequence or phenotype [12, 13] .", [["tissue", "ANATOMY", 22, 28], ["tissue", "TISSUE", 22, 28], ["consensus sequence", "DNA", 93, 111], ["single host", "OBSERVATION_MODIFIER", 9, 20]]], ["Importantly, the consensus sequence should not be considered the \"fittest sequence,\" because selection, competition, and genetic drift act upon the entire viral swarm.", [["consensus sequence", "DNA", 17, 35], ["the consensus sequence", "TEST", 13, 35], ["the entire viral swarm", "PROBLEM", 144, 166]]], ["Therefore, fitness of the swarm exceeds clonal sequence fitness, highlighted by work in vesicular stomatitis virus [3] and bacteriophage systems [14] .Why do RNA viruses form quasispecies?Viruses are obligate intracellular parasites that require a host cell to complete their life cycle.", [["intracellular", "ANATOMY", 209, 222], ["cell", "ANATOMY", 253, 257], ["vesicular stomatitis", "DISEASE", 88, 108], ["vesicular stomatitis virus", "ORGANISM", 88, 114], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 209, 222], ["cell", "CELL", 253, 257], ["stomatitis virus", "SPECIES", 98, 114], ["stomatitis virus", "SPECIES", 98, 114], ["the swarm", "PROBLEM", 22, 31], ["clonal sequence fitness", "PROBLEM", 40, 63], ["vesicular stomatitis virus", "PROBLEM", 88, 114], ["bacteriophage systems", "TEST", 123, 144], ["RNA viruses form quasispecies", "PROBLEM", 158, 187], ["Viruses", "PROBLEM", 188, 195], ["obligate intracellular parasites", "PROBLEM", 200, 232], ["a host cell", "TREATMENT", 246, 257], ["intracellular parasites", "OBSERVATION", 209, 232], ["host cell", "OBSERVATION_MODIFIER", 248, 257]]], ["Barriers to replication exist within and between susceptible hosts, which restrict viral population diversity to quell infections [13] .", [["infections", "DISEASE", 119, 129], ["quell infections", "PROBLEM", 113, 129]]], ["In these wide-ranging environments, a a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 heterogenous viral swarm containing isolates with differing abilities to infect, transmit, and survive environmental and immunological onslaughts may safeguard viral existence.", [["heterogenous viral swarm", "TREATMENT", 98, 122], ["wide", "OBSERVATION_MODIFIER", 9, 13]]], ["The \"Goldilocks\" approach maximizes fitness by avoiding lethal mutagenesis while ensuring amenability to selective pressures [17] .", [["The \"Goldilocks\" approach", "TREATMENT", 0, 25], ["lethal mutagenesis", "TREATMENT", 56, 74], ["selective pressures", "TEST", 105, 124]]], ["Too low fidelity leads to error catastrophe and collapse of the viral population; conversely, a highly clonal population may be extinguished by host defenses [18] [19] [20] [21] .What is the implication of viral diversity on disease severity?Numerous theories have questioned the biological relevance of a quasispecies and challenged its significance [17, 22] .", [["Too low fidelity", "PROBLEM", 0, 16], ["error catastrophe", "PROBLEM", 26, 43], ["collapse", "PROBLEM", 48, 56], ["the viral population", "PROBLEM", 60, 80], ["viral diversity on disease severity", "PROBLEM", 206, 241], ["a quasispecies", "PROBLEM", 304, 318], ["low fidelity", "OBSERVATION_MODIFIER", 4, 16], ["error catastrophe", "OBSERVATION", 26, 43], ["collapse", "OBSERVATION_MODIFIER", 48, 56], ["viral", "OBSERVATION_MODIFIER", 64, 69], ["population", "OBSERVATION_MODIFIER", 70, 80], ["viral diversity", "OBSERVATION", 206, 221]]], ["However, boosting genetic diversity-to a point-is theorized to increase virulence.", [["increase", "OBSERVATION_MODIFIER", 63, 71], ["virulence", "OBSERVATION", 72, 81]]], ["A viral swarm may be better equipped to face bottlenecks imposed by infecting hosts, environmental persistence, and transmission.", [["A viral swarm", "PROBLEM", 0, 13], ["viral swarm", "OBSERVATION", 2, 13]]], ["Even within a single host, blockades due to infection barriers and the immune response diminish sequence variation, leaving a relatively homogenous population until replicative errors replenish the mutant pool [13] .", [["infection", "DISEASE", 44, 53], ["blockades", "TREATMENT", 27, 36], ["infection barriers", "TREATMENT", 44, 62], ["infection", "OBSERVATION", 44, 53]]], ["So, do viruses harboring higher genetic diversity initially fare better in establishing an infection and displaying virulent phenotypes?PLOS PATHOGENSIn studies with classical swine fever virus, higher genetic diversity correlated with virulence [23]; however, this conclusion has been challenged [24] .", [["infection", "DISEASE", 91, 100], ["swine fever", "DISEASE", 176, 187], ["classical swine fever virus", "ORGANISM", 166, 193], ["swine fever virus", "SPECIES", 176, 193], ["swine fever virus", "SPECIES", 176, 193], ["an infection", "PROBLEM", 88, 100], ["virulent phenotypes", "PROBLEM", 116, 135], ["classical swine fever virus", "PROBLEM", 166, 193], ["infection", "OBSERVATION", 91, 100], ["virulent phenotypes", "OBSERVATION", 116, 135]]], ["In other animal viruses, diversity increases precede the selection of virulent genomes [4] .", [["virulent genomes", "PROBLEM", 70, 86], ["viruses", "OBSERVATION", 16, 23], ["virulent genomes", "OBSERVATION", 70, 86]]], ["Parallel conclusions have been made for human pathogens.", [["human", "ORGANISM", 40, 45], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["human pathogens", "PROBLEM", 40, 55]]], ["In hepatitis C virus (HCV)-positive patients, high viral diversity prior to transplantation correlated with higher liver fibrotic scoring 1 year post-transplantation [5] .", [["liver", "ANATOMY", 115, 120], ["hepatitis C virus (HCV)-positive", "DISEASE", 3, 35], ["hepatitis C virus", "ORGANISM", 3, 20], ["HCV", "ORGANISM", 22, 25], ["patients", "ORGANISM", 36, 44], ["liver", "ORGAN", 115, 120], ["hepatitis C virus", "SPECIES", 3, 20], ["patients", "SPECIES", 36, 44], ["hepatitis C virus", "SPECIES", 3, 20], ["HCV", "SPECIES", 22, 25], ["hepatitis C virus", "PROBLEM", 3, 20], ["HCV", "TEST", 22, 25], ["high viral diversity", "PROBLEM", 46, 66], ["transplantation", "TREATMENT", 76, 91], ["higher liver fibrotic scoring", "PROBLEM", 108, 137], ["hepatitis", "OBSERVATION", 3, 12], ["liver", "ANATOMY", 115, 120], ["fibrotic", "OBSERVATION", 121, 129]]], ["Continued genetic evolution of HCV correlated with progressing hepatitis, whereas resolution was associated with genetic stasis of HCV population [25, 26] .", [["HCV", "DISEASE", 31, 34], ["hepatitis", "DISEASE", 63, 72], ["HCV", "ORGANISM", 31, 34], ["HCV", "ORGANISM", 131, 134], ["HCV", "SPECIES", 31, 34], ["HCV", "SPECIES", 131, 134], ["HCV", "PROBLEM", 31, 34], ["progressing hepatitis", "PROBLEM", 51, 72], ["genetic stasis of HCV population", "PROBLEM", 113, 145], ["HCV", "OBSERVATION", 31, 34], ["progressing", "OBSERVATION_MODIFIER", 51, 62], ["hepatitis", "OBSERVATION", 63, 72], ["stasis", "OBSERVATION", 121, 127], ["HCV", "OBSERVATION", 131, 134]]], ["A model low-fidelity RNAdependent RNA polymerase (RdRp) poliovirus variant demonstrates that increasing genetic diversity may not always yield fit populations [10, 27 ], yet high-fidelity RdRp mutants producing nearly clonal populations display reduced fitness in vivo [21].Do host characteristics influence quasispecies structure?Selection pressures ranging from host antiviral responses to pharmaceutical interventions mold the viral swarm.", [["clonal populations", "CELL", 218, 236], ["RNAdependent RNA polymerase (RdRp) poliovirus variant", "PROTEIN", 21, 74], ["RdRp mutants", "PROTEIN", 188, 200], ["A model low-fidelity RNAdependent RNA polymerase (RdRp) poliovirus variant", "PROBLEM", 0, 74], ["increasing genetic diversity", "PROBLEM", 93, 121], ["Selection pressures", "TEST", 331, 350], ["host antiviral responses", "TREATMENT", 364, 388], ["pharmaceutical interventions", "TREATMENT", 392, 420], ["the viral swarm", "PROBLEM", 426, 441], ["low", "OBSERVATION_MODIFIER", 8, 11], ["-fidelity", "OBSERVATION_MODIFIER", 11, 20], ["pressures", "OBSERVATION_MODIFIER", 341, 350], ["host antiviral", "OBSERVATION", 364, 378], ["viral swarm", "OBSERVATION", 430, 441]]], ["Upon infection, immune responses restrict genetic diversity by limiting spread and replication, eloquently demonstrated using a model poliovirus RdRp [13, 20] Exogenous control of infections can affect viral swarm composition.", [["infection", "DISEASE", 5, 14], ["infections", "DISEASE", 180, 190], ["poliovirus RdRp", "ORGANISM", 134, 149], ["infection", "PROBLEM", 5, 14], ["a model poliovirus RdRp", "TREATMENT", 126, 149], ["infections", "PROBLEM", 180, 190], ["infection", "OBSERVATION", 5, 14], ["infections", "OBSERVATION", 180, 190]]], ["As hosts, we have exploited the high mutation rates of viruses by redirecting viral evolution toward error catastrophe via pharmaceutical interventions [18, 19] .", [["error catastrophe", "DISEASE", 101, 118], ["the high mutation rates of viruses", "PROBLEM", 28, 62], ["error catastrophe", "PROBLEM", 101, 118], ["pharmaceutical interventions", "TREATMENT", 123, 151]]], ["Interestingly, high-fidelity foot-and-mouth disease viral variants possess a higher level of resistance to pharmacologics but are attenuated in vivo, suggesting that the resulting restricted quasispecies hampers adaptability in the presence of drug or host pressures [19] .", [["foot-and-mouth", "SPECIES", 29, 43], ["high-fidelity foot", "PROBLEM", 15, 33], ["mouth disease viral variants", "PROBLEM", 38, 66], ["host pressures", "TEST", 252, 266], ["high", "OBSERVATION_MODIFIER", 15, 19], ["-fidelity", "OBSERVATION_MODIFIER", 19, 28], ["foot", "ANATOMY", 29, 33], ["mouth", "ANATOMY", 38, 43], ["disease", "OBSERVATION", 44, 51], ["restricted", "OBSERVATION_MODIFIER", 180, 190], ["quasispecies", "OBSERVATION", 191, 203]]], ["Also, antiviral treatment can lead genetic diversity gains that may precede selection of drug-resistant genotypes, as has been observed with oseltamivir [33, 35] .Is there evidence for altered viral evolution in malnourished hosts?Globally, 1 in 9 people are undernourished and 1 in 3 are overweight or obese, with innumerable others suffering from micronutrient deficiencies [1] .", [["oseltamivir", "CHEMICAL", 141, 152], ["micronutrient deficiencies", "DISEASE", 349, 375], ["oseltamivir", "CHEMICAL", 141, 152], ["oseltamivir", "SIMPLE_CHEMICAL", 141, 152], ["people", "ORGANISM", 248, 254], ["people", "SPECIES", 248, 254], ["antiviral treatment", "TREATMENT", 6, 25], ["drug-resistant genotypes", "PROBLEM", 89, 113], ["oseltamivir", "TREATMENT", 141, 152], ["altered viral evolution in malnourished hosts", "PROBLEM", 185, 230], ["obese", "PROBLEM", 303, 308], ["micronutrient deficiencies", "PROBLEM", 349, 375], ["evidence for", "UNCERTAINTY", 172, 184], ["altered", "OBSERVATION_MODIFIER", 185, 192], ["viral", "OBSERVATION", 193, 198], ["malnourished hosts", "OBSERVATION", 212, 230], ["obese", "OBSERVATION", 303, 308], ["innumerable", "OBSERVATION_MODIFIER", 315, 326], ["micronutrient deficiencies", "OBSERVATION", 349, 375]]], ["Previous work has identified micronutrient deficiencies that may increase pathogen virulence through acquisition of minor variants.", [["micronutrient deficiencies", "PROBLEM", 29, 55], ["minor variants", "PROBLEM", 116, 130], ["micronutrient deficiencies", "OBSERVATION", 29, 55], ["may", "UNCERTAINTY", 61, 64], ["increase", "OBSERVATION_MODIFIER", 65, 73], ["pathogen virulence", "OBSERVATION", 74, 92], ["minor variants", "OBSERVATION", 116, 130]]], ["In mineral-and vitamin-deficient mice, genetic mutations arise in coxsackie B and influenza virus populations that promote virulence even in well-nourished hosts [36] [37] [38] [39] [40] .Is there evidence for altered viral evolution in malnourished hosts?In our work with influenza virus, we determined that nutrient excesses can drive virulence through population diversification [41] .", [["vitamin", "CHEMICAL", 15, 22], ["influenza virus", "DISEASE", 273, 288], ["vitamin", "SIMPLE_CHEMICAL", 15, 22], ["mice", "ORGANISM", 33, 37], ["coxsackie B", "ORGANISM", 66, 77], ["influenza virus", "ORGANISM", 82, 97], ["[36] [37] [38] [39", "SIMPLE_CHEMICAL", 162, 180], ["influenza virus", "ORGANISM", 273, 288], ["mice", "SPECIES", 33, 37], ["influenza virus", "SPECIES", 82, 97], ["coxsackie B", "SPECIES", 66, 77], ["influenza virus", "SPECIES", 82, 97], ["influenza virus", "SPECIES", 273, 288], ["mineral", "TEST", 3, 10], ["vitamin-deficient mice", "TREATMENT", 15, 37], ["genetic mutations", "PROBLEM", 39, 56], ["coxsackie B", "PROBLEM", 66, 77], ["influenza virus populations", "PROBLEM", 82, 109], ["altered viral evolution in malnourished hosts", "PROBLEM", 210, 255], ["influenza virus", "PROBLEM", 273, 288], ["evidence for", "UNCERTAINTY", 197, 209], ["altered", "OBSERVATION_MODIFIER", 210, 217], ["viral", "OBSERVATION", 218, 223], ["malnourished hosts", "OBSERVATION", 237, 255]]], ["Experimental evolution of CA/09 virus through two models of murine obesity resulted in a viral population displaying increased virulence upon inoculation of a wild-type host.", [["obesity", "DISEASE", 67, 74], ["CA/09 virus", "ORGANISM", 26, 37], ["murine", "ORGANISM", 60, 66], ["murine", "SPECIES", 60, 66], ["CA/09 virus", "PROBLEM", 26, 37], ["murine obesity", "PROBLEM", 60, 74], ["a viral population", "PROBLEM", 87, 105], ["increased virulence", "PROBLEM", 117, 136], ["obesity", "OBSERVATION", 67, 74], ["viral", "OBSERVATION_MODIFIER", 89, 94], ["increased", "OBSERVATION_MODIFIER", 117, 126], ["virulence", "OBSERVATION_MODIFIER", 127, 136]]], ["This phenotype was not strain specific; an avirulent H3N2 virus was, upon passage in obese hosts, able to productively infect immunocompetent mice.", [["avirulent H3N2 virus", "ORGANISM", 43, 63], ["mice", "ORGANISM", 142, 146], ["avirulent H3N2 virus", "SPECIES", 43, 63], ["mice", "SPECIES", 142, 146], ["avirulent H3N2 virus", "SPECIES", 43, 63], ["mice", "SPECIES", 142, 146], ["strain", "PROBLEM", 23, 29], ["an avirulent H3N2 virus", "PROBLEM", 40, 63], ["obese hosts", "PROBLEM", 85, 96], ["avirulent", "OBSERVATION_MODIFIER", 43, 52], ["H3N2 virus", "OBSERVATION", 53, 63]]], ["We observed a significant increase in viral diversity and subsequent virulence after a single round of infection, with the phenotype persisting in obese-derived viral populations across 10 passages [41] .", [["infection", "DISEASE", 103, 112], ["a significant increase in viral diversity", "PROBLEM", 12, 53], ["subsequent virulence", "PROBLEM", 58, 78], ["infection", "PROBLEM", 103, 112], ["the phenotype", "PROBLEM", 119, 132], ["obese", "PROBLEM", 147, 152], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["increase", "OBSERVATION_MODIFIER", 26, 34], ["viral diversity", "OBSERVATION", 38, 53], ["infection", "OBSERVATION", 103, 112]]], ["Interestingly, arbovirus-infected obese or protein-deficient mice showed higher morbidity but lower viral diversity, and both malnourished models transmitted virus less efficiently, highlighting that the effects of nutrition may vary based on the natural life cycles of viral families [42] .", [["arbovirus-infected obese", "DISEASE", 15, 39], ["arbovirus", "ORGANISM", 15, 24], ["mice", "ORGANISM", 61, 65], ["mice", "SPECIES", 61, 65], ["mice", "SPECIES", 61, 65], ["arbovirus", "TEST", 15, 24], ["infected obese", "PROBLEM", 25, 39], ["protein-deficient mice", "PROBLEM", 43, 65], ["higher morbidity", "PROBLEM", 73, 89], ["lower viral diversity", "PROBLEM", 94, 115], ["both malnourished models transmitted virus", "PROBLEM", 121, 163], ["nutrition", "TREATMENT", 215, 224], ["arbovirus", "OBSERVATION", 15, 24], ["higher", "OBSERVATION_MODIFIER", 73, 79], ["morbidity", "OBSERVATION", 80, 89], ["lower", "OBSERVATION_MODIFIER", 94, 99], ["viral diversity", "OBSERVATION", 100, 115]]], ["It is yet to be determined how malnourishment may impact transmission of a respiratory, as compared with a vector-borne, virus.How could what we eat shape our viral pathogens?Both undernourishment and obesity are two sides of the same coin and are implicated in blunting immune responses and increasing susceptibility to infection [43, 44] .", [["respiratory", "ANATOMY", 75, 86], ["obesity", "DISEASE", 201, 208], ["infection", "DISEASE", 321, 330], ["virus", "PROBLEM", 121, 126], ["our viral pathogens", "PROBLEM", 155, 174], ["obesity", "PROBLEM", 201, 208], ["blunting immune responses", "PROBLEM", 262, 287], ["increasing susceptibility to infection", "PROBLEM", 292, 330], ["respiratory", "ANATOMY", 75, 86], ["obesity", "OBSERVATION", 201, 208], ["blunting", "OBSERVATION_MODIFIER", 262, 270], ["increasing", "OBSERVATION_MODIFIER", 292, 302], ["susceptibility", "OBSERVATION_MODIFIER", 303, 317], ["infection", "OBSERVATION", 321, 330]]], ["In our studies with influenza virus, we linked the emergence of a more diverse and virulent viral population with blunted interferon responses in obese hosts.", [["influenza virus", "DISEASE", 20, 35], ["influenza virus", "ORGANISM", 20, 35], ["interferon", "PROTEIN", 122, 132], ["influenza virus", "SPECIES", 20, 35], ["influenza virus", "PROBLEM", 20, 35], ["a more diverse and virulent viral population", "PROBLEM", 64, 108], ["blunted interferon responses in obese hosts", "PROBLEM", 114, 157], ["influenza virus", "OBSERVATION", 20, 35], ["virulent", "OBSERVATION_MODIFIER", 83, 91], ["viral population", "OBSERVATION", 92, 108], ["blunted interferon", "OBSERVATION", 114, 132], ["obese hosts", "OBSERVATION", 146, 157]]], ["Interferon treatment of obese mice restricted the emergence of a diverse quasispecies and attenuated the virulence of the resulting viral population, strengthening the claim that a robust innate immune response restricts subsequent infection severity, possibly through reduced viral replication and acquisition of a genetically diverse viral population [8, 20, 41] .", [["infection", "DISEASE", 232, 241], ["Interferon", "GENE_OR_GENE_PRODUCT", 0, 10], ["mice", "ORGANISM", 30, 34], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 30, 34], ["Interferon treatment", "TREATMENT", 0, 20], ["obese mice", "PROBLEM", 24, 34], ["a diverse quasispecies", "PROBLEM", 63, 85], ["the resulting viral population", "PROBLEM", 118, 148], ["subsequent infection severity", "PROBLEM", 221, 250], ["reduced viral replication", "TREATMENT", 269, 294], ["a genetically diverse viral population", "PROBLEM", 314, 352], ["viral population", "OBSERVATION", 132, 148], ["infection", "OBSERVATION", 232, 241], ["viral replication", "OBSERVATION", 277, 294]]], ["Dietary metabolites also influence cellular metabolism and can push the body to a state of metainflammation; this prooxidant environment may also directly influence the genetic composition of the viral population [45] .How could what we eat shape our viral pathogens?Nutritional excess or deficiency may dampen the host immune responses and alter cellular metabolism, indirectly fostering an advantageous environment for viruses to explore the sequence space (Fig 2) .", [["cellular", "ANATOMY", 35, 43], ["body", "ANATOMY", 72, 76], ["cellular", "ANATOMY", 347, 355], ["cellular", "CELL", 35, 43], ["body", "ORGANISM_SUBDIVISION", 72, 76], ["cellular", "CELL", 347, 355], ["Dietary metabolites", "PROBLEM", 0, 19], ["influence cellular metabolism", "PROBLEM", 25, 54], ["metainflammation", "PROBLEM", 91, 107], ["our viral pathogens", "PROBLEM", 247, 266], ["Nutritional excess", "PROBLEM", 267, 285], ["deficiency", "PROBLEM", 289, 299], ["alter cellular metabolism", "PROBLEM", 341, 366], ["viruses", "PROBLEM", 421, 428], ["cellular metabolism", "OBSERVATION", 35, 54]]], ["The dearth of host responses to infection-particularly innate immunity-and the baseline malnourished state facilitates greater viral replication, permits the diversification of the viral swarm, and potentially allows for the emergence of advantageous mutations.", [["infection", "DISEASE", 32, 41], ["infection", "PROBLEM", 32, 41], ["the baseline malnourished state", "PROBLEM", 75, 106], ["greater viral replication", "TREATMENT", 119, 144], ["the viral swarm", "PROBLEM", 177, 192], ["advantageous mutations", "TREATMENT", 238, 260], ["infection", "OBSERVATION", 32, 41], ["viral swarm", "OBSERVATION", 181, 192]]], ["Blunting of immune responses may alter viral tropism and viral-or immune-induced pathology, thus remodeling the microenvironment in which the virus attacks the host.", [["Blunting of immune responses", "PROBLEM", 0, 28], ["alter viral tropism", "PROBLEM", 33, 52], ["viral", "TEST", 57, 62], ["immune-induced pathology", "PROBLEM", 66, 90], ["the virus attacks the host", "PROBLEM", 138, 164], ["immune responses", "OBSERVATION", 12, 28], ["viral tropism", "OBSERVATION", 39, 52]]], ["Also, nutrition is increasingly appreciated as an influence on the gut microbiome (reviewed in [46] ).", [["gut microbiome", "ANATOMY", 67, 81], ["gut", "ORGANISM_SUBDIVISION", 67, 70]]], ["Interestingly, perturbations to the microbiome-both respiratory and gut-dampen interferon responses to respiratory virus infection [47] [48] [49] .", [["respiratory", "ANATOMY", 52, 63], ["gut", "ANATOMY", 68, 71], ["respiratory virus infection", "DISEASE", 103, 130], ["gut", "ORGANISM_SUBDIVISION", 68, 71], ["interferon", "GENE_OR_GENE_PRODUCT", 79, 89], ["respiratory virus", "ORGANISM", 103, 120], ["interferon", "PROTEIN", 79, 89], ["dampen interferon responses", "TREATMENT", 72, 99], ["respiratory virus infection", "PROBLEM", 103, 130], ["respiratory", "ANATOMY", 52, 63], ["gut", "ANATOMY", 68, 71]]], ["However, to our knowledge, no empirical studies connect the obese microbiome to modulating enteric or respiratory viral populations.ConclusionPathogen virulence is a complex interplay of both host and pathogen properties.", [["empirical studies", "TEST", 30, 47], ["modulating enteric or respiratory viral populations", "PROBLEM", 80, 131], ["ConclusionPathogen virulence", "PROBLEM", 132, 160], ["enteric", "ANATOMY", 91, 98], ["respiratory", "ANATOMY", 102, 113], ["viral populations", "OBSERVATION", 114, 131]]], ["Host nutritional status has long been considered a risk for infection susceptibility and severity and is now implicated in shaping viral evolution.", [["infection", "DISEASE", 60, 69], ["infection susceptibility and severity", "PROBLEM", 60, 97], ["infection", "OBSERVATION", 60, 69], ["viral evolution", "OBSERVATION", 131, 146]]], ["Continued studies on the molecular consequences of obesity and malnutrition at the macro-and micronutrient levels will reveal which host defenses are impaired through malnutrition and how they control quasispecies development and viral pathogenesis.", [["obesity", "DISEASE", 51, 58], ["malnutrition", "DISEASE", 63, 75], ["malnutrition", "DISEASE", 167, 179], ["Continued studies", "TEST", 0, 17], ["obesity", "PROBLEM", 51, 58], ["malnutrition", "PROBLEM", 63, 75], ["the macro", "TEST", 79, 88], ["micronutrient levels", "TEST", 93, 113], ["malnutrition", "PROBLEM", 167, 179], ["viral pathogenesis", "PROBLEM", 230, 248], ["obesity", "OBSERVATION", 51, 58], ["malnutrition", "OBSERVATION", 63, 75], ["viral", "OBSERVATION_MODIFIER", 230, 235]]], ["Similarly, as we gain insight into how hosts influence quasispecies formation and pathogen virulence, we too can exploit these features for host benefit [18, 50] .ConclusionThe global ubiquity of malnutrition is shifting our population toward a more susceptible state.", [["malnutrition", "DISEASE", 196, 208], ["quasispecies formation", "PROBLEM", 55, 77], ["pathogen virulence", "PROBLEM", 82, 100], ["malnutrition", "PROBLEM", 196, 208], ["global", "OBSERVATION_MODIFIER", 177, 183], ["malnutrition", "OBSERVATION", 196, 208]]], ["Continued study of how quasispecies evolution relates to other human, animal, and plant pathogens will indeed usher in a greater understanding of host-pathogen interactions and provide novel insights into how pathogens impact hosts and hosts impact pathogens.", [["human", "ORGANISM", 63, 68], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["Continued study", "TEST", 0, 15]]]], "2be0c5b0e602c2c6a95fe6d132277d030070bcd9": [["We analyze the effect of using a screening CT-scan for evaluation of potential COVID-19 infections in order to isolate and perform contact tracing based upon a viral pneumonia diagnosis.", [["infections", "DISEASE", 88, 98], ["pneumonia", "DISEASE", 166, 175], ["a screening CT-scan", "TEST", 31, 50], ["evaluation", "TEST", 55, 65], ["potential COVID-19 infections", "PROBLEM", 69, 98], ["contact tracing", "TEST", 131, 146], ["a viral pneumonia diagnosis", "PROBLEM", 158, 185], ["viral", "OBSERVATION_MODIFIER", 160, 165], ["pneumonia", "OBSERVATION", 166, 175]]], ["RT-PCR is then used for continued isolation based upon a COVID diagnosis.", [["RT-PCR", "TEST", 0, 6]]], ["Both the low false negative rates and rapid results of CT-scans lead to dramatically reduced transmission.", [["CT-scans", "TEST", 55, 63], ["dramatically reduced transmission", "PROBLEM", 72, 105], ["low", "OBSERVATION_MODIFIER", 9, 12], ["false negative rates", "OBSERVATION", 13, 33], ["dramatically", "OBSERVATION_MODIFIER", 72, 84], ["reduced", "OBSERVATION_MODIFIER", 85, 92]]], ["The reduction in cases after 60 days with widespread use of CT-scan screening compared to PCR by itself is as high as 50\u00d7, and the reduction of effective reproduction rate R(t) is 0.20.", [["The reduction", "TREATMENT", 0, 13], ["CT-scan screening", "TEST", 60, 77], ["PCR", "TEST", 90, 93], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["reduction", "OBSERVATION_MODIFIER", 131, 140], ["effective", "OBSERVATION_MODIFIER", 144, 153]]], ["Our results imply that much more rapid extinction of COVID is possible by combining social distancing with CT-scans and contact tracing.", [["CT-scans", "TEST", 107, 115], ["contact tracing", "TEST", 120, 135]]]], "6aef140c41d171cdc5a6000c1c0bb1b09fb81744": [["Novel coronavirus disease is spreading fast around the world, with many uncertainties about treatment and prevention.", [["coronavirus disease", "DISEASE", 6, 25], ["coronavirus", "ORGANISM", 6, 17], ["Novel coronavirus disease", "PROBLEM", 0, 25], ["treatment", "TREATMENT", 92, 101], ["prevention", "TREATMENT", 106, 116], ["coronavirus disease", "OBSERVATION", 6, 25]]], ["Currently, there are no U.S. Food and Drug Administration (FDA)-approved drugs for the treatment of patients with COVID-19.", [["COVID-19", "CHEMICAL", 114, 122], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["drugs", "TREATMENT", 73, 78], ["the treatment", "TREATMENT", 83, 96], ["COVID", "TEST", 114, 119], ["no", "UNCERTAINTY", 21, 23]]], ["A great deal of effort is ongoing to find effective therapeutics and preventive measures against this transmissible virus with high mortality.", [["effective therapeutics", "TREATMENT", 42, 64], ["preventive measures", "TREATMENT", 69, 88], ["this transmissible virus", "PROBLEM", 97, 121], ["high mortality", "PROBLEM", 127, 141], ["great", "OBSERVATION_MODIFIER", 2, 7]]], ["Available data are limited, and there are minimal randomized controlled trial (RCT) data on the efficacy of antiviral or immunomodulatory agents for the treatment of COVID-19.", [["minimal randomized controlled trial (RCT)", "TREATMENT", 42, 83], ["antiviral", "TREATMENT", 108, 117], ["immunomodulatory agents", "TREATMENT", 121, 144], ["COVID", "TEST", 166, 171], ["minimal", "OBSERVATION_MODIFIER", 42, 49]]]], "PMC7148103": [["However, the yearly generated research volume shows an upward trend with an estimated increase of 8\u20139% per year.", [["research volume", "TEST", 30, 45], ["an upward trend", "PROBLEM", 52, 67], ["upward", "OBSERVATION_MODIFIER", 55, 61], ["trend", "OBSERVATION_MODIFIER", 62, 67], ["increase", "OBSERVATION_MODIFIER", 86, 94]]], ["This results in information overload, impacting the literature review process and often, leads to \u2018reinventing the wheel\u2019 syndrome.", [["information overload", "PROBLEM", 16, 36], ["syndrome", "PROBLEM", 122, 130], ["overload", "OBSERVATION", 28, 36]]], ["This negatively affects the efficiency of scientific progress on the knowledge frontier.IntroductionIn the past, significant efforts have been made to curate peer-reviewed open access scientific information.", [["efficiency", "OBSERVATION_MODIFIER", 28, 38]]], ["In particular, the field of Natural Language Processing (NLP) witnessed the development of ACL Anthology since the year 2001, which curates papers (in PDF format) from more than 70 NLP venues including popular conferences like ACL, NAACL, EMNLP, etc. In the year 2008, Bird et al. [2] released the ACL Anthology Reference Corpus (ACL ARC), consisting of OCRed extracted text and metadata of PDF articles.", [["ACL", "MULTI-TISSUE_STRUCTURE", 227, 230], ["NAACL", "PROTEIN", 232, 237], ["EMNLP", "PROTEIN", 239, 244], ["OCRed", "PROTEIN", 354, 359], ["ACL", "TREATMENT", 227, 230], ["NAACL", "TREATMENT", 232, 237], ["EMNLP", "TREATMENT", 239, 244], ["Corpus", "ANATOMY", 322, 328], ["ACL ARC", "ANATOMY", 330, 337]]], ["It supports natural language queries and entity specific queries about the authors, venue, and paper.", [["natural language", "OBSERVATION", 12, 28]]], ["Almost all systems described above are either in dormant condition [2, 8\u201310] or not available [12].IntroductionIn this paper, we discuss the development of NLPExplorer.", [["NLPExplorer", "TREATMENT", 156, 167]]], ["For the first time, we also showcase, the usage of URLs over the years, popular top-level and sub-domains, survey papers, new authors, etc. The system also presents a visualization of the timeline for the first occurrences of sub-topics.IntroductionOur main contributions are as follows: (i) We periodically download, preprocess, and index the ACL Anthology dataset consisting of more than 55 thousand full-text PDF articles. (ii) We invest extensive effort in automatic curation, structured information extraction, cleaning, indexing, and other related preprocessing steps. (iii) We classify papers into a first-of-its-kind detailed list of NLP topics and subtopics. (iv) The proposed system presents content as well as bibliographic statistics along with basic keyword-based search facilities. (v) We deploy the current system in Google Cloud with an API-based retrieval facility.DatasetWe leverage the ACL Anthology dataset [1] that hosts articles dedicated to Computational Linguistics and Natural Language Processing.", [["preprocess", "TEST", 318, 328], ["structured information extraction", "TREATMENT", 481, 514], ["cleaning", "TREATMENT", 516, 524], ["an API-based retrieval facility", "TREATMENT", 850, 881]]], ["Overall, the dataset has 55,565 papers, 39,555 unique authors, 78 venues and 723,976 citations.ArchitectureThe architecture of NLPExplorer is composed of three interdependent modules, (i) data acquisition, (ii) storage and query processing, and (iii) user interface module.", [["NLPExplorer", "DNA", 127, 138], ["data acquisition", "TEST", 188, 204], ["three", "OBSERVATION_MODIFIER", 154, 159], ["interdependent", "OBSERVATION_MODIFIER", 160, 174], ["modules", "OBSERVATION", 175, 182]]], ["The data acquisition module periodically curates newly added semi-structured information such as metadata and the corresponding PDF articles from ACL Anthology.", [["The data acquisition module", "TEST", 0, 27]]], ["It leverages OCR++ [11] tool to extract structural and bibliographical information from each of the PDF articles, and then passes the metadata, structural and bibliographical information to the storage and query processing module.", [["query processing module", "PROBLEM", 206, 229]]], ["MongoDB database handles the basic storage and retrieval, whereas Elasticsearch supports full-text based query search and ranking.", [["Elasticsearch", "PROTEIN", 66, 79], ["the basic storage", "TREATMENT", 25, 42], ["retrieval", "TREATMENT", 47, 56]]], ["The third module, the user interface, fetches processed search results from the storage and query processing module.", [["the storage", "PROBLEM", 76, 87], ["query processing module", "PROBLEM", 92, 115], ["third", "OBSERVATION_MODIFIER", 4, 9]]], ["The user interface is designed using Python\u2019s Flask library, and JavaScript libraries Plotly [7] and Timeline [13] are used to render statistics and graphical components of the interface.", [["Python\u2019s Flask library", "TREATMENT", 37, 59]]]], "22ad89ce56ad3854bd07b0e695723b4f194581d9": [["IntroductionLectins are an important class of proteins or glycoproteins of non-immune origin that bind non-covalently to characteristic carbohydrate structures with specificity or selectivity.", [["carbohydrate", "CHEMICAL", 136, 148], ["glycoproteins", "PROTEIN", 58, 71], ["IntroductionLectins", "TREATMENT", 0, 19], ["glycoproteins of non-immune origin", "TREATMENT", 58, 92]]], ["There are many ways to classify lectins.", [["lectins", "GENE_OR_GENE_PRODUCT", 32, 39], ["lectins", "PROTEIN", 32, 39]]], ["Given the fact that a wide range of living organisms, from microbes to mammals, produce lectins, they can be divided according to species origin, such as microbial lectins, plant lectins, invertebrate lectins and vertebrate lectins.", [["lectins", "GENE_OR_GENE_PRODUCT", 88, 95], ["lectins", "GENE_OR_GENE_PRODUCT", 224, 231], ["microbial lectins", "PROTEIN", 154, 171], ["plant lectins", "PROTEIN", 173, 186], ["invertebrate lectins", "PROTEIN", 188, 208], ["vertebrate lectins", "PROTEIN", 213, 231], ["living organisms", "PROBLEM", 36, 52]]], ["Based on the similarities in sequence of homology and activity, lectins can also be grouped into subfamilies.", [["lectins", "GENE_OR_GENE_PRODUCT", 64, 71], ["lectins", "PROTEIN", 64, 71]]], ["There are at least five groups of vertebrate lectins, such as C-type (calcium dependent), P-type, S-type, I-type, and pentraxins [1] .", [["calcium", "CHEMICAL", 70, 77], ["calcium", "CHEMICAL", 70, 77], ["pentraxins", "CHEMICAL", 118, 128], ["lectins", "GENE_OR_GENE_PRODUCT", 45, 52], ["C-type", "GENE_OR_GENE_PRODUCT", 62, 68], ["calcium", "SIMPLE_CHEMICAL", 70, 77], ["pentraxins [1]", "SIMPLE_CHEMICAL", 118, 132], ["P", "PROTEIN", 90, 91], ["vertebrate lectins", "PROBLEM", 34, 52], ["C-type (calcium dependent)", "PROBLEM", 62, 88], ["at least", "OBSERVATION_MODIFIER", 10, 18], ["five", "OBSERVATION_MODIFIER", 19, 23], ["groups", "OBSERVATION_MODIFIER", 24, 30], ["vertebrate lectins", "OBSERVATION", 34, 52]]], ["Cellular lectin molecules or receptors with lectin-like carbohydrate-binding domains play important roles in cell signaling, protein intracellular trafficking, and cell-cell communication [2] [3] [4] [5] .IntroductionLectins can also be classified according to their binding specificity or selectivity with carbohydrates.", [["cell", "ANATOMY", 109, 113], ["intracellular", "ANATOMY", 133, 146], ["cell", "ANATOMY", 164, 168], ["cell", "ANATOMY", 169, 173], ["carbohydrate", "CHEMICAL", 56, 68], ["carbohydrates", "CHEMICAL", 307, 320], ["lectin", "GENE_OR_GENE_PRODUCT", 44, 50], ["cell", "CELL", 109, 113], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 133, 146], ["cell", "CELL", 164, 168], ["cell", "CELL", 169, 173], ["[2] [3] [4] [5]", "SIMPLE_CHEMICAL", 188, 203], ["carbohydrates", "SIMPLE_CHEMICAL", 307, 320], ["Cellular lectin molecules", "PROTEIN", 0, 25], ["lectin", "PROTEIN", 44, 50], ["carbohydrate-binding domains", "PROTEIN", 56, 84], ["Cellular lectin molecules", "PROBLEM", 0, 25], ["lectin", "TEST", 44, 50], ["intracellular trafficking", "TEST", 133, 158], ["IntroductionLectins", "TREATMENT", 205, 224], ["lectin molecules", "OBSERVATION", 9, 25]]], ["This type of classification is helpful for selection of lectins as structural probes in biomedical applications.", [["lectins", "PROTEIN", 56, 63], ["selection of lectins", "TREATMENT", 43, 63]]], ["By the early seventies, the carbohydrate-binding activity of a lectin was commonly described in terms of monosaccharide specificity.", [["carbohydrate", "CHEMICAL", 28, 40], ["monosaccharide", "CHEMICAL", 105, 119], ["lectin", "GENE_OR_GENE_PRODUCT", 63, 69], ["monosaccharide", "SIMPLE_CHEMICAL", 105, 119], ["lectin", "PROTEIN", 63, 69], ["a lectin", "TREATMENT", 61, 69], ["monosaccharide specificity", "TEST", 105, 131]]], ["Experimentally, a type of inhibition assay, such as agglutination inhibition, was performed to identify the monosaccharide that most effectively inhibited the binding reaction.", [["monosaccharide", "CHEMICAL", 108, 122], ["inhibition assay", "TEST", 26, 42], ["agglutination inhibition", "TEST", 52, 76], ["the binding reaction", "PROBLEM", 155, 175]]], ["Many lectins are able to cross-react with a panel of sugar chains with a common terminal sugar residue.", [["sugar", "CHEMICAL", 53, 58], ["sugar", "CHEMICAL", 89, 94], ["lectins", "GENE_OR_GENE_PRODUCT", 5, 12], ["sugar chains", "SIMPLE_CHEMICAL", 53, 65], ["sugar", "SIMPLE_CHEMICAL", 89, 94], ["lectins", "PROTEIN", 5, 12], ["sugar chains", "PROTEIN", 53, 65], ["Many lectins", "PROBLEM", 0, 12], ["sugar chains", "TREATMENT", 53, 65], ["a common terminal sugar residue", "PROBLEM", 71, 102], ["lectins", "OBSERVATION", 5, 12], ["sugar residue", "OBSERVATION", 89, 102]]], ["Lately, disaccharides are considered to be a better way to define a lectin's specificity.IntroductionHowever, some lectin-binding sites accommodate glyco-epitopes larger than mono-and disaccharides and recognize conformational epitopes.", [["disaccharides", "CHEMICAL", 8, 21], ["disaccharides", "SIMPLE_CHEMICAL", 8, 21], ["lectin", "GENE_OR_GENE_PRODUCT", 68, 74], ["lectin", "GENE_OR_GENE_PRODUCT", 115, 121], ["disaccharides", "SIMPLE_CHEMICAL", 184, 197], ["lectin", "PROTEIN", 68, 74], ["lectin", "PROTEIN", 115, 121], ["conformational epitopes", "PROTEIN", 212, 235], ["disaccharides", "PROBLEM", 8, 21], ["a lectin's specificity", "TEST", 66, 88], ["Introduction", "TREATMENT", 89, 101], ["some lectin-binding sites", "PROBLEM", 110, 135], ["disaccharides", "TREATMENT", 184, 197], ["conformational epitopes", "PROBLEM", 212, 235], ["larger", "OBSERVATION_MODIFIER", 163, 169]]], ["The latter may consist of much longer oligosaccharide or polysaccharide chains.", [["polysaccharide chains", "PROBLEM", 57, 78], ["polysaccharide chains", "OBSERVATION", 57, 78]]], ["There is also evidence that lectins recognize certain cluster configurations of complex carbohydrates with high selectivity and avidity.IntroductionX-ray crystallographic studies identified some common characteristics in the binding pockets of lectins and antibodies [2, 6, 7] .", [["carbohydrates", "CHEMICAL", 88, 101], ["carbohydrates", "SIMPLE_CHEMICAL", 88, 101], ["lectins", "GENE_OR_GENE_PRODUCT", 244, 251], ["lectins", "PROTEIN", 244, 251], ["antibodies", "PROTEIN", 256, 266], ["high selectivity and avidity", "PROBLEM", 107, 135], ["IntroductionX-ray crystallographic studies", "TEST", 136, 178], ["the binding pockets of lectins and antibodies", "PROBLEM", 221, 266], ["cluster", "OBSERVATION_MODIFIER", 54, 61], ["configurations", "OBSERVATION_MODIFIER", 62, 76], ["complex", "OBSERVATION_MODIFIER", 80, 87], ["carbohydrates", "OBSERVATION_MODIFIER", 88, 101], ["high selectivity", "OBSERVATION_MODIFIER", 107, 123], ["avidity", "OBSERVATION_MODIFIER", 128, 135], ["common", "OBSERVATION_MODIFIER", 195, 201], ["binding pockets", "OBSERVATION", 225, 240]]], ["Aromatic amino acid residues appear frequently in carbohydrate-binding sites of various fine specificities.", [["amino acid", "CHEMICAL", 9, 19], ["Aromatic amino acid", "CHEMICAL", 0, 19], ["carbohydrate", "CHEMICAL", 50, 62], ["Aromatic", "SIMPLE_CHEMICAL", 0, 8], ["amino acid", "AMINO_ACID", 9, 19], ["carbohydrate-binding sites", "PROTEIN", 50, 76], ["Aromatic amino acid residues", "PROBLEM", 0, 28], ["amino", "OBSERVATION", 9, 14], ["acid residues", "OBSERVATION", 15, 28]]], ["Such residues are large and participate in a wide variety of van der Waals and electrostatic interactions.", [["Such residues", "PROBLEM", 0, 13], ["a wide variety of van der Waals", "TREATMENT", 43, 74], ["large", "OBSERVATION_MODIFIER", 18, 23]]], ["The majority of crystal structures so far resolved are associated with a network of H-bonds, frequently with water molecules, in their combining sites.", [["H", "CHEMICAL", 84, 85], ["H-bonds", "SIMPLE_CHEMICAL", 84, 91], ["water molecules", "PROBLEM", 109, 124], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["crystal", "OBSERVATION_MODIFIER", 16, 23]]], ["Such bound water molecules play important roles at the contacting interface between carbohydrate ligands and receptors.", [["carbohydrate", "CHEMICAL", 84, 96]]], ["In addition, polyamphiphilic surfaces were identified in the interfaces of a number of carbohydrate ligands and binding sites.", [["carbohydrate", "CHEMICAL", 87, 99], ["binding sites", "PROTEIN", 112, 125], ["polyamphiphilic surfaces", "PROBLEM", 13, 37], ["binding sites", "PROBLEM", 112, 125], ["polyamphiphilic surfaces", "OBSERVATION", 13, 37], ["number", "OBSERVATION_MODIFIER", 77, 83], ["carbohydrate ligands", "OBSERVATION", 87, 107], ["binding sites", "OBSERVATION", 112, 125]]], ["Presence of relatively rigid structures is required to produce an amphiphilic surface in solution.", [["surface", "ANATOMY", 78, 85], ["relatively rigid structures", "PROBLEM", 12, 39], ["an amphiphilic surface in solution", "TREATMENT", 63, 97], ["relatively", "OBSERVATION_MODIFIER", 12, 22], ["rigid", "OBSERVATION", 23, 28], ["amphiphilic", "OBSERVATION_MODIFIER", 66, 77], ["surface", "OBSERVATION_MODIFIER", 78, 85]]], ["Carbohydrate molecules with branched termini, such as many blood group substances, which are formed by oligosaccharide chains, are favorable for the generation of such contact surfaces.IntroductionMuch remains to be learned regarding the specificity and cross-reactivity of the carbohydrate-lectin interactions and their functional outcome in biological systems.", [["blood", "ANATOMY", 59, 64], ["Carbohydrate", "CHEMICAL", 0, 12], ["carbohydrate", "CHEMICAL", 278, 290], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["lectin", "GENE_OR_GENE_PRODUCT", 291, 297], ["Carbohydrate molecules", "PROTEIN", 0, 22], ["lectin", "PROTEIN", 291, 297], ["Carbohydrate molecules with branched termini", "PROBLEM", 0, 44], ["many blood group substances", "PROBLEM", 54, 81], ["branched termini", "OBSERVATION_MODIFIER", 28, 44], ["oligosaccharide chains", "OBSERVATION", 103, 125], ["favorable", "OBSERVATION_MODIFIER", 131, 140]]], ["Challenging issues in lectin characterization may include but are not limited to (a) the spectrum or repertoire of carbohydrate structures that are reactive with given lectins, (b) conformational properties of glyco-epitopes that are selectively recognized by lectins, and (c) the cluster effect in lectin-carbohydrate interactions, especially those that take place on cell surfaces and trigger the events of intracellular cell signaling, cell differentiation and proliferation.", [["cell surfaces", "ANATOMY", 369, 382], ["intracellular cell", "ANATOMY", 409, 427], ["cell", "ANATOMY", 439, 443], ["carbohydrate", "CHEMICAL", 115, 127], ["carbohydrate", "CHEMICAL", 306, 318], ["lectin", "GENE_OR_GENE_PRODUCT", 22, 28], ["glyco-epitopes", "GENE_OR_GENE_PRODUCT", 210, 224], ["lectins", "GENE_OR_GENE_PRODUCT", 260, 267], ["lectin", "GENE_OR_GENE_PRODUCT", 299, 305], ["cell", "CELL", 369, 373], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 409, 422], ["cell", "CELL", 423, 427], ["cell", "CELL", 439, 443], ["lectin", "PROTEIN", 22, 28], ["glyco-epitopes", "PROTEIN", 210, 224], ["lectins", "PROTEIN", 260, 267], ["lectin", "PROTEIN", 299, 305], ["lectin characterization", "TEST", 22, 45], ["lectins, (b) conformational properties of glyco-epitopes", "PROBLEM", 168, 224], ["lectin-carbohydrate interactions", "TREATMENT", 299, 331], ["cell surfaces", "TREATMENT", 369, 382], ["intracellular cell signaling", "PROBLEM", 409, 437], ["proliferation", "PROBLEM", 464, 477], ["reactive", "OBSERVATION_MODIFIER", 148, 156], ["intracellular cell signaling", "OBSERVATION", 409, 437], ["cell differentiation", "OBSERVATION", 439, 459], ["proliferation", "OBSERVATION_MODIFIER", 464, 477]]], ["Recent development of microarray-based broad-range binding assays offers new tools to facilitate these investigations.IntroductionIn this chapter, we summarize the concept and the updated information regarding the specificity-based lectin classification (Section 2).", [["lectin", "PROTEIN", 232, 238], ["microarray-based broad-range binding assays", "PROBLEM", 22, 65], ["these investigations", "TEST", 97, 117]]], ["Then, we introduce a practical platform of carbohydrate microarrays that is likely useful for lectin characterization and classification (Section 3).", [["carbohydrate", "CHEMICAL", 43, 55], ["lectin", "GENE_OR_GENE_PRODUCT", 94, 100], ["lectin", "PROTEIN", 94, 100], ["a practical platform of carbohydrate microarrays", "TREATMENT", 19, 67], ["lectin characterization", "TEST", 94, 117]]], ["Lastly, we discuss a few examples to illustrate the application of this technology in lectin-related experimental investigations (Section 4).The Specificity-Based Lectin ClassificationLectins are functionally classified based on their relative binding reactivities with the structural units of carbohydrate or glyco-epitopes.", [["carbohydrate", "CHEMICAL", 294, 306], ["lectin", "GENE_OR_GENE_PRODUCT", 86, 92], ["carbohydrate", "SIMPLE_CHEMICAL", 294, 306], ["glyco-epitopes", "SIMPLE_CHEMICAL", 310, 324], ["lectin", "PROTEIN", 86, 92], ["carbohydrate or glyco-epitopes", "PROTEIN", 294, 324], ["The Specificity", "TEST", 141, 156], ["carbohydrate or glyco-epitopes", "TREATMENT", 294, 324]]], ["They are grouped according to their monosaccharide specificities and then further sub-grouped based on their reactivities with more complex structures.", [["monosaccharide", "CHEMICAL", 36, 50]]], ["As listed below, carbohydrate specificities of biomedically important lectins are classified into six groups according to their specificities to monosaccharides.", [["carbohydrate", "CHEMICAL", 17, 29], ["monosaccharides", "CHEMICAL", 145, 160], ["monosaccharides", "SIMPLE_CHEMICAL", 145, 160]]], ["They are further subgrouped based on the binding affinities to (a) GalNAc 1 ; O to Ser(Thr) of the peptide chain; (b) disaccharides; (c) trisaccharides; and (d) the number and the location of LFuc 1 ; linked to oligosaccharides.", [["GalNAc", "CHEMICAL", 67, 73], ["O", "CHEMICAL", 78, 79], ["Ser", "CHEMICAL", 83, 86], ["Thr", "CHEMICAL", 87, 90], ["disaccharides", "CHEMICAL", 118, 131], ["trisaccharides", "CHEMICAL", 137, 151], ["GalNAc 1", "GENE_OR_GENE_PRODUCT", 67, 75], ["Ser", "AMINO_ACID", 83, 86], ["Thr)", "AMINO_ACID", 87, 91], ["(c) trisaccharides", "SIMPLE_CHEMICAL", 133, 151], ["LFuc 1", "GENE_OR_GENE_PRODUCT", 192, 198], ["LFuc 1", "PROTEIN", 192, 198], ["the peptide chain", "TREATMENT", 95, 112]]], ["These structures are frequently found in soluble glycoproteins and as cell surface glycoconjugates in mammals [8] [9] [10] [11] .", [["cell surface", "ANATOMY", 70, 82], ["cell", "CELL", 70, 74], ["soluble glycoproteins", "PROTEIN", 41, 62], ["cell surface glycoconjugates", "TEST", 70, 98]]], ["This scheme of lectin classification is, thus, practically useful in biomedical application of lectins.Group I. GalNAc-specific agglutinins(1) F/A, GalNAc 1 ; 3GalNAc (Forssman) and GalNAc 1 ; 3Gal (blood group A determinant disaccharide) specific agglutinins -Dolichos biflorus (DBA) and Helix pomatia (HPA).", [["blood", "ANATOMY", 199, 204], ["GalNAc", "CHEMICAL", 112, 118], ["GalNAc", "CHEMICAL", 148, 154], ["GalNAc", "CHEMICAL", 182, 188], ["disaccharide", "CHEMICAL", 225, 237], ["lectin", "GENE_OR_GENE_PRODUCT", 15, 21], ["lectins", "GENE_OR_GENE_PRODUCT", 95, 102], ["GalNAc", "GENE_OR_GENE_PRODUCT", 112, 118], ["F/A", "SIMPLE_CHEMICAL", 143, 146], ["GalNAc 1 ; 3GalNAc", "SIMPLE_CHEMICAL", 148, 166], ["Forssman", "SIMPLE_CHEMICAL", 168, 176], ["GalNAc 1", "GENE_OR_GENE_PRODUCT", 182, 190], ["3Gal", "SIMPLE_CHEMICAL", 193, 197], ["blood", "ORGANISM_SUBSTANCE", 199, 204], ["group A determinant disaccharide", "SIMPLE_CHEMICAL", 205, 237], ["agglutinins -Dolichos biflorus", "SIMPLE_CHEMICAL", 248, 278], ["DBA", "MULTI-TISSUE_STRUCTURE", 280, 283], ["Helix pomatia", "ORGANISM", 289, 302], ["lectin", "PROTEIN", 15, 21], ["lectins", "PROTEIN", 95, 102], ["3Gal", "PROTEIN", 193, 197], ["Dolichos biflorus", "SPECIES", 261, 278], ["Helix pomatia", "SPECIES", 289, 302], ["Dolichos biflorus", "SPECIES", 261, 278], ["Helix pomatia", "SPECIES", 289, 302], ["biomedical application of lectins", "TREATMENT", 69, 102], ["GalNAc", "TEST", 148, 154], ["GalNAc", "TEST", 182, 188], ["3Gal (blood group A determinant disaccharide", "TREATMENT", 193, 237], ["specific agglutinins", "TEST", 239, 259], ["Helix pomatia (HPA)", "TREATMENT", 289, 308]]], ["(2) A, GalNAc 1 ; 3Gal (blood group A determinant disaccharide) -specific agglutinins -Soybean (SBA) and Lima bean (LBA).", [["blood", "ANATOMY", 24, 29], ["GalNAc", "CHEMICAL", 7, 13], ["disaccharide", "CHEMICAL", 50, 62], ["(2) A", "SIMPLE_CHEMICAL", 0, 5], ["GalNAc 1 ; 3Gal", "SIMPLE_CHEMICAL", 7, 22], ["blood", "ORGANISM_SUBSTANCE", 24, 29], ["group A determinant disaccharide", "SIMPLE_CHEMICAL", 30, 62], ["Soybean", "ORGANISM", 87, 94], ["SBA", "SIMPLE_CHEMICAL", 96, 99], ["Lima bean", "ORGANISM", 105, 114], ["Soybean", "SPECIES", 87, 94], ["bean", "SPECIES", 110, 114], ["Soybean", "SPECIES", 87, 94], ["Lima bean", "SPECIES", 105, 114], ["specific agglutinins", "TEST", 65, 85], ["Soybean (SBA)", "TREATMENT", 87, 100], ["Lima bean (LBA", "TREATMENT", 105, 119], ["Lima", "ANATOMY", 105, 109]]], ["(3) Tn, GalNAc 1 ; Ser/Thr-specific agglutinins -Vicia villosa B 4 (VVL-B 4 ) and Salvia sclarea (SSA).Group II.", [["VVL-B 4", "CHEMICAL", 68, 75], ["GalNAc", "CHEMICAL", 8, 14], ["Ser", "CHEMICAL", 19, 22], ["Tn", "GENE_OR_GENE_PRODUCT", 4, 6], ["GalNAc 1", "GENE_OR_GENE_PRODUCT", 8, 16], ["Ser", "GENE_OR_GENE_PRODUCT", 19, 22], ["Thr-", "GENE_OR_GENE_PRODUCT", 23, 27], ["VVL-B 4", "CELL", 68, 75], ["Salvia sclarea", "ORGANISM", 82, 96], ["Tn", "PROTEIN", 4, 6], ["VVL", "PROTEIN", 68, 71], ["Vicia villosa", "SPECIES", 49, 62], ["Salvia sclarea", "SPECIES", 82, 96], ["Vicia villosa", "SPECIES", 49, 62], ["Salvia sclarea", "SPECIES", 82, 96], ["Tn", "TEST", 4, 6], ["GalNAc", "TEST", 8, 14], ["Ser/Thr-specific agglutinins", "TEST", 19, 47], ["Vicia villosa B", "TEST", 49, 64], ["VVL", "TEST", 68, 71], ["Vicia villosa", "ANATOMY", 49, 62], ["Salvia sclarea", "ANATOMY", 82, 96]]], ["Gal-specific agglutinins(1) T, Gal 1 ; 3GalNAc (T , Gal 1 ; 3GalNAc 1 ; the mucin-type sugar sequence on human erythrocyte membrane or T , Gal 1 ; 3GalNAc 1 ; at the terminal non-reducing end of the gangliosides) specific agglutinins -Peanut (PNA), and Bauhinia purpurea alba (BPA).", [["erythrocyte membrane", "ANATOMY", 111, 131], ["BPA", "CHEMICAL", 277, 280], ["sugar", "CHEMICAL", 87, 92], ["Gal-specific agglutinins(1) T", "GENE_OR_GENE_PRODUCT", 0, 29], ["Gal 1", "GENE_OR_GENE_PRODUCT", 31, 36], ["3GalNAc", "GENE_OR_GENE_PRODUCT", 39, 46], ["Gal 1 ; 3GalNAc 1", "GENE_OR_GENE_PRODUCT", 52, 69], ["mucin", "GENE_OR_GENE_PRODUCT", 76, 81], ["human", "ORGANISM", 105, 110], ["erythrocyte membrane", "CELLULAR_COMPONENT", 111, 131], ["Gal 1", "GENE_OR_GENE_PRODUCT", 139, 144], ["3GalNAc 1", "GENE_OR_GENE_PRODUCT", 147, 156], ["Peanut", "GENE_OR_GENE_PRODUCT", 235, 241], ["PNA", "SIMPLE_CHEMICAL", 243, 246], ["Bauhinia purpurea alba", "ORGANISM", 253, 275], ["BPA", "SIMPLE_CHEMICAL", 277, 280], ["Gal-specific agglutinins(1) T", "PROTEIN", 0, 29], ["mucin-type sugar sequence", "PROTEIN", 76, 101], ["human erythrocyte membrane or T , Gal 1", "PROTEIN", 105, 144], ["3GalNAc 1", "PROTEIN", 147, 156], ["terminal non-reducing end", "PROTEIN", 166, 191], ["human", "SPECIES", 105, 110], ["Peanut", "SPECIES", 235, 241], ["Bauhinia purpurea alba", "SPECIES", 253, 275], ["human", "SPECIES", 105, 110], ["Bauhinia purpurea alba", "SPECIES", 253, 275], ["Gal-specific agglutinins", "TEST", 0, 24], ["T", "TEST", 28, 29], ["Gal", "TEST", 31, 34], ["3GalNAc", "TEST", 39, 46], ["Gal", "TEST", 52, 55], ["3GalNAc", "TEST", 60, 67], ["the mucin", "TEST", 72, 81], ["human erythrocyte membrane", "TREATMENT", 105, 131], ["T , Gal", "TREATMENT", 135, 142], ["3GalNAc", "TREATMENT", 147, 154], ["specific agglutinins", "TEST", 213, 233], ["Peanut (PNA)", "TREATMENT", 235, 247], ["Bauhinia purpurea alba (BPA", "TREATMENT", 253, 280]]], ["(2) I/II, Gal 1 ; 3(4)GlcNAc 1 ; (Lacto-N-biose/N-acetyllactosamine) specific agglutinins (Human blood group type I (Gal 1 ; 3GlcNAc) and type II (Gal 1 ; 4GlcNAc) carbohydrate sequences [16] [17] [18] , the disaccharide residues at the non-reducing end of the carbohydrate chains derived from either N-glycosidic or O-glycosidic linkages.) -Ricinus communis agglutinin (RCA 1 ), Datura stramonium (thorn apple, TAA) and wheat germ agglutinin (WGA).", [["Lacto-N-biose/N-acetyllactosamine", "CHEMICAL", 34, 67], ["[16] [17] [18]", "CHEMICAL", 187, 201], ["Gal 1 ; 3(4)GlcNAc", "CHEMICAL", 10, 28], ["(Lacto-N-biose", "CHEMICAL", 33, 47], ["N-acetyllactosamine", "CHEMICAL", 48, 67], ["carbohydrate", "CHEMICAL", 164, 176], ["disaccharide", "CHEMICAL", 208, 220], ["carbohydrate", "CHEMICAL", 261, 273], ["N", "CHEMICAL", 301, 302], ["O", "CHEMICAL", 317, 318], ["Gal 1 ; 3(4)GlcNAc 1", "SIMPLE_CHEMICAL", 10, 30], ["Lacto-N-biose/N-acetyllactosamine", "SIMPLE_CHEMICAL", 34, 67], ["Human", "ORGANISM", 91, 96], ["blood group type I", "GENE_OR_GENE_PRODUCT", 97, 115], ["Gal 1", "GENE_OR_GENE_PRODUCT", 117, 122], ["3GlcNAc", "GENE_OR_GENE_PRODUCT", 125, 132], ["type II", "GENE_OR_GENE_PRODUCT", 138, 145], ["Gal 1", "GENE_OR_GENE_PRODUCT", 147, 152], ["4GlcNAc", "GENE_OR_GENE_PRODUCT", 155, 162], ["[16] [17] [18]", "SIMPLE_CHEMICAL", 187, 201], ["O-glycosidic", "SIMPLE_CHEMICAL", 317, 329], ["Ricinus communis agglutinin", "ORGANISM", 342, 369], ["RCA 1", "ORGANISM", 371, 376], ["Datura stramonium", "ORGANISM", 380, 397], ["thorn apple", "ORGANISM", 399, 410], ["TAA", "ORGANISM", 412, 415], ["wheat germ agglutinin", "GENE_OR_GENE_PRODUCT", 421, 442], ["WGA", "TISSUE", 444, 447], ["N-acetyllactosamine) specific agglutinins", "PROTEIN", 48, 89], ["Human blood group type I (Gal 1 ; 3GlcNAc) and type II (Gal 1 ; 4GlcNAc) carbohydrate sequences", "PROTEIN", 91, 186], ["non-reducing end", "PROTEIN", 237, 253], ["carbohydrate chains", "PROTEIN", 261, 280], ["TAA", "PROTEIN", 412, 415], ["wheat germ agglutinin", "PROTEIN", 421, 442], ["WGA", "PROTEIN", 444, 447], ["Human", "SPECIES", 91, 96], ["Ricinus communis", "SPECIES", 342, 358], ["Datura stramonium", "SPECIES", 380, 397], ["apple", "SPECIES", 405, 410], ["wheat", "SPECIES", 421, 426], ["Ricinus communis", "SPECIES", 342, 358], ["Datura stramonium (thorn apple", "SPECIES", 380, 410], ["wheat", "SPECIES", 421, 426], ["Gal", "TEST", 10, 13], ["GlcNAc", "TEST", 22, 28], ["Lacto", "TEST", 34, 39], ["biose", "TREATMENT", 42, 47], ["acetyllactosamine", "TREATMENT", 50, 67], ["specific agglutinins", "TEST", 69, 89], ["Human blood group type I (Gal", "TREATMENT", 91, 120], ["type II (Gal", "TREATMENT", 138, 150], ["carbohydrate sequences", "TEST", 164, 186], ["the disaccharide residues", "TREATMENT", 204, 229], ["the carbohydrate chains", "TEST", 257, 280], ["Ricinus communis agglutinin (RCA", "TREATMENT", 342, 374], ["Datura stramonium", "TREATMENT", 380, 397], ["wheat germ agglutinin", "PROBLEM", 421, 442], ["germ agglutinin", "OBSERVATION", 427, 442]]], ["(3) B, Gal 1 ; 3Gal (Human blood group B disaccharide-Griffonia (Bandeiraea) simplicifolia B 4 (GSI-B 4 ).", [["blood", "ANATOMY", 27, 32], ["disaccharide", "CHEMICAL", 41, 53], ["Gal 1", "GENE_OR_GENE_PRODUCT", 7, 12], ["3Gal", "GENE_OR_GENE_PRODUCT", 15, 19], ["Human", "ORGANISM", 21, 26], ["blood", "ORGANISM_SUBSTANCE", 27, 32], ["GSI-B 4", "CELL", 96, 103], ["Human", "SPECIES", 21, 26], ["Gal", "TEST", 7, 10], ["Human blood group B disaccharide", "TEST", 21, 53], ["Griffonia", "TEST", 54, 63], ["Bandeiraea", "TEST", 65, 75], ["simplicifolia B", "TEST", 77, 92], ["GSI", "TEST", 96, 99]]], ["(4) E, Gal 1;4Gal, blood group P k active disaccharide -Abrin-a and Mistletoe lectin-I (ML-I).Group III.", [["blood", "ANATOMY", 19, 24], ["disaccharide", "CHEMICAL", 42, 54], ["(4) E", "SIMPLE_CHEMICAL", 0, 5], ["Gal 1;4Gal", "GENE_OR_GENE_PRODUCT", 7, 17], ["blood", "ORGANISM_SUBSTANCE", 19, 24], ["disaccharide -Abrin-a", "SIMPLE_CHEMICAL", 42, 63], ["Mistletoe lectin-I", "GENE_OR_GENE_PRODUCT", 68, 86], ["ML-I", "GENE_OR_GENE_PRODUCT", 88, 92], ["Abrin", "PROTEIN", 56, 61], ["Mistletoe lectin", "PROTEIN", 68, 84], ["I (ML-I", "PROTEIN", 85, 92], ["Gal", "TEST", 7, 10], ["disaccharide", "TEST", 42, 54], ["Abrin", "TEST", 56, 61], ["a and Mistletoe lectin", "TREATMENT", 62, 84]]], ["Man and/or Glc-specific agglutininsMan-linked oligosaccharide-specific agglutinins -Concanavalin ensiformis (Jack bean, ConA) and Lens culinaris (LCA).Group IV.", [["Man", "GENE_OR_GENE_PRODUCT", 0, 3], ["Man-linked oligosaccharide", "SIMPLE_CHEMICAL", 35, 61], ["Concanavalin ensiformis", "SIMPLE_CHEMICAL", 84, 107], ["Jack bean", "ORGANISM", 109, 118], ["ConA", "GENE_OR_GENE_PRODUCT", 120, 124], ["Lens culinaris", "ORGANISM", 130, 144], ["LCA", "MULTI-TISSUE_STRUCTURE", 146, 149], ["ConA", "PROTEIN", 120, 124], ["Man", "SPECIES", 0, 3], ["Man", "SPECIES", 35, 38], ["Concanavalin ensiformis", "SPECIES", 84, 107], ["bean", "SPECIES", 114, 118], ["Lens culinaris", "SPECIES", 130, 144], ["Concanavalin ensiformis", "SPECIES", 84, 107], ["Jack bean", "SPECIES", 109, 118], ["Lens culinaris", "SPECIES", 130, 144], ["Glc-specific agglutinins", "TEST", 11, 35], ["oligosaccharide", "TEST", 46, 61], ["specific agglutinins", "TEST", 62, 82], ["Concanavalin ensiformis", "TREATMENT", 84, 107], ["Group IV", "TREATMENT", 151, 159], ["Lens culinaris", "ANATOMY", 130, 144], ["LCA", "OBSERVATION_MODIFIER", 146, 149]]], ["GlcNAc, and/or Gal 1;4GlcNAc 1;linked specific agglutininsChitin oligosaccharide-specific agglutinins -WGA and Griffonia (Bandeiraea) simplicifolia II (GSA-II).Group V. LFuc-specific agglutinins(1) Monofucosyl-specific agglutinins -Ulex europaeus I (UEA-I) and UEA-II.Group V. LFuc-specific agglutinins(2) Difucosyl-specific agglutinins -Griffonia (Bandeiraea) simplicifolia IV (GSA-IV). ) for Gal-and GalNAc-specific lectins, which are shown in Fig.1 as part of carbohydrate structures, are shown in Fig. 2 and Table 1 .", [["Chitin oligosaccharide", "CHEMICAL", 58, 80], ["Griffonia", "CHEMICAL", 111, 120], ["GlcNAc", "CHEMICAL", 0, 6], ["GlcNAc", "CHEMICAL", 22, 28], ["GalNAc", "CHEMICAL", 402, 408], ["carbohydrate", "CHEMICAL", 463, 475], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 0, 6], ["Gal 1;4GlcNAc 1", "GENE_OR_GENE_PRODUCT", 15, 30], ["Chitin oligosaccharide", "SIMPLE_CHEMICAL", 58, 80], ["Griffonia", "SIMPLE_CHEMICAL", 111, 120], ["simplicifolia II", "ORGANISM", 134, 150], ["GSA-II", "GENE_OR_GENE_PRODUCT", 152, 158], ["Monofucosyl", "GENE_OR_GENE_PRODUCT", 198, 209], ["Ulex europaeus I", "GENE_OR_GENE_PRODUCT", 232, 248], ["UEA-I", "GENE_OR_GENE_PRODUCT", 250, 255], ["UEA-II.", "SIMPLE_CHEMICAL", 261, 268], ["Difucosyl", "SIMPLE_CHEMICAL", 306, 315], ["Griffonia", "SIMPLE_CHEMICAL", 338, 347], ["simplicifolia IV", "ORGANISM", 361, 377], ["Gal", "GENE_OR_GENE_PRODUCT", 394, 397], ["GalNAc", "GENE_OR_GENE_PRODUCT", 402, 408], ["lectins", "GENE_OR_GENE_PRODUCT", 418, 425], ["Gal 1;4GlcNAc 1", "PROTEIN", 15, 30], ["agglutinins", "PROTEIN", 47, 58], ["GSA", "PROTEIN", 152, 155], ["LFuc", "PROTEIN", 169, 173], ["agglutinins(1) Monofucosyl-specific agglutinins", "PROTEIN", 183, 230], ["Ulex europaeus I", "PROTEIN", 232, 248], ["UEA", "PROTEIN", 250, 253], ["I", "PROTEIN", 254, 255], ["UEA", "PROTEIN", 261, 264], ["Gal", "PROTEIN", 394, 397], ["Fig.1", "PROTEIN", 446, 451], ["Griffonia", "SPECIES", 111, 120], ["Bandeiraea) simplicifolia", "SPECIES", 122, 147], ["Ulex europaeus", "SPECIES", 232, 246], ["Ulex europaeus", "SPECIES", 232, 246], ["GlcNAc", "TEST", 0, 6], ["Gal", "TEST", 15, 18], ["GlcNAc", "TEST", 22, 28], ["specific agglutinins", "TEST", 38, 58], ["Chitin oligosaccharide", "TEST", 58, 80], ["specific agglutinins", "TEST", 81, 101], ["WGA", "PROBLEM", 103, 106], ["Griffonia", "TEST", 111, 120], ["Group V. LFuc", "TEST", 160, 173], ["specific agglutinins", "TEST", 174, 194], ["Monofucosyl", "TEST", 198, 209], ["specific agglutinins", "TEST", 210, 230], ["Group V. LFuc", "TEST", 268, 281], ["specific agglutinins", "TEST", 282, 302], ["Difucosyl", "TEST", 306, 315], ["specific agglutinins", "TEST", 316, 336], ["Griffonia", "TEST", 338, 347], ["Gal", "TEST", 394, 397], ["agglutinins", "OBSERVATION", 47, 58]]], ["Most of the lectin F and T determinants are found in glycosphingolipids [12] [13] [14] , and the other determinants are present in mammalian glycoproteins [9, [15] [16] [17] [18] [19] , especially in the human blood group A, B, H, Le a , Le b , and Ii active glycoproteins prepared from human ovarian cyst fluid [15, 18] and salivary glycoproteins [20] .", [["blood", "ANATOMY", 210, 215], ["ovarian cyst fluid", "ANATOMY", 293, 311], ["9, [15] [16] [17] [18] [19]", "CHEMICAL", 156, 183], ["lectin F", "GENE_OR_GENE_PRODUCT", 12, 20], ["T", "GENE_OR_GENE_PRODUCT", 25, 26], ["glycosphingolipids [12] [13] [14]", "SIMPLE_CHEMICAL", 53, 86], ["[15] [16] [17] [18] [19]", "SIMPLE_CHEMICAL", 159, 183], ["human", "ORGANISM", 204, 209], ["blood", "ORGANISM_SUBSTANCE", 210, 215], ["B", "GENE_OR_GENE_PRODUCT", 225, 226], ["H", "GENE_OR_GENE_PRODUCT", 228, 229], ["Le b", "SIMPLE_CHEMICAL", 238, 242], ["Ii", "GENE_OR_GENE_PRODUCT", 249, 251], ["human", "ORGANISM", 287, 292], ["ovarian cyst fluid", "ORGANISM_SUBSTANCE", 293, 311], ["lectin F and T determinants", "PROTEIN", 12, 39], ["mammalian glycoproteins", "PROTEIN", 131, 154], ["Ii active glycoproteins", "PROTEIN", 249, 272], ["human", "SPECIES", 204, 209], ["human", "SPECIES", 287, 292], ["human", "SPECIES", 204, 209], ["human", "SPECIES", 287, 292], ["glycosphingolipids", "TEST", 53, 71], ["B", "TEST", 225, 226], ["Le b", "TEST", 238, 242], ["Ii active glycoproteins", "PROBLEM", 249, 272], ["human ovarian cyst fluid", "TEST", 287, 311], ["salivary glycoproteins", "TREATMENT", 325, 347], ["ovarian", "ANATOMY", 293, 300], ["cyst", "OBSERVATION", 301, 305]]], ["The reactivities of lectin determinants represent a combined result of the binding of individual sugars.", [["sugars", "CHEMICAL", 97, 103], ["lectin", "GENE_OR_GENE_PRODUCT", 20, 26], ["sugars", "SIMPLE_CHEMICAL", 97, 103], ["lectin determinants", "PROTEIN", 20, 39], ["individual sugars", "TEST", 86, 103]]], ["The contribution of each sugar to the binding is not necessarily equal, and is different among lectins, for example, both Amaranthus caudatus (ACL) and PNA are Gal 1;3GalNAc specific [8, 21] .", [["Gal 1;3GalNAc", "CHEMICAL", 160, 173], ["sugar", "CHEMICAL", 25, 30], ["GalNAc", "CHEMICAL", 167, 173], ["sugar", "SIMPLE_CHEMICAL", 25, 30], ["lectins", "GENE_OR_GENE_PRODUCT", 95, 102], ["Amaranthus caudatus", "ORGANISM", 122, 141], ["ACL", "GENE_OR_GENE_PRODUCT", 143, 146], ["PNA", "SIMPLE_CHEMICAL", 152, 155], ["Gal 1;3GalNAc", "GENE_OR_GENE_PRODUCT", 160, 173], ["lectins", "PROTEIN", 95, 102], ["Amaranthus caudatus", "SPECIES", 122, 141], ["Amaranthus caudatus", "SPECIES", 122, 141], ["PNA", "PROBLEM", 152, 155], ["not necessarily", "UNCERTAINTY", 49, 64], ["ACL", "ANATOMY", 143, 146], ["PNA", "OBSERVATION", 152, 155]]], ["However, the inhibitory profile of the monosaccharides with these two lectins is quite different; Figure 2 .", [["monosaccharides", "CHEMICAL", 39, 54], ["monosaccharides", "SIMPLE_CHEMICAL", 39, 54]]], ["Mammalian structural units (lectin determinants) present in glycoconjugates.", [["lectin", "GENE_OR_GENE_PRODUCT", 28, 34], ["Mammalian structural units", "PROTEIN", 0, 26], ["lectin determinants", "PROTEIN", 28, 47], ["Mammalian structural units (lectin determinants", "TREATMENT", 0, 47]]], ["Lectin F determinant is found in glycosphingolipid (the principal glycolipid of mammalian tissues) of the tissues of the guinea pig, horse, cat, and chicken.", [["tissues", "ANATOMY", 90, 97], ["tissues", "ANATOMY", 106, 113], ["horse", "ANATOMY", 133, 138], ["cat", "ANATOMY", 140, 143], ["Lectin F", "GENE_OR_GENE_PRODUCT", 0, 8], ["glycosphingolipid", "SIMPLE_CHEMICAL", 33, 50], ["mammalian tissues", "TISSUE", 80, 97], ["tissues", "TISSUE", 106, 113], ["guinea pig", "ORGANISM", 121, 131], ["horse", "ORGANISM", 133, 138], ["cat", "ORGANISM", 140, 143], ["chicken", "ORGANISM", 149, 156], ["Lectin F determinant", "PROTEIN", 0, 20], ["guinea pig", "SPECIES", 121, 131], ["horse", "SPECIES", 133, 138], ["cat", "SPECIES", 140, 143], ["chicken", "SPECIES", 149, 156], ["guinea pig", "SPECIES", 121, 131], ["chicken", "SPECIES", 149, 156], ["glycosphingolipid", "TREATMENT", 33, 50], ["tissues", "ANATOMY", 106, 113], ["guinea pig", "ANATOMY", 121, 131]]], ["It can also be found on the surface of some bacteria, viruses, human gastric carcinoma, and colon tumors [14, 15, 18, 38] .", [["surface", "ANATOMY", 28, 35], ["gastric carcinoma", "ANATOMY", 69, 86], ["colon tumors", "ANATOMY", 92, 104], ["gastric carcinoma", "DISEASE", 69, 86], ["colon tumors", "DISEASE", 92, 104], ["surface", "CELLULAR_COMPONENT", 28, 35], ["human", "ORGANISM", 63, 68], ["gastric carcinoma", "CANCER", 69, 86], ["colon tumors", "CANCER", 92, 104], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["some bacteria", "PROBLEM", 39, 52], ["viruses", "PROBLEM", 54, 61], ["human gastric carcinoma", "PROBLEM", 63, 86], ["colon tumors", "PROBLEM", 92, 104], ["some", "OBSERVATION_MODIFIER", 39, 43], ["bacteria", "OBSERVATION", 44, 52], ["viruses", "OBSERVATION", 54, 61], ["gastric", "ANATOMY", 69, 76], ["carcinoma", "OBSERVATION", 77, 86], ["colon", "ANATOMY", 92, 97], ["tumors", "OBSERVATION", 98, 104]]], ["All (F, A/A h , B, I/II, T, Tn) determinants are found in human blood groups A, B, H, Le a , Le b , and Ii active glycoconjugates prepared from human ovarian cyst fluid (HOC) [16, 18, 22, 42] .", [["blood", "ANATOMY", 64, 69], ["ovarian cyst fluid", "ANATOMY", 150, 168], ["HOC", "ANATOMY", 170, 173], ["B", "GENE_OR_GENE_PRODUCT", 16, 17], ["T, Tn", "GENE_OR_GENE_PRODUCT", 25, 30], ["human", "ORGANISM", 58, 63], ["blood", "ORGANISM_SUBSTANCE", 64, 69], ["B, H", "SIMPLE_CHEMICAL", 80, 84], ["Le a", "SIMPLE_CHEMICAL", 86, 90], ["Le b", "SIMPLE_CHEMICAL", 93, 97], ["Ii", "GENE_OR_GENE_PRODUCT", 104, 106], ["human", "ORGANISM", 144, 149], ["ovarian cyst fluid", "ORGANISM_SUBSTANCE", 150, 168], ["T", "PROTEIN", 25, 26], ["Tn", "PROTEIN", 28, 30], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 144, 149], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 144, 149], ["human ovarian cyst fluid", "PROBLEM", 144, 168], ["Le", "ANATOMY", 86, 88], ["Le", "ANATOMY", 93, 95], ["ovarian", "ANATOMY", 150, 157], ["cyst", "OBSERVATION", 158, 162]]], ["The Gal 1;3GalNAc group at the non-reducing end of asialo-GM 1 is also considered as a lectin T determinant.", [["Gal 1;3GalNAc", "CHEMICAL", 4, 17], ["GM", "CHEMICAL", 58, 60], ["Gal 1;3GalNAc", "CHEMICAL", 4, 17], ["Gal 1;3GalNAc", "GENE_OR_GENE_PRODUCT", 4, 17], ["asialo-GM 1", "GENE_OR_GENE_PRODUCT", 51, 62], ["lectin T", "GENE_OR_GENE_PRODUCT", 87, 95], ["Gal 1;3GalNAc group", "PROTEIN", 4, 23], ["lectin T determinant", "PROTEIN", 87, 107], ["The Gal 1;3GalNAc group", "TREATMENT", 0, 23], ["Gal", "ANATOMY_MODIFIER", 4, 7]]], ["Determinants of lectins I and II discussed in this article are equivalent to human blood group type I (Lacto-N-biose, Gal 1;3GlcNAc) and type II (N-acetyllactosamine) carbohydrate sequences [39] .", [["blood", "ANATOMY", 83, 88], ["Lacto-N-biose", "CHEMICAL", 103, 116], ["carbohydrate", "CHEMICAL", 167, 179], ["lectins I", "GENE_OR_GENE_PRODUCT", 16, 25], ["human", "ORGANISM", 77, 82], ["blood", "ORGANISM_SUBSTANCE", 83, 88], ["Lacto-N-biose", "SIMPLE_CHEMICAL", 103, 116], ["Gal 1;3GlcNAc", "GENE_OR_GENE_PRODUCT", 118, 131], ["type II (N-acetyllactosamine", "SIMPLE_CHEMICAL", 137, 165], ["lectins I and II", "PROTEIN", 16, 32], ["human blood group type I (Lacto-N-biose, Gal 1;3GlcNAc", "PROTEIN", 77, 131], ["type II (N-acetyllactosamine) carbohydrate sequences", "PROTEIN", 137, 189], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["human blood group type I (Lacto-N-biose, Gal 1;3GlcNAc", "TREATMENT", 77, 131], ["type II (N-acetyllactosamine) carbohydrate sequences", "TREATMENT", 137, 189]]], ["S determinant is found in human TammGroup V. LFuc-specific agglutininsII \u03b2 (1) Gal\u03b21\u2192 3GlcNAc\u03b21\u2192 3Gal\u03b21\u2192 3GlcNAc\u03b21\u2192 3Gal\u03b21\u2192 3GalNAc\u03b11\u2192 Ser or Thr [40, 41] .", [["Ser", "CHEMICAL", 135, 138], ["Thr", "CHEMICAL", 142, 145], ["human", "ORGANISM", 26, 31], ["\u03b2 (1) Gal\u03b21", "GENE_OR_GENE_PRODUCT", 73, 84], ["3Gal\u03b21", "GENE_OR_GENE_PRODUCT", 116, 122], ["3GalNAc\u03b11", "GENE_OR_GENE_PRODUCT", 124, 133], ["Ser", "AMINO_ACID", 135, 138], ["Thr", "AMINO_ACID", 142, 145], ["LFuc", "PROTEIN", 45, 49], ["agglutininsII \u03b2 (1) Gal\u03b21", "PROTEIN", 59, 84], ["\u03b21", "PROTEIN", 93, 95], ["3Gal", "PROTEIN", 97, 101], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["LFuc", "TEST", 45, 49], ["Gal\u03b21", "TEST", 79, 84], ["3GlcNAc", "TEST", 86, 93], ["3GalNAc", "TEST", 124, 131]]], ["C: Chitin disaccharide. (d) Representative carbohydrate chains of blood group glycoprotein from human ovarian cyst fluids.", [["blood", "ANATOMY", 66, 71], ["ovarian cyst fluids", "ANATOMY", 102, 121], ["carbohydrate", "CHEMICAL", 43, 55], ["C: Chitin disaccharide", "SIMPLE_CHEMICAL", 0, 22], ["blood", "ORGANISM_SUBSTANCE", 66, 71], ["human", "ORGANISM", 96, 101], ["ovarian cyst fluids", "ORGANISM_SUBSTANCE", 102, 121], ["carbohydrate chains", "PROTEIN", 43, 62], ["blood group glycoprotein", "PROTEIN", 66, 90], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["Chitin disaccharide", "TREATMENT", 3, 22], ["Representative carbohydrate chains", "TREATMENT", 28, 62], ["blood group glycoprotein", "TREATMENT", 66, 90], ["human ovarian cyst fluids", "TREATMENT", 96, 121], ["Chitin disaccharide", "OBSERVATION", 3, 22], ["ovarian", "ANATOMY", 102, 109], ["cyst", "OBSERVATION", 110, 114]]], ["The four-branched internal structure (I-IV) shown is the representative internal portion of the carbohydrate moiety of blood group substances to which the residues responsible for A, B, H, Le a , and Le b activities are attached.", [["blood", "ANATOMY", 119, 124], ["carbohydrate", "CHEMICAL", 96, 108], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["B", "GENE_OR_GENE_PRODUCT", 183, 184], ["H", "GENE_OR_GENE_PRODUCT", 186, 187], ["Le b", "SIMPLE_CHEMICAL", 200, 204], ["blood group substances", "TREATMENT", 119, 141], ["the residues", "PROBLEM", 151, 163], ["four", "OBSERVATION_MODIFIER", 4, 8], ["branched", "ANATOMY_MODIFIER", 9, 17], ["internal", "ANATOMY_MODIFIER", 18, 26], ["carbohydrate moiety", "OBSERVATION", 96, 115]]], ["This structure represents precursor blood group active glycoproteins [16] and can be prepared by Smith degradation of A, B, H active glycoproteins, purified from human ovarian cyst fluids.", [["blood", "ANATOMY", 36, 41], ["ovarian cyst fluids", "ANATOMY", 168, 187], ["blood", "ORGANISM_SUBSTANCE", 36, 41], ["A", "SIMPLE_CHEMICAL", 118, 119], ["B, H active glycoproteins", "GENE_OR_GENE_PRODUCT", 121, 146], ["human", "ORGANISM", 162, 167], ["ovarian cyst fluids", "ORGANISM_SUBSTANCE", 168, 187], ["B, H active glycoproteins", "PROTEIN", 121, 146], ["human", "SPECIES", 162, 167], ["human", "SPECIES", 162, 167], ["precursor blood group active glycoproteins", "PROBLEM", 26, 68], ["H active glycoproteins", "TREATMENT", 124, 146], ["human ovarian cyst fluids", "TREATMENT", 162, 187], ["ovarian", "ANATOMY", 168, 175], ["cyst", "OBSERVATION", 176, 180]]], ["Numbers in parentheses indicate the site of attachment for the human blood group A, B, H, Le a , and Le b determinants.", [["blood", "ANATOMY", 69, 74], ["human", "ORGANISM", 63, 68], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["B", "GENE_OR_GENE_PRODUCT", 84, 85], ["H", "GENE_OR_GENE_PRODUCT", 87, 88], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["Le", "ANATOMY_MODIFIER", 90, 92]]], ["These determinants as well as the structural units at the non-reducing end are the sources of lectin A/A h , B/B h , I/II, T, and Tn determinants in (a) [9] .", [["lectin", "GENE_OR_GENE_PRODUCT", 94, 100], ["T", "GENE_OR_GENE_PRODUCT", 123, 124], ["Tn", "GENE_OR_GENE_PRODUCT", 130, 132], ["non-reducing end", "PROTEIN", 58, 74], ["lectin A", "PROTEIN", 94, 102], ["B", "PROTEIN", 109, 110], ["I", "PROTEIN", 117, 118], ["II", "PROTEIN", 119, 121], ["T", "PROTEIN", 123, 124], ["Tn determinants", "PROTEIN", 130, 145]]], ["A megalosaccharide of 24 sugars has not been isolated.", [["megalosaccharide of 24 sugars", "CHEMICAL", 2, 31], ["megalosaccharide", "CHEMICAL", 2, 18], ["sugars", "CHEMICAL", 25, 31], ["megalosaccharide", "SIMPLE_CHEMICAL", 2, 18], ["24 sugars", "SIMPLE_CHEMICAL", 22, 31], ["A megalosaccharide of 24 sugars", "TEST", 0, 31]]], ["However, most of the carbohydrate chains isolated are parts of this structure.", [["carbohydrate", "CHEMICAL", 21, 33], ["carbohydrate chains", "GENE_OR_GENE_PRODUCT", 21, 40], ["carbohydrate chains", "PROTEIN", 21, 40], ["carbohydrate chains", "OBSERVATION", 21, 40]]], ["GalNAc\u03fe\u03fe\u03feGal (inactive) in ACL and Gal\u03fe\u03feGalNAc (poor) in PNA.", [["GalNAc\u03fe\u03fe\u03feGal", "CHEMICAL", 0, 12], ["GalNAc\u03fe\u03fe\u03feGal", "CHEMICAL", 0, 12], ["GalNAc\u03fe\u03fe\u03feGal", "SIMPLE_CHEMICAL", 0, 12], ["ACL", "PATHOLOGICAL_FORMATION", 27, 30], ["Gal\u03fe\u03feGalNAc", "SIMPLE_CHEMICAL", 35, 46], ["PNA", "SIMPLE_CHEMICAL", 57, 60], ["GalNAc\u03fe\u03fe\u03feGal", "PROTEIN", 0, 12], ["GalNAc\u03fe\u03fe\u03feGal (inactive) in ACL and Gal\u03fe\u03feGalNAc", "PROBLEM", 0, 46], ["PNA", "PROBLEM", 57, 60], ["inactive", "OBSERVATION_MODIFIER", 14, 22], ["ACL", "ANATOMY", 27, 30], ["Gal\u03fe\u03feGalNAc", "ANATOMY", 35, 46], ["PNA", "OBSERVATION", 57, 60]]], ["Both RCA 120 and WGAs are Gal 1;4GlcNAc 1;6 specific, and the inhibitory profile of the monosaccharide residues with these two lectins is also very different: Gal\u03fe\u03fe\u03feGlcNAc in RCA 120 and GlcNAc 1; \u03fe\u03fe Gal in wheat germ [8, 9] .", [["monosaccharide", "CHEMICAL", 88, 102], ["GlcNAc", "CHEMICAL", 187, 193], ["WGAs", "SIMPLE_CHEMICAL", 17, 21], ["Gal 1;4GlcNAc 1;6", "GENE_OR_GENE_PRODUCT", 26, 43], ["Gal\u03fe\u03fe\u03feGlcNAc", "SIMPLE_CHEMICAL", 159, 171], ["RCA 120", "GENE_OR_GENE_PRODUCT", 175, 182], ["GlcNAc 1", "GENE_OR_GENE_PRODUCT", 187, 195], ["\u03fe\u03fe Gal", "GENE_OR_GENE_PRODUCT", 197, 203], ["RCA 120", "DNA", 5, 12], ["wheat", "SPECIES", 207, 212], ["RCA", "TEST", 5, 8], ["WGAs", "TEST", 17, 21], ["Gal", "TEST", 26, 29], ["the monosaccharide residues", "PROBLEM", 84, 111], ["these two lectins", "TEST", 117, 134], ["Gal\u03fe\u03fe\u03feGlcNAc", "TEST", 159, 171], ["RCA", "TEST", 175, 178], ["GlcNAc", "TEST", 187, 193], ["RCA", "ANATOMY", 5, 8], ["monosaccharide residues", "OBSERVATION", 88, 111], ["RCA", "ANATOMY", 175, 178]]], ["From the data available, expressions of the Gal/GalNAc-specific lectins based on mammalian structural units [8] [9] [10] [11] [22] [23] [24] are shown in Table 2 .Group V. LFuc-specific agglutininsDuring the past two decades, it has been established that many multi-branched oligosaccharides exhibit a significant increase in lectin-binding reactivities as compared to their linear counterparts [25, 26] , \"the glycoside cluster effect\" in mammalian hepatic asialoglycoprotein receptors [25] is one of the important findings in this field.", [["hepatic", "ANATOMY", 450, 457], ["GalNAc", "CHEMICAL", 48, 54], ["Gal", "GENE_OR_GENE_PRODUCT", 44, 47], ["GalNAc", "GENE_OR_GENE_PRODUCT", 48, 54], ["[8] [9] [10] [11] [22] [23] [24]", "SIMPLE_CHEMICAL", 108, 140], ["LFuc", "SIMPLE_CHEMICAL", 172, 176], ["agglutinins", "ORGANISM", 186, 197], ["lectin", "GENE_OR_GENE_PRODUCT", 326, 332], ["Gal/GalNAc-specific lectins", "PROTEIN", 44, 71], ["LFuc", "PROTEIN", 172, 176], ["agglutinins", "PROTEIN", 186, 197], ["lectin", "PROTEIN", 326, 332], ["mammalian hepatic asialoglycoprotein receptors", "PROTEIN", 440, 486], ["the Gal/GalNAc", "TREATMENT", 40, 54], ["mammalian structural units", "TREATMENT", 81, 107], ["Group V. LFuc", "TEST", 163, 176], ["specific agglutinins", "TEST", 177, 197], ["many multi-branched oligosaccharides", "PROBLEM", 255, 291], ["a significant increase in lectin-binding reactivities", "PROBLEM", 300, 353], ["the glycoside cluster effect", "PROBLEM", 407, 435], ["mammalian hepatic asialoglycoprotein receptors", "TREATMENT", 440, 486], ["agglutinins", "OBSERVATION", 186, 197], ["significant", "OBSERVATION_MODIFIER", 302, 313], ["increase", "OBSERVATION_MODIFIER", 314, 322], ["lectin", "OBSERVATION_MODIFIER", 326, 332], ["binding reactivities", "OBSERVATION", 333, 353], ["hepatic", "ANATOMY", 450, 457]]], ["Effect of polyvalencies of glyco-epitopes on the binding of a lectin from the edible mushroom, Agaricus bisporus [27] is another important example, in which the disaccharide II monomer and tri-antennary Gal 1-4GlcNAc (Tri-II) glycopeptides, the major carbohydrate side chains of Pneumococcus type 14 ps, asialo fetuin and asialo human 1 -acid glycoprotein, were poor inhibitors, while their polyvalent carriers were very active, implying that there are other more complicated structural factors involved in binding besides the multi-antennary II sequences.", [["glyco-epitopes", "CHEMICAL", 27, 41], ["Gal 1-4GlcNAc", "CHEMICAL", 203, 216], ["Tri-II", "CHEMICAL", 218, 224], ["disaccharide", "CHEMICAL", 161, 173], ["Gal 1-4GlcNAc", "CHEMICAL", 203, 216], ["carbohydrate", "CHEMICAL", 251, 263], ["glyco-epitopes", "SIMPLE_CHEMICAL", 27, 41], ["lectin", "GENE_OR_GENE_PRODUCT", 62, 68], ["Agaricus bisporus", "ORGANISM", 95, 112], ["tri-antennary Gal 1-4GlcNAc", "SIMPLE_CHEMICAL", 189, 216], ["Tri-II", "GENE_OR_GENE_PRODUCT", 218, 224], ["Pneumococcus type 14", "ORGANISM", 279, 299], ["asialo fetuin", "GENE_OR_GENE_PRODUCT", 304, 317], ["asialo human 1 -acid glycoprotein", "GENE_OR_GENE_PRODUCT", 322, 355], ["lectin", "PROTEIN", 62, 68], ["disaccharide II monomer", "PROTEIN", 161, 184], ["asialo fetuin", "PROTEIN", 304, 317], ["asialo human 1 -acid glycoprotein", "PROTEIN", 322, 355], ["structural factors", "PROTEIN", 476, 494], ["multi-antennary II sequences", "DNA", 527, 555], ["Agaricus bisporus", "SPECIES", 95, 112], ["human", "SPECIES", 329, 334], ["Agaricus bisporus", "SPECIES", 95, 112], ["human", "SPECIES", 329, 334], ["polyvalencies of glyco-epitopes", "PROBLEM", 10, 41], ["tri-antennary Gal", "TREATMENT", 189, 206], ["4GlcNAc (Tri-II) glycopeptides", "TREATMENT", 209, 239], ["the major carbohydrate side chains", "TREATMENT", 241, 275], ["Pneumococcus type 14 ps", "TREATMENT", 279, 302], ["asialo fetuin", "TREATMENT", 304, 317], ["asialo human 1 -acid glycoprotein", "TREATMENT", 322, 355], ["poor inhibitors", "TREATMENT", 362, 377], ["their polyvalent carriers", "TREATMENT", 385, 410], ["edible mushroom", "ANATOMY", 78, 93]]], ["To explain this phenomenon, the present concept of glycoside cluster effect has to be further defined and classified into two groups -(a) the \"Multiantennary or simple glycoside cluster effect\" as in galactosides with hepatic lectin (12) Cyst JS phenol insoluble H LFuc\u03b11\u2192 2 (5), (7), (9), (11) Tighe phenol insoluble LFuc\u03b11\u2192 2 (5), (7), (9) and/or (11) H, Le y H, Le x > Le b and others as in Le a (6) , (8), (12) A 1 or A 2 MSS, nativeGroup V. LFuc-specific agglutininsGalNAc\u03b11\u21923 (1), (2), (3) and/or (4) and others as in MSM H, Le b and Le y Cyst 9Group V. LFuc-specific agglutininsin addition to Cyst 14 (5) to (12) Cyst Beach phenol insoluble B Gal\u03b11\u21923 and Same as H Le b and Le y (1), (2), (3) and/or (4), in addition to (5) to (12) [25, 26] and tri-antennary II with a galectin from chicken liver (CG-16) [28] as well as (b) the \"High-density polyvalent or complex glycoside cluster effect\" as in macromolecular interaction of high-density II cluster containing glycoproteins (Pneumococcus type 14 ps and asialo human 1 -acid glycoproteins) with ABA.", [["liver", "ANATOMY", 798, 803], ["phenol", "CHEMICAL", 246, 252], ["H", "CHEMICAL", 263, 264], ["phenol", "CHEMICAL", 301, 307], ["ABA", "CHEMICAL", 1053, 1056], ["glycoside", "CHEMICAL", 168, 177], ["galactosides", "CHEMICAL", 200, 212], ["phenol", "CHEMICAL", 246, 252], ["H", "CHEMICAL", 263, 264], ["phenol", "CHEMICAL", 301, 307], ["LFuc\u03b11", "CHEMICAL", 318, 324], ["(11) H", "CHEMICAL", 349, 355], ["agglutininsin", "CHEMICAL", 574, 587], ["phenol", "CHEMICAL", 631, 637], ["galactosides", "SIMPLE_CHEMICAL", 200, 212], ["H LFuc\u03b11\u2192 2 (5), (7), (9), (11) Tighe phenol", "SIMPLE_CHEMICAL", 263, 307], ["LFuc\u03b11\u2192 2 (5), (7), (9)", "SIMPLE_CHEMICAL", 318, 341], ["(11) H", "SIMPLE_CHEMICAL", 349, 355], ["Le y H", "SIMPLE_CHEMICAL", 357, 363], ["Le x", "SIMPLE_CHEMICAL", 365, 369], ["Le b", "GENE_OR_GENE_PRODUCT", 372, 376], ["LFuc", "SIMPLE_CHEMICAL", 446, 450], ["GalNAc\u03b11\u21923 (1), (2)", "SIMPLE_CHEMICAL", 471, 490], ["MSM H", "SIMPLE_CHEMICAL", 524, 529], ["Le b", "SIMPLE_CHEMICAL", 531, 535], ["agglutininsin", "GENE_OR_GENE_PRODUCT", 574, 587], ["B Gal\u03b11\u21923", "GENE_OR_GENE_PRODUCT", 648, 657], ["H Le b", "SIMPLE_CHEMICAL", 670, 676], ["Le y (1)", "SIMPLE_CHEMICAL", 681, 689], ["(2)", "SIMPLE_CHEMICAL", 691, 694], ["(4)", "SIMPLE_CHEMICAL", 707, 710], ["(12) [25, 26]", "SIMPLE_CHEMICAL", 734, 747], ["tri-antennary II", "SIMPLE_CHEMICAL", 752, 768], ["galectin", "GENE_OR_GENE_PRODUCT", 776, 784], ["chicken", "ORGANISM", 790, 797], ["liver", "ORGAN", 798, 803], ["human", "ORGANISM", 1019, 1024], ["1 -acid glycoproteins", "GENE_OR_GENE_PRODUCT", 1025, 1046], ["ABA", "SIMPLE_CHEMICAL", 1053, 1056], ["tri-antennary II", "PROTEIN", 752, 768], ["galectin", "PROTEIN", 776, 784], ["high-density II cluster", "PROTEIN", 934, 957], ["glycoproteins", "PROTEIN", 969, 982], ["Pneumococcus type 14 ps and asialo human 1 -acid glycoproteins", "PROTEIN", 984, 1046], ["chicken", "SPECIES", 790, 797], ["human", "SPECIES", 1019, 1024], ["chicken", "SPECIES", 790, 797], ["human", "SPECIES", 1019, 1024], ["this phenomenon", "PROBLEM", 11, 26], ["glycoside cluster effect", "PROBLEM", 51, 75], ["simple glycoside cluster effect", "PROBLEM", 161, 192], ["hepatic lectin", "TEST", 218, 232], ["Cyst JS phenol insoluble", "TEST", 238, 262], ["Tighe phenol insoluble LFuc\u03b11", "TEST", 295, 324], ["Le y H", "TEST", 357, 363], ["LFuc", "TEST", 560, 564], ["Cyst", "TEST", 600, 604], ["Cyst Beach phenol insoluble", "TEST", 620, 647], ["Same as H Le b and Le y", "TEST", 662, 685], ["a galectin", "TEST", 774, 784], ["CG", "TEST", 805, 807], ["the \"High-density polyvalent", "PROBLEM", 832, 860], ["complex glycoside cluster effect", "PROBLEM", 864, 896], ["high-density II cluster containing glycoproteins", "PROBLEM", 934, 982], ["Pneumococcus type 14 ps", "TREATMENT", 984, 1007], ["asialo human 1 -acid glycoproteins", "TREATMENT", 1012, 1046], ["ABA", "PROBLEM", 1053, 1056], ["hepatic", "ANATOMY", 218, 225], ["lectin", "ANATOMY_MODIFIER", 226, 232], ["Le", "ANATOMY", 531, 533], ["Cyst", "OBSERVATION", 600, 604], ["Le", "ANATOMY_MODIFIER", 681, 683], ["liver", "ANATOMY", 798, 803], ["density polyvalent", "OBSERVATION_MODIFIER", 842, 860], ["glycoside cluster", "OBSERVATION_MODIFIER", 872, 889], ["high-density II", "OBSERVATION_MODIFIER", 934, 949]]], ["The clustered glyco-epitopes present on macromolecules generate a great enhancement in affinity with ABA up to 4.7 \u03eb 10 6 times as compared to their monomeric counterparts, and demonstrate the structural importance of complex carbohydrates.Group V. LFuc-specific agglutininsTo obtain a complete description of the carbohydrate specificities of the applied lectins, the following information is suggested to be necessary -(1) monosaccharide specificity (Gal, GalNAc, GlcNAc, and/or Man); (2) expression of reactivities toward mammalian disaccharide structural units or their derivatives (Table 1) in decreasing order ( Table 2) ; (3) the most active ligand; (4) simple multivalent or cluster effect, such as glycopeptides and multi-antennary glyco-epitopes to inhibit binding; (5) complex multivalent or cluster effects present in macromolecules with known glyco-epitopes.", [["ABA", "CHEMICAL", 101, 104], ["carbohydrates", "CHEMICAL", 226, 239], ["carbohydrate", "CHEMICAL", 314, 326], ["monosaccharide", "CHEMICAL", 425, 439], ["Gal", "CHEMICAL", 453, 456], ["GalNAc", "CHEMICAL", 458, 464], ["GlcNAc", "CHEMICAL", 466, 472], ["disaccharide", "CHEMICAL", 535, 547], ["ABA", "SIMPLE_CHEMICAL", 101, 104], ["LFuc", "SIMPLE_CHEMICAL", 249, 253], ["agglutinins", "ORGANISM", 263, 274], ["Gal, GalNAc", "GENE_OR_GENE_PRODUCT", 453, 464], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 466, 472], ["LFuc", "PROTEIN", 249, 253], ["agglutinins", "PROTEIN", 263, 274], ["glyco-epitopes", "PROTEIN", 856, 870], ["a great enhancement in affinity", "PROBLEM", 64, 95], ["ABA", "TEST", 101, 104], ["Group V. LFuc", "TEST", 240, 253], ["specific agglutinins", "TEST", 254, 274], ["GlcNAc", "TREATMENT", 466, 472], ["mammalian disaccharide structural units", "TREATMENT", 525, 564], ["their derivatives (Table", "TREATMENT", 568, 592], ["cluster effect", "PROBLEM", 683, 697], ["glycopeptides", "TREATMENT", 707, 720], ["multi-antennary glyco-epitopes", "TREATMENT", 725, 755], ["known glyco-epitopes", "PROBLEM", 850, 870], ["clustered", "OBSERVATION_MODIFIER", 4, 13], ["glyco-epitopes", "OBSERVATION", 14, 28], ["great", "OBSERVATION_MODIFIER", 66, 71], ["enhancement", "OBSERVATION_MODIFIER", 72, 83], ["agglutinins", "OBSERVATION", 263, 274]]], ["In this report, we illustrate only, as shown in Table 2 , the abilities of mammalian disaccharide structural units or their derivatives to inhibit lectin-glycan binding and express it in decreasing order.", [["disaccharide", "CHEMICAL", 85, 97], ["lectin-glycan", "GENE_OR_GENE_PRODUCT", 147, 160], ["lectin", "PROTEIN", 147, 153], ["mammalian disaccharide structural units", "TREATMENT", 75, 114], ["their derivatives", "TREATMENT", 118, 135], ["lectin-glycan binding", "TREATMENT", 147, 168]]], ["During the past years, many cases of the effect of polyvalency on binding have been found [28] [29] [30] [31] [32] [33] [34] [35] .", [["polyvalency", "CHEMICAL", 51, 62], ["polyvalency", "SIMPLE_CHEMICAL", 51, 62], ["[28] [29] [30] [31] [32] [33] [34] [35]", "SIMPLE_CHEMICAL", 90, 129], ["polyvalency on binding", "PROBLEM", 51, 73]]], ["However, the available data are insufficient to make a solid conclusion, therefore, it is not included in this review.Group V. LFuc-specific agglutininsDue to the multiple reactivity of lectins toward mammalian glyco-epitopes (Table 2 ), the possible existence of different combining sites or subsites in the same molecule has to be examined, and the differential binding properties of these combining sites (if any) have to be characterized.", [["LFuc", "SIMPLE_CHEMICAL", 127, 131], ["agglutinins", "ORGANISM", 141, 152], ["LFuc", "PROTEIN", 127, 131], ["agglutinins", "PROTEIN", 141, 152], ["lectins", "PROTEIN", 186, 193], ["mammalian glyco-epitopes", "PROTEIN", 201, 225], ["Group V. LFuc", "TEST", 118, 131], ["specific agglutinins", "TEST", 132, 152], ["the multiple reactivity of lectins", "PROBLEM", 159, 193], ["different combining sites", "PROBLEM", 264, 289], ["subsites in the same molecule", "PROBLEM", 293, 322], ["agglutinins", "OBSERVATION", 141, 152], ["multiple", "OBSERVATION_MODIFIER", 163, 171], ["reactivity", "OBSERVATION", 172, 182]]], ["Recent advances in characterization, cloning, and structural analysis have allowed us to classify plant lectins into seven families of structurally and evolutionarily related proteins.", [["structural analysis", "TEST", 50, 69], ["evolutionarily related proteins", "PROBLEM", 152, 183]]], ["Within each lectin family the overall profile and structure of the carbohydratebinding site(s) are conserved.", [["lectin", "GENE_OR_GENE_PRODUCT", 12, 18], ["lectin family", "PROTEIN", 12, 25], ["carbohydratebinding site", "DNA", 67, 91]]], ["A closer examination of the carbohydrate specificity further indicates that most plant lectins are not targeted against plant carbohydrates but preferentially bind foreign glycans [36, 37] .", [["carbohydrate", "CHEMICAL", 28, 40], ["carbohydrates", "CHEMICAL", 126, 139], ["lectins", "GENE_OR_GENE_PRODUCT", 87, 94], ["A closer examination", "TEST", 0, 20], ["the carbohydrate specificity", "TEST", 24, 52]]], ["Establishing the relationship between the amino acid sequences of the combining sites of plant lectins and mammalian glyco-epitopes should be an important direction to be addressed in lectinology.Carbohydrate MicroarraysOur laboratories have established a high-throughput biochip platform for constructing carbohydrate microarrays [42] [43] [44] .", [["amino acid", "CHEMICAL", 42, 52], ["amino acid", "CHEMICAL", 42, 52], ["Carbohydrate", "CHEMICAL", 196, 208], ["carbohydrate", "CHEMICAL", 306, 318], ["amino acid", "AMINO_ACID", 42, 52], ["lectins", "GENE_OR_GENE_PRODUCT", 95, 102], ["amino acid sequences", "PROTEIN", 42, 62], ["plant lectins", "PROTEIN", 89, 102], ["the amino acid sequences", "TREATMENT", 38, 62], ["plant lectins", "TREATMENT", 89, 102], ["mammalian glyco-epitopes", "TREATMENT", 107, 131], ["Carbohydrate MicroarraysOur laboratories", "TEST", 196, 236], ["constructing carbohydrate microarrays", "TEST", 293, 330], ["plant lectins", "OBSERVATION", 89, 102]]], ["Using this technology, carbohydratecontaining macromolecules of diverse structures, including polysaccharides, natural glycoconjugates, and mono-and oligosaccharides coupled to carrier molecules, can be stably immobilized on a glass chip without chemical modification.", [["this technology", "TREATMENT", 6, 21], ["carbohydratecontaining macromolecules of diverse structures", "PROBLEM", 23, 82], ["polysaccharides", "TREATMENT", 94, 109], ["natural glycoconjugates", "TREATMENT", 111, 134], ["mono-and oligosaccharides", "TREATMENT", 140, 165], ["a glass chip", "TREATMENT", 225, 237], ["chemical modification", "TREATMENT", 246, 267], ["diverse structures", "OBSERVATION", 64, 82]]], ["This technology takes advantage of existing cDNA microarray system, including spotter and scanner, for an efficient production and application of carbohydrate microarrays.Carbohydrate MicroarraysWe have demonstrated that this current platform is able to overcome a number of expected technical difficulties, by proving that (1) carbohydrate molecules can be immobilized on a nitrocellulose-coated glass slide without chemical conjugation, (2) the immobilized carbohydrates are able to preserve their immunological properties and solvent accessibility, (3) the system reaches the sensitivity, specificity, and capacity to detect a broad range of antibody specificities in clinical specimens, and (4) this technology allows highly sensitive detection, as compared to other existing technologies, of the broad range of carbohydrate-lectin/antibody interactions.Carbohydrate MicroarraysIn this section, we provide a practical protocol for this high-throughput carbohydrate microarray system.", [["specimens", "ANATOMY", 680, 689], ["carbohydrate", "CHEMICAL", 146, 158], ["Carbohydrate", "CHEMICAL", 171, 183], ["carbohydrate", "CHEMICAL", 328, 340], ["nitrocellulose", "CHEMICAL", 375, 389], ["carbohydrates", "CHEMICAL", 459, 472], ["carbohydrate", "CHEMICAL", 816, 828], ["Carbohydrate", "CHEMICAL", 858, 870], ["carbohydrate", "CHEMICAL", 956, 968], ["carbohydrates", "SIMPLE_CHEMICAL", 459, 472], ["carbohydrate-lectin", "GENE_OR_GENE_PRODUCT", 816, 835], ["carbohydrate molecules", "PROTEIN", 328, 350], ["lectin", "PROTEIN", 829, 835], ["existing cDNA microarray system", "TREATMENT", 35, 66], ["carbohydrate microarrays", "TREATMENT", 146, 170], ["Carbohydrate MicroarraysWe", "TREATMENT", 171, 197], ["a nitrocellulose-coated glass slide", "TREATMENT", 373, 408], ["chemical conjugation", "TREATMENT", 417, 437], ["the immobilized carbohydrates", "TREATMENT", 443, 472], ["antibody specificities", "TEST", 645, 667], ["this technology", "TEST", 699, 714], ["lectin/antibody interactions", "TREATMENT", 829, 857], ["Carbohydrate Microarrays", "TREATMENT", 858, 882], ["a practical protocol", "TREATMENT", 910, 930]]], ["We focus on an eight-chamber sub-array system that is in active use in our laboratory's routine carbohydrate research.", [["carbohydrate", "CHEMICAL", 96, 108], ["an eight-chamber sub-array system", "TREATMENT", 12, 45], ["active", "OBSERVATION_MODIFIER", 57, 63]]], ["It is our wish that the readers who have access to a standard cDNA microarray facility would be able to explore this technology for their own carbohydrate research.MethodsThe methods described below outline (1) design and construction of an eightchamber sub-array system for defined purposes, (2) microspotting carbohydratecontaining molecules onto nitrocellulose-coated glass slides, (3) immunostaining and scanning of microarrays, (4) analysis of microarray data, and (5) validation of microarray findings by conventional immunological assays.Design and construction of carbohydrate arraysWe have been applying an eight-chamber sub-array system to construct customized carbohydrate microarrays for defined purposes.", [["carbohydrate", "CHEMICAL", 142, 154], ["nitrocellulose", "CHEMICAL", 349, 363], ["carbohydrate", "CHEMICAL", 572, 584], ["carbohydrate", "CHEMICAL", 671, 683], ["carbohydratecontaining molecules", "PROTEIN", 311, 343], ["a standard cDNA microarray facility", "TREATMENT", 51, 86], ["an eightchamber sub-array system", "TREATMENT", 238, 270], ["microspotting carbohydratecontaining molecules", "TREATMENT", 297, 343], ["nitrocellulose-coated glass slides", "TREATMENT", 349, 383], ["scanning of microarrays", "TEST", 408, 431], ["microarray data", "TEST", 449, 464], ["microarray findings", "TEST", 488, 507], ["conventional immunological assays", "TEST", 511, 544], ["carbohydrate arrays", "TREATMENT", 572, 591], ["an eight-chamber sub-array system", "TREATMENT", 613, 646], ["customized carbohydrate microarrays", "TREATMENT", 660, 695]]], ["As illustrated in Fig. 3 , each microglass slide contains eight separated sub-arrays.", [["each microglass slide", "TREATMENT", 27, 48], ["eight", "OBSERVATION_MODIFIER", 58, 63], ["separated sub", "OBSERVATION_MODIFIER", 64, 77]]], ["The microarray capacity is \u03f3500 microspots per sub-array.", [["The microarray capacity", "TEST", 0, 23]]], ["A single slide is, thus, designed to enable eight microarray assays.", [["eight microarray assays", "TEST", 44, 67]]], ["Similar sub-array designs with various array capacities are commercially available (Schleicher & Schuell, Keene, NH; ArrayIt, Sunnyvale, CA).Design and construction of carbohydrate arrays\u2022 Each microglass slide contains eight sub-arrays of identical content.", [["carbohydrate", "CHEMICAL", 168, 180], ["Similar sub-array designs with various array capacities", "PROBLEM", 0, 55], ["carbohydrate arrays", "TREATMENT", 168, 187], ["Each microglass slide", "TREATMENT", 189, 210], ["various", "OBSERVATION_MODIFIER", 31, 38], ["array capacities", "OBSERVATION", 39, 55], ["eight sub-arrays", "OBSERVATION_MODIFIER", 220, 236], ["identical content", "OBSERVATION", 240, 257]]], ["There is chip space for 500 microspots per sub-array, with spot sizes of \u03f3200 m and at 300 m intervals, center to center.", [["chip space", "PROBLEM", 9, 19], ["chip space", "OBSERVATION", 9, 19]]], ["A single slide is, therefore, designed to enable eight detections. \u2022 Repeats and dilutions: We usually print carbohydrate antigens at the initial concentration of 0.1-0.5 g/ l.", [["carbohydrate", "CHEMICAL", 109, 121], ["carbohydrate antigens", "GENE_OR_GENE_PRODUCT", 109, 130], ["carbohydrate antigens", "PROTEIN", 109, 130]]], ["The absolute amount of antigens printed on chip substrate is in the range of 0.1-0.25 ng per microspot for the highest concentration.", [["antigens", "PROTEIN", 23, 31], ["chip substrate", "TREATMENT", 43, 57], ["absolute", "OBSERVATION_MODIFIER", 4, 12], ["amount", "OBSERVATION_MODIFIER", 13, 19], ["antigens printed", "OBSERVATION", 23, 39]]], ["A given concentration of each preparation is repeated at least three times to allow statistic analysis of detection of identical preparation at given antigen concentration. \u2022 Standard curves: For serological study, we include antibodies of IgG, IgA, and IgM isotype of corresponding species to serve as standard curves in microarray format.", [["IgG", "GENE_OR_GENE_PRODUCT", 240, 243], ["IgA", "GENE_OR_GENE_PRODUCT", 245, 248], ["antibodies", "PROTEIN", 226, 236], ["IgG", "PROTEIN", 240, 243], ["IgA", "PROTEIN", 245, 248], ["IgM isotype", "PROTEIN", 254, 265], ["A given concentration of each preparation", "TREATMENT", 0, 41], ["statistic analysis", "TEST", 84, 102], ["identical preparation", "TREATMENT", 119, 140], ["antigen concentration", "TREATMENT", 150, 171], ["serological study", "TEST", 196, 213], ["antibodies", "TEST", 226, 236], ["IgG", "TEST", 240, 243], ["IgA", "TEST", 245, 248], ["IgM isotype of corresponding species", "PROBLEM", 254, 290]]], ["This design allows quantifying antibody signals that are captured by spotted carbohydrate antigens.", [["carbohydrate", "CHEMICAL", 77, 89], ["carbohydrate antigens", "GENE_OR_GENE_PRODUCT", 77, 98], ["spotted carbohydrate antigens", "PROTEIN", 69, 98], ["quantifying antibody signals", "PROBLEM", 19, 47]]], ["In addition, such standard curves are useful for microarray data normalization and cross-chip scaling of microarray detection.", [["such standard curves", "TEST", 13, 33], ["microarray data normalization", "TEST", 49, 78], ["microarray detection", "TEST", 105, 125]]], ["For lectin study, we spot fluorescent conjugates, such as BSA conjugates of FITC, Cy5, or other dyes, to generate standard curves. \u2022 Adjust program so that carbohydrate antigens are printed at spot sizes of \u03f3150 m and at 300 m intervals, center to center. \u2022 Each antigen or antibody is spotted as triplet replicates in parallel. \u2022 The printed carbohydrate microarrays are air-dried and stored at room temperature (RT) without desiccant before application.Immunostaining of carbohydrate microarraysThe staining procedure for carbohydrate microarrays is basically identical to the routine procedure for immunohistology.", [["FITC", "CHEMICAL", 76, 80], ["carbohydrate", "CHEMICAL", 156, 168], ["carbohydrate", "CHEMICAL", 343, 355], ["carbohydrate", "CHEMICAL", 473, 485], ["carbohydrate", "CHEMICAL", 524, 536], ["lectin", "GENE_OR_GENE_PRODUCT", 4, 10], ["BSA conjugates", "SIMPLE_CHEMICAL", 58, 72], ["FITC", "SIMPLE_CHEMICAL", 76, 80], ["Cy5", "SIMPLE_CHEMICAL", 82, 85], ["carbohydrate antigens", "GENE_OR_GENE_PRODUCT", 156, 177], ["lectin", "PROTEIN", 4, 10], ["carbohydrate antigens", "PROTEIN", 156, 177], ["lectin study", "TEST", 4, 16], ["spot fluorescent conjugates", "TEST", 21, 48], ["FITC, Cy5", "TREATMENT", 76, 85], ["other dyes", "TREATMENT", 90, 100], ["carbohydrate antigens", "TREATMENT", 156, 177], ["Each antigen", "TEST", 258, 270], ["The printed carbohydrate microarrays", "TREATMENT", 331, 367], ["carbohydrate microarrays", "TEST", 473, 497], ["The staining procedure", "TREATMENT", 497, 519], ["carbohydrate microarrays", "TREATMENT", 524, 548], ["the routine procedure", "TREATMENT", 575, 596], ["immunohistology", "TEST", 601, 616], ["carbohydrate microarrays", "OBSERVATION", 343, 367]]], ["Immunostaining steps of carbohydrate arrays are listed below.Immunostaining of carbohydrate microarrays\u2022 Rinse printed microarray slides with 1 \u03eb PBS, pH 7.4 with 0.05% Tween 20 at RT for 5 min. \u2022 Block slides with 1% BSA in PBS containing 0.05% NaN 3 at RT for 30 min.Immunostaining of carbohydrate microarrays\u2022 Stain each sub-array with 50 l of test sample, which is diluted in 1% BSA PBS containing 0.05% NaN 3 and 0.05% Tween 20. \u2022 Incubate the slide in a humidified chamber at RT for 60 min. \u2022 Wash slides by dipping them in washing buffer (1 \u03eb PBS, pH 7.4 with 0.05% Tween 20) five times with at least one-time incubation at RT for 5 min. \u2022 Stain slides with 50 l of titrated secondary antibodies.", [["sample", "ANATOMY", 352, 358], ["BSA", "CHEMICAL", 218, 221], ["NaN", "CHEMICAL", 246, 249], ["NaN", "CHEMICAL", 408, 411], ["carbohydrate", "CHEMICAL", 24, 36], ["carbohydrate", "CHEMICAL", 79, 91], ["Tween 20", "CHEMICAL", 169, 177], ["carbohydrate", "CHEMICAL", 287, 299], ["Tween 20", "CHEMICAL", 424, 432], ["Tween 20", "CHEMICAL", 573, 581], ["BSA", "SIMPLE_CHEMICAL", 218, 221], ["titrated secondary antibodies", "PROTEIN", 673, 702], ["carbohydrate arrays", "TREATMENT", 24, 43], ["carbohydrate microarrays", "TEST", 79, 103], ["1 \u03eb PBS", "TREATMENT", 142, 149], ["pH", "TEST", 151, 153], ["Block slides", "TREATMENT", 197, 209], ["1% BSA in PBS", "TREATMENT", 215, 228], ["carbohydrate microarrays", "TEST", 287, 311], ["test sample", "TEST", 347, 358], ["a humidified chamber at RT", "TREATMENT", 458, 484], ["pH", "TEST", 555, 557], ["Stain slides", "TEST", 647, 659], ["titrated secondary antibodies", "TREATMENT", 673, 702]]], ["Anti-human (or other species) IgG, IgM, or IgA antibodies with distinct fluorescent tags, Cy5, PE or FITC, are mixed and then applied on the chips. \u2022 Incubate the slide in a humidified chamber, protected from light at RT for 30 min. \u2022 Wash slides five times as specified above.Immunostaining of carbohydrate microarrays\u2022 Place slide in a 50 ml falcon centrifuge tube and spin at 1,000 rpm for 5 min to remove washing buffer. \u2022 Cover slides in a histology slide box to prevent fluorescent quenching of signal by light.Microarray scanning, data processing, and statistical analysis\u2022 Scan microarray with ScanArray Microarray Scanner (PerkinElmer Life Science) following the manufacturer's instructions. \u2022 Fluorescence intensity values for each array spot and its background were calculated using Packard Bioscience's QuantArray software analysis packages or the updated ScanArray Express software.", [["FITC", "CHEMICAL", 101, 105], ["carbohydrate", "CHEMICAL", 295, 307], ["IgG", "GENE_OR_GENE_PRODUCT", 30, 33], ["IgM", "GENE_OR_GENE_PRODUCT", 35, 38], ["IgA", "GENE_OR_GENE_PRODUCT", 43, 46], ["Cy5", "SIMPLE_CHEMICAL", 90, 93], ["PE", "SIMPLE_CHEMICAL", 95, 97], ["FITC", "SIMPLE_CHEMICAL", 101, 105], ["Anti-human (or other species) IgG", "PROTEIN", 0, 33], ["IgM", "PROTEIN", 35, 38], ["IgA antibodies", "PROTEIN", 43, 57], ["histology slide box", "DNA", 445, 464], ["Anti-human", "TEST", 0, 10], ["other species", "TEST", 15, 28], ["IgG", "TEST", 30, 33], ["IgM", "TEST", 35, 38], ["IgA antibodies", "TEST", 43, 57], ["fluorescent tags", "TEST", 72, 88], ["PE", "PROBLEM", 95, 97], ["FITC", "PROBLEM", 101, 105], ["the chips", "TREATMENT", 137, 146], ["a humidified chamber", "TREATMENT", 172, 192], ["carbohydrate microarrays", "TEST", 295, 319], ["a 50 ml falcon centrifuge tube", "TREATMENT", 336, 366], ["washing buffer", "TREATMENT", 409, 423], ["a histology slide box", "TREATMENT", 443, 464], ["Microarray scanning", "TEST", 517, 536], ["data processing", "TEST", 538, 553], ["statistical analysis", "TEST", 559, 579], ["Scan microarray", "TEST", 581, 596], ["Fluorescence intensity values", "TEST", 703, 732], ["each array spot", "TEST", 737, 752], ["PE", "OBSERVATION", 95, 97]]], ["A staining result is considered positive if the mean fluorescent intensity value of microspot is significantly higher than the mean background of an identically stained microarray with the same fluorescent color. \u2022 Microarray data processing and statistical analysis: a number of advanced software packages are available for microarray data normalization, statistical analysis, and pattern-recognition-based advanced data-processing (http:// genome-www5.stanford.edu/resources/restech.shtml).", [["A staining result", "TEST", 0, 17], ["the mean fluorescent intensity value", "TEST", 44, 80], ["Microarray data", "TEST", 215, 230], ["statistical analysis", "TEST", 246, 266], ["advanced software packages", "TREATMENT", 280, 306], ["microarray data", "TEST", 325, 340], ["statistical analysis", "TEST", 356, 376], ["significantly", "OBSERVATION_MODIFIER", 97, 110], ["higher", "OBSERVATION_MODIFIER", 111, 117]]], ["We have been using Stanford University's Significance Analysis of Microarrays (SAM, http://www-stat.stanford.edu/\u03f3tibs/SAM/) and SAS Institute's JMP-Genomics, Proteomics, and Microarrays (http://www.jmp.com/).", [["Microarrays", "TEST", 66, 77], ["SAS", "TEST", 129, 132], ["Proteomics", "TREATMENT", 159, 169], ["Microarrays", "TREATMENT", 175, 186]]], ["It is important to conceptually understand the functions of these bioinformatics tools in order to correctly interpret the results.Validation of microarray observationsIt is important to verify microarray findings by other experimental approaches.", [["microarray observations", "TEST", 145, 168]]], ["We usually confirm our results by at least one of the alternative immunoassays, such as ELISA, dot blot, western blot, flow cytometry, or immunohistology.", [["the alternative immunoassays", "TEST", 50, 78], ["ELISA", "TEST", 88, 93], ["dot blot", "TEST", 95, 103], ["western blot", "TEST", 105, 117], ["flow cytometry", "TEST", 119, 133], ["immunohistology", "TEST", 138, 153]]], ["Detailed examples of such investigations have been described in our recent publications [42, 44] .", [["such investigations", "TEST", 21, 40]]], ["However, given the fact that microarray assays are highly sensitive, a positive detection in a microarray may not necessarily be reproduced by other assays that are less sensitive than microarray assays.", [["microarray assays", "TEST", 29, 46], ["a positive detection", "PROBLEM", 69, 89], ["a microarray", "TEST", 93, 105], ["other assays", "TEST", 143, 155], ["microarray assays", "TEST", 185, 202]]], ["Under such circumstances, we usually repeat the detection by microarray assays to confirm the reproducibility of a positive result.", [["the detection", "TEST", 44, 57], ["microarray assays", "TEST", 61, 78], ["a positive result", "PROBLEM", 113, 130]]], ["The most important validation is, however, to further characterize the molecular targets that are discovered or suggested by microarray assays in a relevant biological system.", [["microarray assays", "TEST", 125, 142], ["most important", "OBSERVATION_MODIFIER", 4, 18]]], ["This is discussed in the subsequent section.Exploring Lectin-Binding Profiles Using Carbohydrate MicroarraysCarbohydrate microarrays share the technical advantages of miniaturized multiplex binding assays [45] [46] [47] [48] [49] [50] [51] .", [["Carbohydrate", "CHEMICAL", 84, 96], ["[45] [46] [47] [48] [49] [50] [51]", "SIMPLE_CHEMICAL", 205, 239], ["Carbohydrate MicroarraysCarbohydrate microarrays", "TREATMENT", 84, 132], ["miniaturized multiplex binding assays", "TEST", 167, 204]]], ["It is suitable for displaying a diverse panel of carbohydrates in a limited amount of chip space.", [["carbohydrates", "CHEMICAL", 49, 62], ["chip space", "OBSERVATION", 86, 96]]], ["It is \"economical\" in using carbohydrates since each saccharide is spotted on a microarray substrate in an amount (approximately sub-nanograms) that is drastically smaller than that which is required for conventional molecular or immunological assays (approximately submicrograms or more).", [["carbohydrates", "CHEMICAL", 28, 41], ["saccharide", "CHEMICAL", 53, 63], ["carbohydrates", "SIMPLE_CHEMICAL", 28, 41], ["a microarray substrate", "PROBLEM", 78, 100], ["immunological assays", "TEST", 230, 250], ["amount", "OBSERVATION_MODIFIER", 107, 113], ["drastically", "OBSERVATION_MODIFIER", 152, 163], ["smaller", "OBSERVATION_MODIFIER", 164, 171]]], ["Its detection sensitivity is also higher than many conventional molecular and immunological assays [43, 45, 48] , which is an intrinsic property of the microarray-based miniaturized assays.", [["Its detection sensitivity", "TEST", 0, 25], ["immunological assays", "TEST", 78, 98], ["the microarray", "TEST", 148, 162]]], ["Theoretically, the improved detection sensitivity can be attributed to the fact that the binding in a microarray assay meets the so-called \"ambient analyte condition\" [45] .", [["the binding", "PROBLEM", 85, 96], ["a microarray assay", "TEST", 100, 118]]], ["A key factor for achieving this assay condition is the use of \"tiny\" amounts of carbohydrate ligand in microarrays.", [["carbohydrate", "CHEMICAL", 80, 92], ["carbohydrate ligand", "GENE_OR_GENE_PRODUCT", 80, 99], ["carbohydrate ligand", "PROTEIN", 80, 99], ["this assay condition", "PROBLEM", 27, 47], ["carbohydrate ligand in microarrays", "TREATMENT", 80, 114]]], ["For the microarray platform we discuss here, only sub-nanogram amounts of carbohydrates are immobilized in the microarray substrate.", [["carbohydrates", "CHEMICAL", 74, 87], ["carbohydrates", "SIMPLE_CHEMICAL", 74, 87], ["the microarray platform", "TEST", 4, 27], ["sub-nanogram amounts of carbohydrates", "TREATMENT", 50, 87]]], ["Binding to these miniaturized carbohydrate spots has no or minimum reduction of the concentration of lectins in the solution phase.", [["carbohydrate", "CHEMICAL", 30, 42]]], ["Under such conditions, the carbohydrate-lectin interactions reach equilibrium rapidly and result in highly sensitive detection of lectins or anti-carbohydrate antibodies.Exploring Lectin-Binding Profiles Using Carbohydrate MicroarraysThus, carbohydrate microarray is, in principle, well suited for measuring the relative binding reactivities of lectins with a spectrum of diverse carbohydrate structures.", [["carbohydrate", "CHEMICAL", 27, 39], ["Carbohydrate", "CHEMICAL", 210, 222], ["carbohydrate", "CHEMICAL", 240, 252], ["carbohydrate", "CHEMICAL", 380, 392], ["lectin", "GENE_OR_GENE_PRODUCT", 40, 46], ["lectins", "GENE_OR_GENE_PRODUCT", 130, 137], ["anti-carbohydrate antibodies", "GENE_OR_GENE_PRODUCT", 141, 169], ["lectins", "GENE_OR_GENE_PRODUCT", 345, 352], ["lectin", "PROTEIN", 40, 46], ["lectins", "PROTEIN", 130, 137], ["anti-carbohydrate antibodies", "PROTEIN", 141, 169], ["lectins", "PROTEIN", 345, 352], ["lectins or anti-carbohydrate antibodies", "PROBLEM", 130, 169], ["Carbohydrate Microarrays", "TREATMENT", 210, 234], ["carbohydrate microarray", "TEST", 240, 263]]], ["A few specific examples are discussed below to illustrate its application in lectin characterization.Visualizing carbohydrate-binding profiles using carbohydrate arraysAs summarized in Section 2, the binding property of a lectin is expressed as its specific or selective reactivity with a number of glyco-epitopes that share various degrees of structural similarities or antigenic cross-reactivities.", [["carbohydrate", "CHEMICAL", 113, 125], ["carbohydrate", "CHEMICAL", 149, 161], ["lectin", "GENE_OR_GENE_PRODUCT", 77, 83], ["lectin", "GENE_OR_GENE_PRODUCT", 222, 228], ["lectin", "PROTEIN", 77, 83], ["lectin", "PROTEIN", 222, 228], ["lectin characterization", "TEST", 77, 100], ["carbohydrate arrays", "TREATMENT", 149, 168], ["glyco-epitopes", "TREATMENT", 299, 313]]], ["For examples, PHA-L and GS-I are Gal/GalNAc-specific lectins but have significant differences in their fine specificities ( Table 2 ).", [["PHA", "CHEMICAL", 14, 17], ["GalNAc", "CHEMICAL", 37, 43], ["PHA-L", "SIMPLE_CHEMICAL", 14, 19], ["GS-I", "GENE_OR_GENE_PRODUCT", 24, 28], ["Gal/GalNAc", "GENE_OR_GENE_PRODUCT", 33, 43], ["PHA", "PROTEIN", 14, 17], ["GS", "PROTEIN", 24, 26], ["Gal/GalNAc-specific lectins", "PROTEIN", 33, 60], ["examples", "TEST", 4, 12], ["PHA", "TEST", 14, 17], ["GS", "TEST", 24, 26], ["Gal/GalNAc", "TEST", 33, 43], ["significant", "OBSERVATION_MODIFIER", 70, 81], ["differences", "OBSERVATION_MODIFIER", 82, 93]]], ["The binding property of PHA-L is expressed as \"Tri-II and mII clusters \u03fe Penta-2,6 \u03fe Tri-2,6 \u03fe Hepta-3,6 \u03fe II \u03fe GlcNAc 1,2Man\".", [["PHA", "CHEMICAL", 24, 27], ["mII", "CHEMICAL", 58, 61], ["Penta-2,6 \u03fe Tri-2,6 \u03fe Hepta-3,6 \u03fe II", "CHEMICAL", 73, 109], ["GlcNAc", "CHEMICAL", 112, 118], ["PHA-L", "SIMPLE_CHEMICAL", 24, 29], ["Penta-2,6 \u03fe Tri-2,6 \u03fe Hepta-3,6 \u03fe II \u03fe GlcNAc 1,2Man", "SIMPLE_CHEMICAL", 73, 125], ["PHA", "PROTEIN", 24, 27], ["Tri-II", "PROTEIN", 47, 53], ["Penta", "TEST", 73, 78], ["Tri", "TEST", 85, 88], ["Hepta", "TEST", 95, 100]]], ["The specificity of GS-IA 4 is defined as \"F penta-\u03fe A h (GalNAc 1;2 (LFuc 1;3)Gal) \u03fe GalNAc \u03fe E \u03fe B \u03fe I, T \u03fe L, II; GSI-B 4 isolectin defined as \"B \u03fe E \u03fe A\" ( Table 2) .", [["GalNAc 1;2 (LFuc 1;3)Gal) \u03fe GalNAc \u03fe E \u03fe B \u03fe I, T \u03fe L, II; GSI-B", "CHEMICAL", 57, 121], ["GS-IA 4", "GENE_OR_GENE_PRODUCT", 19, 26], ["GalNAc 1;2 (LFuc 1;3)Gal) \u03fe GalNAc \u03fe E", "SIMPLE_CHEMICAL", 57, 95], ["T \u03fe L", "SIMPLE_CHEMICAL", 105, 110], ["GSI-B 4 isolectin", "SIMPLE_CHEMICAL", 116, 133], ["The specificity", "TEST", 0, 15], ["GS", "TEST", 19, 21], ["penta", "TEST", 44, 49], ["GalNAc", "TEST", 57, 63], ["LFuc", "TEST", 69, 73], ["Gal", "TEST", 78, 81], ["GalNAc", "TEST", 85, 91], ["GSI", "TEST", 116, 119], ["isolectin", "TEST", 124, 133]]], ["These lectins may serve as good models for testing the potential of microarray technology in lectin characterization.", [["lectin", "GENE_OR_GENE_PRODUCT", 93, 99], ["lectin", "PROTEIN", 93, 99], ["microarray technology", "TEST", 68, 89], ["lectin characterization", "TEST", 93, 116]]], ["Therefore, we constructed a carbohydrate array to display a panel of 22 Gal/GalNAc-containing glycoconjugates for a \"proof-of-concept\" study.", [["carbohydrate", "CHEMICAL", 28, 40], ["GalNAc", "CHEMICAL", 76, 82], ["Gal", "GENE_OR_GENE_PRODUCT", 72, 75], ["GalNAc", "GENE_OR_GENE_PRODUCT", 76, 82], ["a carbohydrate array", "TEST", 26, 46], ["a panel", "TEST", 58, 65], ["Gal/GalNAc", "TREATMENT", 72, 82], ["glycoconjugates", "TREATMENT", 94, 109]]], ["The eight-chamber sub-array system described in the Section 3 above was applied to produce this carbohydrate array.", [["carbohydrate", "CHEMICAL", 96, 108], ["eight", "OBSERVATION_MODIFIER", 4, 9], ["-chamber", "OBSERVATION_MODIFIER", 9, 17]]], ["Each of carbohydrate preparations were spotted in four dilutions and with triplicate microspots for each dilution.", [["carbohydrate", "CHEMICAL", 8, 20], ["carbohydrate preparations", "TREATMENT", 8, 33]]], ["This design is helpful for the quantitation and statistical analysis of microarray results.", [["the quantitation", "TEST", 27, 43], ["statistical analysis", "TEST", 48, 68], ["microarray results", "TEST", 72, 90]]], ["It also facilitates the graphical presentation or visualization of the binding profiles of lectins.Visualizing carbohydrate-binding profiles using carbohydrate arraysWe assumed that if this microarray platform reached the sensitivity for measuring the lectin binding and if it reflected well the results of conventional binding assays, we would expect to visualize the lectin-binding profiles by glycan arrays.", [["carbohydrate", "CHEMICAL", 111, 123], ["carbohydrate", "CHEMICAL", 147, 159], ["lectins", "GENE_OR_GENE_PRODUCT", 91, 98], ["lectin", "GENE_OR_GENE_PRODUCT", 252, 258], ["lectin", "GENE_OR_GENE_PRODUCT", 369, 375], ["lectins", "PROTEIN", 91, 98], ["lectin", "PROTEIN", 252, 258], ["lectin", "PROTEIN", 369, 375], ["carbohydrate arrays", "TREATMENT", 147, 166], ["this microarray platform", "TEST", 185, 209], ["the lectin binding", "PROBLEM", 248, 266], ["conventional binding assays", "TEST", 307, 334]]], ["We applied lectin PHA-L and GS-I at 0.5 g/ml for microarray staining, which is a titrated condition for cell or tissue section staining using these reagents [44] .", [["cell", "ANATOMY", 104, 108], ["tissue section", "ANATOMY", 112, 126], ["PHA-L", "GENE_OR_GENE_PRODUCT", 18, 23], ["GS-I", "GENE_OR_GENE_PRODUCT", 28, 32], ["cell", "CELL", 104, 108], ["tissue", "TISSUE", 112, 118], ["lectin PHA-L and GS-I", "PROTEIN", 11, 32], ["lectin PHA", "TREATMENT", 11, 21], ["GS-I", "TREATMENT", 28, 32], ["microarray staining", "PROBLEM", 49, 68], ["cell or tissue section staining", "TREATMENT", 104, 135], ["these reagents", "TEST", 142, 156]]], ["The images of the stained microarrays are shown in Fig. 4 (I and II) for lectin PHA-L and GS-I, respectively.", [["lectin", "GENE_OR_GENE_PRODUCT", 73, 79], ["PHA-L", "SIMPLE_CHEMICAL", 80, 85], ["GS-I", "GENE_OR_GENE_PRODUCT", 90, 94], ["lectin", "PROTEIN", 73, 79], ["PHA", "PROTEIN", 80, 83], ["L", "PROTEIN", 84, 85], ["GS", "PROTEIN", 90, 92], ["The images", "TEST", 0, 10], ["the stained microarrays", "TEST", 14, 37], ["lectin PHA", "TEST", 73, 83]]], ["The content and location of carbohydrates are listed in the table under the microarray images.", [["carbohydrates", "CHEMICAL", 28, 41], ["carbohydrates", "SIMPLE_CHEMICAL", 28, 41], ["carbohydrates", "TREATMENT", 28, 41], ["the microarray images", "TEST", 72, 93], ["content", "OBSERVATION_MODIFIER", 4, 11]]], ["A dye marker (Cy5 conjugate) was spotted in triplicates at the bottom right corner of each array.Visualizing carbohydrate-binding profiles using carbohydrate arraysThis assay shows clearly that PHA-L is highly specific for asialoorosomucoid (ASOR) (array location C3) that expresses glyco-epitopes Tri-II and mII.", [["PHA", "CHEMICAL", 194, 197], ["carbohydrate", "CHEMICAL", 109, 121], ["carbohydrate", "CHEMICAL", 145, 157], ["Cy5 conjugate", "SIMPLE_CHEMICAL", 14, 27], ["PHA-L", "GENE_OR_GENE_PRODUCT", 194, 199], ["asialoorosomucoid", "SIMPLE_CHEMICAL", 223, 240], ["glyco-epitopes Tri-II", "GENE_OR_GENE_PRODUCT", 283, 304], ["mII", "GENE_OR_GENE_PRODUCT", 309, 312], ["PHA", "PROTEIN", 194, 197], ["glyco-epitopes", "PROTEIN", 283, 297], ["Tri-II", "PROTEIN", 298, 304], ["mII", "PROTEIN", 309, 312], ["A dye marker (Cy5 conjugate", "TREATMENT", 0, 27], ["carbohydrate arrays", "TREATMENT", 145, 164], ["This assay", "TEST", 164, 174], ["PHA", "TEST", 194, 197], ["asialoorosomucoid (ASOR)", "PROBLEM", 223, 247], ["bottom", "ANATOMY_MODIFIER", 63, 69], ["right", "ANATOMY_MODIFIER", 70, 75], ["corner", "ANATOMY_MODIFIER", 76, 82]]], ["Given that PHA-L has no staining of AGOR (array location A4), which is a D-galactose derivative of ASOR, the terminal non-reducing end Gal-residues are likely key elements for the specificities.", [["PHA", "CHEMICAL", 11, 14], ["D-galactose", "CHEMICAL", 73, 84], ["D-galactose", "CHEMICAL", 73, 84], ["PHA-L", "GENE_OR_GENE_PRODUCT", 11, 16], ["AGOR", "GENE_OR_GENE_PRODUCT", 36, 40], ["array location A4", "GENE_OR_GENE_PRODUCT", 42, 59], ["D-galactose", "SIMPLE_CHEMICAL", 73, 84], ["ASOR", "SIMPLE_CHEMICAL", 99, 103], ["PHA", "PROTEIN", 11, 14], ["AGOR", "PROTEIN", 36, 40], ["ASOR", "PROTEIN", 99, 103], ["terminal non-reducing end Gal-residues", "PROTEIN", 109, 147], ["PHA", "TEST", 11, 14], ["staining of AGOR", "PROBLEM", 24, 40], ["ASOR", "TREATMENT", 99, 103], ["the terminal non-reducing end Gal-residues", "PROBLEM", 105, 147], ["no", "UNCERTAINTY", 21, 23], ["staining", "OBSERVATION_MODIFIER", 24, 32]]], ["In striking contrast to the highly selective binding of PHA-L, lectin GS-I shows a broad spectrum of carbohydrate-binding activities.", [["PHA", "CHEMICAL", 56, 59], ["carbohydrate", "CHEMICAL", 101, 113], ["PHA-L", "GENE_OR_GENE_PRODUCT", 56, 61], ["lectin", "GENE_OR_GENE_PRODUCT", 63, 69], ["GS-I", "GENE_OR_GENE_PRODUCT", 70, 74], ["carbohydrate", "SIMPLE_CHEMICAL", 101, 113], ["PHA", "PROTEIN", 56, 59], ["L", "PROTEIN", 60, 61], ["lectin GS-I", "PROTEIN", 63, 74], ["PHA", "TEST", 56, 59], ["lectin GS", "TEST", 63, 72]]], ["It is reactive with seven different Gal/GalNAc-containing glycoconjugates.", [["GalNAc", "CHEMICAL", 40, 46], ["Gal/GalNAc", "GENE_OR_GENE_PRODUCT", 36, 46], ["reactive", "OBSERVATION_MODIFIER", 6, 14], ["GalNAc", "ANATOMY_MODIFIER", 40, 46]]], ["They are Tn-HAS, Asialo-PSM, B-dimer-BSA, Asialo-OSM, Beach OH, Tij20%fr.", [["OH", "CHEMICAL", 60, 62], ["Tn-HAS", "SIMPLE_CHEMICAL", 9, 15], ["Asialo-PSM", "SIMPLE_CHEMICAL", 17, 27], ["B-dimer-BSA", "SIMPLE_CHEMICAL", 29, 40], ["Asialo-OSM", "SIMPLE_CHEMICAL", 42, 52], ["Beach OH", "SIMPLE_CHEMICAL", 54, 62], ["Tn", "PROTEIN", 9, 11], ["B", "PROTEIN", 29, 30], ["dimer", "PROTEIN", 31, 36], ["OSM", "PROTEIN", 49, 52], ["Tn", "TEST", 9, 11], ["Asialo", "TEST", 17, 23], ["PSM", "TEST", 24, 27], ["BSA", "TEST", 37, 40], ["Asialo", "TEST", 42, 48]]], ["2nd 10%, and Beach P1 OH insoluble.", [["OH", "CHEMICAL", 22, 24]]], ["These carbohydrate preparations display a number of well-characterized glyco-epitopes, including Tn, T, I, i, B, and Bh.Visualizing carbohydrate-binding profiles using carbohydrate arraysIt is interesting to compare the microarray-binding profile of GS-I with the specificities of its isolectins.", [["carbohydrate", "CHEMICAL", 6, 18], ["carbohydrate", "CHEMICAL", 132, 144], ["carbohydrate", "CHEMICAL", 168, 180], ["Tn", "GENE_OR_GENE_PRODUCT", 97, 99], ["T", "GENE_OR_GENE_PRODUCT", 101, 102], ["B", "GENE_OR_GENE_PRODUCT", 110, 111], ["GS-I", "GENE_OR_GENE_PRODUCT", 250, 254], ["isolectins", "GENE_OR_GENE_PRODUCT", 285, 295], ["glyco-epitopes", "PROTEIN", 71, 85], ["Tn", "PROTEIN", 97, 99], ["T", "PROTEIN", 101, 102], ["B", "PROTEIN", 110, 111], ["GS-I", "PROTEIN", 250, 254], ["isolectins", "PROTEIN", 285, 295], ["Tn", "TEST", 97, 99], ["carbohydrate arrays", "TREATMENT", 168, 187], ["the microarray", "TEST", 216, 230]]], ["GS-I is known as a tetramer consisting of subunit A and subunit B in different ratios.", [["GS-I", "GENE_OR_GENE_PRODUCT", 0, 4], ["subunit A", "GENE_OR_GENE_PRODUCT", 42, 51], ["subunit B", "GENE_OR_GENE_PRODUCT", 56, 65], ["GS-I", "PROTEIN", 0, 4], ["subunit A", "PROTEIN", 42, 51], ["subunit B", "PROTEIN", 56, 65], ["a tetramer", "TREATMENT", 17, 27]]], ["GS-IA 4 and GS-IB 4 have equal binding affinity for -galactose end groups.", [["galactose", "CHEMICAL", 53, 62], ["GS-IA 4", "GENE_OR_GENE_PRODUCT", 0, 7], ["GS-IB 4", "GENE_OR_GENE_PRODUCT", 12, 19], ["IB 4", "PROTEIN", 15, 19], ["GS", "TEST", 0, 2], ["GS", "TEST", 12, 14]]], ["However, the A 4 isolectin has a greater affinity for -GalNAc than the B 4 isoform.", [["GalNAc", "CHEMICAL", 55, 61], ["A 4 isolectin", "GENE_OR_GENE_PRODUCT", 13, 26], ["-GalNAc", "GENE_OR_GENE_PRODUCT", 54, 61], ["B 4", "GENE_OR_GENE_PRODUCT", 71, 74], ["A 4 isolectin", "PROTEIN", 13, 26], ["B 4 isoform", "PROTEIN", 71, 82]]], ["The natural product of GS-I is a mixture of the five isolectins, A 4 , A 1 B 3 , A 2 B 2 , A 3 B 1 , and B 4 .", [["isolectins, A 4 , A 1 B 3 , A 2 B 2 , A 3 B 1 , and B", "CHEMICAL", 53, 106], ["GS-I", "GENE_OR_GENE_PRODUCT", 23, 27], ["A 1 B 3", "ORGANISM", 71, 78], ["A 3 B 1", "GENE_OR_GENE_PRODUCT", 91, 98], ["B 4", "CELL", 105, 108]]], ["Such molecular diversification may extend the spectrum of carbohydrate-binding profile of GS-I.Visualizing carbohydrate-binding profiles using carbohydrate arraysSome but not all the GS-I reactivities detected by microarray assay can be directly attributed to its subunit A and B specificities that were determined by previous studies.", [["carbohydrate", "CHEMICAL", 58, 70], ["carbohydrate", "CHEMICAL", 107, 119], ["carbohydrate", "CHEMICAL", 143, 155], ["GS-I", "GENE_OR_GENE_PRODUCT", 183, 187], ["B", "GENE_OR_GENE_PRODUCT", 278, 279], ["subunit A", "PROTEIN", 264, 273], ["Such molecular diversification", "PROBLEM", 0, 30], ["carbohydrate arrays", "TREATMENT", 143, 162], ["microarray assay", "TEST", 213, 229], ["previous studies", "TEST", 318, 334], ["diversification", "OBSERVATION", 15, 30]]], ["For example, its binding to Tn-containing carbohydrates (location C1 and C2) reflects the affinity of A subunit for -GalNAc.", [["Tn-", "CHEMICAL", 28, 31], ["Tn-", "CHEMICAL", 28, 31], ["carbohydrates", "CHEMICAL", 42, 55], ["GalNAc", "CHEMICAL", 117, 123], ["Tn-", "GENE_OR_GENE_PRODUCT", 28, 31], ["-GalNAc", "GENE_OR_GENE_PRODUCT", 116, 123], ["C2", "PROTEIN", 73, 75], ["A subunit", "PROTEIN", 102, 111], ["C2", "ANATOMY", 73, 75]]], ["Both A and B subunits are likely responsible for the binding to the terminal Gal in B, T, I, and i glyco-epitopes.", [["A", "GENE_OR_GENE_PRODUCT", 5, 6], ["B subunits", "GENE_OR_GENE_PRODUCT", 11, 21], ["Gal", "GENE_OR_GENE_PRODUCT", 77, 80], ["B", "GENE_OR_GENE_PRODUCT", 84, 85], ["T", "GENE_OR_GENE_PRODUCT", 87, 88], ["A and B subunits", "PROTEIN", 5, 21], ["terminal Gal", "PROTEIN", 68, 80], ["B, T, I, and i glyco-epitopes", "PROTEIN", 84, 113], ["A and B subunits", "TREATMENT", 5, 21], ["the binding", "PROBLEM", 49, 60], ["likely responsible for", "UNCERTAINTY", 26, 48]]], ["However, this preparation of GS-I has no binding to cyst 9 (blood group A/location B 4 ) and Hog 4 (blood group A/location D 4 ).", [["cyst", "ANATOMY", 52, 56], ["blood", "ANATOMY", 60, 65], ["blood", "ANATOMY", 100, 105], ["GS-I", "CHEMICAL", 29, 33], ["GS-I", "GENE_OR_GENE_PRODUCT", 29, 33], ["blood", "ORGANISM_SUBSTANCE", 60, 65], ["Hog 4", "GENE_OR_GENE_PRODUCT", 93, 98], ["blood", "ORGANISM_SUBSTANCE", 100, 105], ["Hog 4", "PROTEIN", 93, 98], ["binding to cyst", "PROBLEM", 41, 56], ["cyst", "OBSERVATION", 52, 56]]], ["This is unexpected given that its A subunit is specific for the A-glyco-epitopes.", [["A-glyco-epitopes", "PROTEIN", 64, 80], ["the A-glyco-epitopes", "TREATMENT", 60, 80]]], ["It is also 186 D. Wangand A.M. Wunot clear why this lectin is strongly reactive with asialo-OSM that displays T-glyco-epitopes but is completely negative to T-HAS.", [["lectin", "GENE_OR_GENE_PRODUCT", 52, 58], ["asialo-OSM", "GENE_OR_GENE_PRODUCT", 85, 95], ["T-HAS", "GENE_OR_GENE_PRODUCT", 157, 162], ["lectin", "PROTEIN", 52, 58], ["asialo", "PROTEIN", 85, 91], ["OSM", "PROTEIN", 92, 95], ["T-glyco-epitopes", "PROTEIN", 110, 126], ["this lectin", "TEST", 47, 58], ["asialo-OSM", "TEST", 85, 95], ["T-glyco-epitopes", "PROBLEM", 110, 126], ["reactive", "OBSERVATION_MODIFIER", 71, 79]]], ["A possible interpretation of this result is that asialo-OSM displays the T-glyco-epitopes in a specific cluster configuration that substantially facilitates the binding to GS-I.", [["asialo-OSM", "GENE_OR_GENE_PRODUCT", 49, 59], ["OSM", "PROTEIN", 56, 59], ["T-glyco-epitopes", "PROTEIN", 73, 89], ["asialo", "TEST", 49, 55], ["OSM", "TEST", 56, 59], ["the T", "TEST", 69, 74]]], ["By contrast, the T-glyco-epitopes of T-HAS are in the unfavorable configuration for GS-I.", [["T-HAS", "GENE_OR_GENE_PRODUCT", 37, 42], ["T-glyco-epitopes", "PROTEIN", 17, 33], ["T-HAS", "PROTEIN", 37, 42], ["the T", "TEST", 13, 18], ["GS", "TEST", 84, 86]]], ["It is important to further characterize the specificities of individual GS-I isolectins (A 4 , A 1 B 3 , A 2 B 2 , A 3 B 1 , and B 4 ).", [["GS-I isolectins", "GENE_OR_GENE_PRODUCT", 72, 87], ["A 1 B 3", "ORGANISM", 95, 102], ["A 2 B", "ORGANISM", 105, 110], ["A 3 B 1", "GENE_OR_GENE_PRODUCT", 115, 122], ["B 4", "GENE_OR_GENE_PRODUCT", 129, 132], ["I isolectins", "PROTEIN", 75, 87], ["B 4", "PROTEIN", 129, 132], ["individual GS", "TEST", 61, 74]]], ["Using carbohydrate microarrays of extended structural diversity, in combination with saccharide inhibition or blocking assays, may provide more information to better understand the selective binding to specific cluster of glyco-epitopes.", [["carbohydrate", "CHEMICAL", 6, 18], ["saccharide", "CHEMICAL", 85, 95], ["glyco-epitopes", "GENE_OR_GENE_PRODUCT", 222, 236], ["glyco-epitopes", "PROTEIN", 222, 236], ["carbohydrate microarrays", "TREATMENT", 6, 30], ["extended structural diversity", "TREATMENT", 34, 63], ["saccharide inhibition", "TREATMENT", 85, 106]]], ["Table 1 or with its structural key elements.Lectins as structural probes for glyco-epitope identificationLectins and anti-carbohydrate antibodies of defined specificities are useful probes for complex carbohydrates expressed by living organisms.", [["carbohydrates", "CHEMICAL", 201, 214], ["glyco-epitope identificationLectins", "SIMPLE_CHEMICAL", 77, 112], ["anti-carbohydrate antibodies", "GENE_OR_GENE_PRODUCT", 117, 145], ["structural key elements", "DNA", 20, 43], ["glyco-epitope identificationLectins", "PROTEIN", 77, 112], ["anti-carbohydrate antibodies", "PROTEIN", 117, 145], ["structural probes", "TEST", 55, 72], ["glyco-epitope identificationLectins", "TREATMENT", 77, 112], ["anti-carbohydrate antibodies of defined specificities", "PROBLEM", 117, 170], ["complex carbohydrates", "PROBLEM", 193, 214], ["key elements", "OBSERVATION", 31, 43]]], ["We present, here, an integrated strategy using these probes to facilitate the identification of immunogenic sugar moieties that are expressed by microbial pathogens.", [["sugar", "CHEMICAL", 108, 113], ["sugar moieties", "SIMPLE_CHEMICAL", 108, 122], ["these probes", "TREATMENT", 47, 59], ["immunogenic sugar moieties", "PROBLEM", 96, 122], ["microbial pathogens", "PROBLEM", 145, 164]]], ["This involves three steps of experimental investigation.", [["experimental investigation", "TEST", 29, 55]]], ["The first step is to perform carbohydrate microarray characterization of the antibody responses to an infectious agent or antigen preparation in order to recognize the disease-or pathogenassociated anti-carbohydrate antibody specificities.", [["carbohydrate", "CHEMICAL", 29, 41], ["anti-carbohydrate antibody", "PROTEIN", 198, 224], ["carbohydrate microarray characterization", "TEST", 29, 69], ["an infectious agent", "TREATMENT", 99, 118], ["antigen preparation", "TREATMENT", 122, 141], ["the disease", "PROBLEM", 164, 175], ["pathogenassociated anti-carbohydrate antibody specificities", "PROBLEM", 179, 238]]], ["The second step focuses on identification of lectins and/or antibodies that are specific for the glyco-epitopes that are recognized by the pathogen-elicited antibodies.", [["lectins", "GENE_OR_GENE_PRODUCT", 45, 52], ["lectins", "PROTEIN", 45, 52], ["antibodies", "PROTEIN", 60, 70], ["glyco-epitopes", "PROTEIN", 97, 111], ["pathogen-elicited antibodies", "PROTEIN", 139, 167], ["lectins and/or antibodies", "PROBLEM", 45, 70], ["the glyco-epitopes", "PROBLEM", 93, 111], ["the pathogen", "TEST", 135, 147]]], ["This provides specific structural probes to enable the third step of investigation, that is, to identify the glyco-epitopes in the candidate pathogens using specific lectins or antibodies identified by Steps 1 and 2.", [["lectins", "PROTEIN", 166, 173], ["antibodies", "PROTEIN", 177, 187]]], ["We applied this strategy to explore the glyco-epitopes expressed by a previously unrecognized viral pathogen, SARS-CoV [52] [53] [54] .", [["SARS-CoV", "SPECIES", 110, 118], ["this strategy", "TREATMENT", 11, 24], ["a previously unrecognized viral pathogen", "PROBLEM", 68, 108]]], ["Our rationale was that if SARS-CoV expressed antigenic carbohydrate structures, then immunizing animals using the whole virus-based vaccines would elicit antibodies specific for these structures.", [["SARS", "DISEASE", 26, 30], ["carbohydrate", "CHEMICAL", 55, 67], ["SARS-CoV", "ORGANISM", 26, 34], ["antibodies", "PROTEIN", 154, 164], ["SARS-CoV", "SPECIES", 26, 34], ["SARS", "PROBLEM", 26, 30], ["CoV expressed antigenic carbohydrate structures", "PROBLEM", 31, 78], ["immunizing animals", "TREATMENT", 85, 103], ["the whole virus-based vaccines", "TREATMENT", 110, 140]]], ["In addition, if SARS-CoV displayed a carbohydrate structure that mimics host cellular glycans, then vaccinated animals may develop antibodies with autoimmune reactivity to their corresponding cellular glycans.Lectins as structural probes for glyco-epitope identificationBy characterizing the SARS-CoV neutralizing antibodies elicited by an inactivated SARS-CoV vaccine, we detected autoantibody reactivity specific for the carbohydrate moieties of an abundant human serum glycoprotein ASOR [44] .", [["cellular", "ANATOMY", 77, 85], ["cellular", "ANATOMY", 192, 200], ["serum", "ANATOMY", 466, 471], ["SARS", "DISEASE", 16, 20], ["carbohydrate", "CHEMICAL", 37, 49], ["carbohydrate", "CHEMICAL", 423, 435], ["SARS-CoV", "ORGANISM", 16, 24], ["cellular", "CELL", 77, 85], ["cellular", "CELL", 192, 200], ["SARS-CoV", "ORGANISM", 292, 300], ["SARS-CoV", "ORGANISM", 352, 360], ["human", "ORGANISM", 460, 465], ["serum", "ORGANISM_SUBSTANCE", 466, 471], ["antibodies", "PROTEIN", 131, 141], ["SARS-CoV neutralizing antibodies", "PROTEIN", 292, 324], ["carbohydrate moieties", "PROTEIN", 423, 444], ["human serum glycoprotein", "PROTEIN", 460, 484], ["human", "SPECIES", 460, 465], ["SARS-CoV", "SPECIES", 16, 24], ["SARS-CoV", "SPECIES", 292, 300], ["SARS-CoV", "SPECIES", 352, 360], ["human", "SPECIES", 460, 465], ["SARS", "PROBLEM", 16, 20], ["CoV", "PROBLEM", 21, 24], ["host cellular glycans", "PROBLEM", 72, 93], ["antibodies", "PROBLEM", 131, 141], ["autoimmune reactivity", "PROBLEM", 147, 168], ["glyco-epitope", "TREATMENT", 242, 255], ["the SARS", "PROBLEM", 288, 296], ["CoV neutralizing antibodies", "PROBLEM", 297, 324], ["an inactivated SARS", "PROBLEM", 337, 356], ["CoV vaccine", "TREATMENT", 357, 368], ["autoantibody reactivity", "TEST", 382, 405]]], ["This surveillance provides important clues for the selection of specific immunologic probes to further examine whether SARS-CoV expresses antigenic structures that imitate the host glycan.", [["SARS-CoV", "ORGANISM", 119, 127], ["SARS-CoV", "SPECIES", 119, 127], ["SARS", "PROBLEM", 119, 123], ["CoV expresses antigenic structures", "PROBLEM", 124, 158]]], ["As shown in the Fig. 4 above, lectin PHA-L is specific for glyco-epitopes Tri-II or mII of ASOR.", [["lectin", "GENE_OR_GENE_PRODUCT", 30, 36], ["PHA-L", "GENE_OR_GENE_PRODUCT", 37, 42], ["Tri-II", "GENE_OR_GENE_PRODUCT", 74, 80], ["ASOR", "GENE_OR_GENE_PRODUCT", 91, 95], ["lectin PHA-L", "PROTEIN", 30, 42], ["Tri-II", "PROTEIN", 74, 80], ["mII", "PROTEIN", 84, 87], ["ASOR", "PROTEIN", 91, 95], ["lectin PHA", "TEST", 30, 40], ["glyco-epitopes", "PROBLEM", 59, 73]]], ["Using PHA-L as a structural probe, we confirmed that SARS-CoV expresses the PHA-L reactive antigenic structure (see Ref.", [["PHA", "CHEMICAL", 6, 9], ["PHA-L", "GENE_OR_GENE_PRODUCT", 6, 11], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 53, 61], ["PHA-L", "GENE_OR_GENE_PRODUCT", 76, 81], ["PHA-L", "DNA", 6, 11], ["PHA", "PROTEIN", 76, 79], ["SARS-CoV", "SPECIES", 53, 61], ["SARS", "PROBLEM", 53, 57], ["the PHA", "TEST", 72, 79], ["L reactive antigenic structure", "PROBLEM", 80, 110], ["reactive", "OBSERVATION_MODIFIER", 82, 90], ["antigenic structure", "OBSERVATION", 91, 110]]], ["We, thus obtained, immunological evidence that a carbohydrate structure of SARS-CoV shares antigenic similarity with host glycan complex carbohydrates.", [["SARS", "DISEASE", 75, 79], ["carbohydrate", "CHEMICAL", 49, 61], ["carbohydrates", "CHEMICAL", 137, 150], ["SARS-CoV", "ORGANISM", 75, 83], ["SARS-CoV", "SPECIES", 75, 83], ["SARS", "PROBLEM", 75, 79], ["host glycan complex carbohydrates", "TREATMENT", 117, 150]]], ["This viral component is probably responsible for the stimulation of the autoantibodies directed at a cellular glycan complex carbohydrate.Lectins as structural probes for glyco-epitope identificationThese observations raise important questions about whether autoimmune responses are in fact elicited by SARS-CoV infection and whether such autoimmunity contributes to SARS pathogenesis.", [["cellular", "ANATOMY", 101, 109], ["SARS-CoV infection", "DISEASE", 303, 321], ["autoimmunity", "DISEASE", 339, 351], ["SARS", "DISEASE", 367, 371], ["carbohydrate", "CHEMICAL", 125, 137], ["cellular", "CELL", 101, 109], ["SARS-CoV", "ORGANISM", 303, 311], ["autoantibodies", "PROTEIN", 72, 86], ["cellular glycan complex carbohydrate", "PROTEIN", 101, 137], ["SARS-CoV", "SPECIES", 303, 311], ["This viral component", "PROBLEM", 0, 20], ["the autoantibodies", "PROBLEM", 68, 86], ["glyco-epitope identification", "TEST", 171, 199], ["autoimmune responses", "PROBLEM", 258, 278], ["SARS", "PROBLEM", 303, 307], ["CoV infection", "PROBLEM", 308, 321], ["such autoimmunity", "PROBLEM", 334, 351], ["SARS pathogenesis", "PROBLEM", 367, 384], ["probably responsible for", "UNCERTAINTY", 24, 48], ["infection", "OBSERVATION", 312, 321]]], ["ASOR is an abundant human serum glycoprotein and the ASOR-type complex carbohydrates are also expressed by other host glycoproteins [55, 56] .", [["serum", "ANATOMY", 26, 31], ["carbohydrates", "CHEMICAL", 71, 84], ["ASOR", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 20, 25], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["ASOR", "GENE_OR_GENE_PRODUCT", 53, 57], ["ASOR", "PROTEIN", 0, 4], ["human serum glycoprotein", "PROTEIN", 20, 44], ["ASOR", "PROTEIN", 53, 57], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["an abundant human serum glycoprotein", "PROBLEM", 8, 44], ["the ASOR-type complex carbohydrates", "TREATMENT", 49, 84]]], ["Thus, the human immune system is generally non-responsive to these \"self \" carbohydrate structures.", [["immune system", "ANATOMY", 16, 29], ["carbohydrate", "CHEMICAL", 75, 87], ["human", "ORGANISM", 10, 15], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 10, 15], ["the human immune system", "TEST", 6, 29]]], ["However, when similar sugar moieties were expressed by a viral glycoprotein, their cluster configuration could differ significantly from those displayed by a cellular glycan, and in this manner generate a novel \"non-self \" antigenic structure.Lectins as structural probes for glyco-epitope identificationA documented example of such antigenic structure is a broad-range HIV-1 neutralization epitope recognized by a monoclonal antibody 2G12.", [["cellular", "ANATOMY", 158, 166], ["sugar", "CHEMICAL", 22, 27], ["sugar moieties", "SIMPLE_CHEMICAL", 22, 36], ["cellular", "CELL", 158, 166], ["HIV-1", "ORGANISM", 370, 375], ["viral glycoprotein", "PROTEIN", 57, 75], ["monoclonal antibody 2G12", "PROTEIN", 415, 439], ["HIV-1", "SPECIES", 370, 375], ["HIV-1", "SPECIES", 370, 375], ["similar sugar moieties", "PROBLEM", 14, 36], ["a viral glycoprotein", "PROBLEM", 55, 75], ["a novel \"non-self \" antigenic structure", "PROBLEM", 203, 242], ["glyco-epitope identificationA", "TEST", 276, 305], ["such antigenic structure", "PROBLEM", 328, 352], ["1 neutralization epitope", "TREATMENT", 374, 398], ["a monoclonal antibody 2G12", "TREATMENT", 413, 439], ["viral glycoprotein", "OBSERVATION", 57, 75], ["cellular glycan", "OBSERVATION", 158, 173]]], ["This antibody is specific for a unique cluster of sugar chains displayed by the gp120 glycoprotein of HIV-1 [57] .", [["sugar", "CHEMICAL", 50, 55], ["HIV-1", "ORGANISM", 102, 107], ["sugar chains", "PROTEIN", 50, 62], ["gp120 glycoprotein", "PROTEIN", 80, 98], ["HIV-1", "SPECIES", 102, 107], ["HIV-1", "SPECIES", 102, 107], ["This antibody", "TEST", 0, 13], ["sugar chains", "TEST", 50, 62], ["HIV", "TEST", 102, 105]]], ["It is, therefore, important to examine whether naturally occurring SARS-CoV expresses the Tri-II or mII-type autoimmune reactive sugar moieties.", [["SARS", "DISEASE", 67, 71], ["sugar", "CHEMICAL", 129, 134], ["SARS-CoV", "ORGANISM", 67, 75], ["Tri-II", "GENE_OR_GENE_PRODUCT", 90, 96], ["mII", "GENE_OR_GENE_PRODUCT", 100, 103], ["Tri-II", "PROTEIN", 90, 96], ["mII", "PROTEIN", 100, 103], ["SARS-CoV", "SPECIES", 67, 75], ["SARS", "PROBLEM", 67, 71], ["type autoimmune reactive sugar moieties", "PROBLEM", 104, 143]]], ["During SARS epidemic, the viruses replicate in human cells.", [["cells", "ANATOMY", 53, 58], ["SARS", "DISEASE", 7, 11], ["human", "ORGANISM", 47, 52], ["cells", "CELL", 53, 58], ["human cells", "CELL_TYPE", 47, 58], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["SARS epidemic", "PROBLEM", 7, 20], ["the viruses replicate in human cells", "PROBLEM", 22, 58], ["viruses", "OBSERVATION", 26, 33], ["human cells", "OBSERVATION", 47, 58]]], ["Their sugar chain expression may differ from the monkey cell produced viral particles.", [["cell", "ANATOMY", 56, 60], ["sugar", "CHEMICAL", 6, 11], ["sugar chain", "GENE_OR_GENE_PRODUCT", 6, 17], ["monkey", "ORGANISM", 49, 55], ["cell", "CELL", 56, 60], ["monkey cell", "CELL_TYPE", 49, 60], ["viral particles", "PROBLEM", 70, 85], ["viral particles", "OBSERVATION", 70, 85]]], ["Scanning of the serum antibodies of SARS patients using glycan arrays or other specific immunologic tools may provide information that can shed light on this question.Lectins as structural probes for glyco-epitope identificationIn summary, the recent establishment of carbohydrate-based microarrays, and especially the availability of different technological platforms to meet the multiple needs of carbohydrate research [42, [58] [59] [60] [61] [62] [63] [64] , marks an important developmental stage of postgenomic research.", [["serum", "ANATOMY", 16, 21], ["SARS", "DISEASE", 36, 40], ["carbohydrate", "CHEMICAL", 268, 280], ["carbohydrate", "CHEMICAL", 399, 411], ["[42, [58] [59] [60] [61] [62] [63] [64]", "CHEMICAL", 421, 460], ["serum", "ORGANISM_SUBSTANCE", 16, 21], ["patients", "ORGANISM", 41, 49], ["[58] [59] [60] [61] [62] [63] [64]", "SIMPLE_CHEMICAL", 426, 460], ["serum antibodies", "PROTEIN", 16, 32], ["patients", "SPECIES", 41, 49], ["Scanning", "TEST", 0, 8], ["the serum antibodies", "TEST", 12, 32], ["SARS", "PROBLEM", 36, 40], ["glycan arrays", "TREATMENT", 56, 69], ["glyco-epitope identification", "TEST", 200, 228], ["developmental stage", "OBSERVATION_MODIFIER", 482, 501], ["postgenomic research", "OBSERVATION", 505, 525]]], ["It is our prediction that microarray-based broad-range binding assays may substantially extend the scope of current carbohydrate research, including lectin characterization and classification.", [["carbohydrate", "CHEMICAL", 116, 128], ["lectin", "GENE_OR_GENE_PRODUCT", 149, 155], ["lectin", "PROTEIN", 149, 155], ["microarray", "TEST", 26, 36], ["lectin characterization", "TEST", 149, 172]]], ["We have described here a practical platform of carbohydrate microarrays and discussed a few examples to illustrate the application of this technology in lectin characterization.", [["carbohydrate", "CHEMICAL", 47, 59], ["lectin", "GENE_OR_GENE_PRODUCT", 153, 159], ["lectin", "PROTEIN", 153, 159], ["carbohydrate microarrays", "TREATMENT", 47, 71], ["lectin characterization", "TEST", 153, 176]]], ["We also present an integrated experimental strategy to facilitate the identification of the glyco-epitopes in biological systems, such as a newly emerged viral pathogen, SARS-CoV.", [["SARS", "DISEASE", 170, 174], ["SARS-CoV", "ORGANISM", 170, 178], ["SARS-CoV", "SPECIES", 170, 178], ["the glyco-epitopes in biological systems", "PROBLEM", 88, 128], ["a newly emerged viral pathogen", "PROBLEM", 138, 168]]], ["This research strategy is likely applicable for the exploration of complex carbohydrates that are differentially expressed by host cells, including human cancers and stem cells at various stages of differentiation.", [["cells", "ANATOMY", 131, 136], ["cancers", "ANATOMY", 154, 161], ["stem cells", "ANATOMY", 166, 176], ["cancers", "DISEASE", 154, 161], ["carbohydrates", "CHEMICAL", 75, 88], ["host cells", "CELL", 126, 136], ["human", "ORGANISM", 148, 153], ["cancers", "CANCER", 154, 161], ["stem cells", "CELL", 166, 176], ["host cells", "CELL_TYPE", 126, 136], ["stem cells", "CELL_TYPE", 166, 176], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 148, 153], ["the exploration", "TEST", 48, 63], ["complex carbohydrates", "PROBLEM", 67, 88], ["human cancers and stem cells", "PROBLEM", 148, 176], ["host cells", "OBSERVATION", 126, 136], ["cancers", "OBSERVATION", 154, 161], ["stem cells", "OBSERVATION", 166, 176]]]], "38148f8d1ea3eded1159e8a498a074e8ed98e5f4": [["IntroductionThe normal rhythm of livelihood of the people exclusively world's economy, socio-cultural compatibility, national and international political waves, academic atmosphere, and moreover people's regular lifestyle has been incredibly disrupted due to the fatal novel coronavirus .", [["coronavirus", "DISEASE", 275, 286], ["people", "ORGANISM", 51, 57], ["people", "ORGANISM", 195, 201], ["coronavirus", "ORGANISM", 275, 286], ["people", "SPECIES", 51, 57], ["people", "SPECIES", 195, 201], ["academic atmosphere", "TREATMENT", 161, 180], ["the fatal novel coronavirus", "PROBLEM", 259, 286], ["normal rhythm", "OBSERVATION", 16, 29]]], ["The outbreak of catastrophic coronavirus occurred during the end of December 2019 and creates the gigantic turmoil particularly in socio-economic backbone of the nations (Tian et al. 2020; Wang et al. 2020a, b) .", [["coronavirus", "DISEASE", 29, 40], ["coronavirus", "ORGANISM", 29, 40], ["catastrophic coronavirus", "PROBLEM", 16, 40], ["outbreak", "OBSERVATION_MODIFIER", 4, 12], ["catastrophic coronavirus", "OBSERVATION", 16, 40], ["gigantic", "OBSERVATION_MODIFIER", 98, 106], ["turmoil", "OBSERVATION", 107, 114]]], ["The novel coronavirus has been emerged as an extraordinary disastrous influence worldwide.", [["coronavirus", "DISEASE", 10, 21], ["coronavirus", "ORGANISM", 10, 21], ["The novel coronavirus", "PROBLEM", 0, 21], ["coronavirus", "OBSERVATION", 10, 21], ["extraordinary", "OBSERVATION_MODIFIER", 45, 58], ["disastrous", "OBSERVATION", 59, 69]]], ["On December 29, 2019, this new infectious disease was first identified at Wuhan City, the capital of Hubei Province in China (Huang et al. 2020a, b; Zhou et al. 2020a, b; Zhu et al. 2020 ).", [["infectious disease", "DISEASE", 31, 49], ["infectious", "OBSERVATION", 31, 41]]], ["After detecting a lot of positive cases throughout the country, the Government of China imposed countrywide lockdown system to regulate the transmission of infectivity and wanted to reduce the excessive pressure on health infrastructure (Wilder-Smith and Freedman 2020).", [["the excessive pressure on health infrastructure", "PROBLEM", 189, 236], ["positive", "OBSERVATION_MODIFIER", 25, 33], ["cases", "OBSERVATION", 34, 39], ["excessive", "OBSERVATION_MODIFIER", 193, 202], ["pressure", "OBSERVATION_MODIFIER", 203, 211]]], ["The World Health Organization (WHO) authenticated the fact related with the contagious nature of coronavirus through human globules inhalation during January 2020 (WHO 2020e) .WHO has declared that the COVID-19 is a sixth Public Health Emergency of International Concern (on January 30, 2020) because of the enormous aftermath of this fatal disease throughout the world (Wee et al. 2020; WHO 2020c) .The global transmission of coronavirus and its harmful impacts have been started to transmit through human interaction from February 2020.", [["coronavirus", "DISEASE", 97, 108], ["coronavirus", "DISEASE", 427, 438], ["coronavirus", "ORGANISM", 97, 108], ["human", "ORGANISM", 117, 122], ["coronavirus", "ORGANISM", 427, 438], ["human", "ORGANISM", 501, 506], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 501, 506], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 501, 506], ["coronavirus through human globules inhalation", "TREATMENT", 97, 142], ["this fatal disease", "PROBLEM", 330, 348], ["coronavirus", "PROBLEM", 427, 438], ["enormous", "OBSERVATION_MODIFIER", 308, 316], ["global", "OBSERVATION_MODIFIER", 404, 410], ["coronavirus", "OBSERVATION", 427, 438]]], ["Many relevant studies revealed that COVID-19 is a severe respiratory infectious disease which can attack the whole respiratory system and lungs of human being (Gautam and Trivedi 2020; Chen et al. 2020) .", [["respiratory system", "ANATOMY", 115, 133], ["lungs", "ANATOMY", 138, 143], ["COVID-19", "CHEMICAL", 36, 44], ["respiratory infectious disease", "DISEASE", 57, 87], ["lungs", "ORGAN", 138, 143], ["human", "ORGANISM", 147, 152], ["human", "SPECIES", 147, 152], ["human", "SPECIES", 147, 152], ["Many relevant studies", "TEST", 0, 21], ["COVID", "TEST", 36, 41], ["a severe respiratory infectious disease", "PROBLEM", 48, 87], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["respiratory", "ANATOMY", 57, 68], ["infectious", "OBSERVATION", 69, 79], ["respiratory system", "ANATOMY", 115, 133], ["lungs", "ANATOMY", 138, 143]]], ["Italian Institute of Health clearly notified that around 481 people, who were previously suffering due to acute illness, have now lost their lives because of the attack of fatal COVID-19 (Gautam 2020a) .", [["COVID", "DISEASE", 178, 183], ["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67], ["acute illness", "PROBLEM", 106, 119]]], ["In this context, the old-age persons are considered to be extremely vulnerable as the rate of contagion and mortality are noticeably higher in this age group (\u2265 65 years) (Zhou et al. 2020a, b; Gautam and Hens 2020) .IntroductionAs the COVID-19 disease has been originated from the novel coronavirus SARS-CoV-2, WHO declared as COVID-19 a pandemic on March 11, 2020 (WHO 2020d).", [["SARS", "DISEASE", 300, 304], ["persons", "ORGANISM", 29, 36], ["coronavirus SARS-CoV-2", "ORGANISM", 288, 310], ["persons", "SPECIES", 29, 36], ["coronavirus", "SPECIES", 288, 299], ["the COVID-19 disease", "PROBLEM", 232, 252], ["COVID", "TEST", 328, 333]]], ["Coronavirus has snatched 3,00,000 lives including 4.5 million confirmed cases around 216 countries across the world as of May 15, 2020 (WHO 2020a .", [["Coronavirus", "CHEMICAL", 0, 11], ["Coronavirus", "PROBLEM", 0, 11]]], ["The social distancing measure has been enforced by Chinese Government and it is widely accepted as a compulsory defensive technique to deal with coronavirus pandemic whenever there is no other substitute to combat against this lethal disease (Huang et al. 2020a, b; Zhang et al. 2020) .", [["coronavirus pandemic", "DISEASE", 145, 165], ["coronavirus", "ORGANISM", 145, 156], ["a compulsory defensive technique", "TREATMENT", 99, 131], ["coronavirus pandemic", "PROBLEM", 145, 165], ["this lethal disease", "PROBLEM", 222, 241]]], ["In this context, it is noteworthy that India has enlisted as a hot spot point in the list of COVID-19 affected Asian countries where 81,970 confirmed cases and 2649 deaths have been recorded as of May 15, 2020 (https ://covid 19ind ia.org).", [["deaths", "DISEASE", 165, 171], ["COVID", "TEST", 93, 98]]], ["At the end of January 2020, the first COVID-19 positive case had been identified in Kerala state of India and the infected person who travelled from China (Gautam and Hens 2020) .", [["person", "ORGANISM", 123, 129], ["person", "SPECIES", 123, 129], ["the first COVID", "TEST", 28, 43], ["infected", "OBSERVATION", 114, 122]]], ["In India, Maharashtra, Tamil Nadu and Delhi are the leading states in terms of total confirmed cases, whereas Meghalaya, Sikkim and Mizoram witness very few numbers of COVID-19 cases (covid19india.org).", [["COVID", "TEST", 168, 173]]], ["The honourable Prime Minister of India appealed to the citizens for effective implementation of lockdown system.", [["effective implementation of lockdown system", "TREATMENT", 68, 111]]], ["To prevent rapid transmission of coronavirus, countrywide lockdown had been enforced through the halting of economic production and restrictions on mobility of the citizens (Gautam and Hens 2020) .", [["coronavirus", "DISEASE", 33, 44], ["coronavirus", "ORGANISM", 33, 44], ["coronavirus", "PROBLEM", 33, 44], ["economic production", "PROBLEM", 108, 127], ["rapid", "OBSERVATION_MODIFIER", 11, 16], ["coronavirus", "OBSERVATION", 33, 44]]], ["In India, West Bengal has witnessed the brutal strike of coronavirus with surging growth rate of confirmed cases, whereas Kolkata (the capital of West Bengal) is recognized as the epicentre of COVID-19 pandemic in the state (Fig. 1) .", [["coronavirus", "DISEASE", 57, 68], ["coronavirus", "ORGANISM", 57, 68], ["coronavirus", "PROBLEM", 57, 68], ["COVID", "TEST", 193, 198]]], ["Government of India has already implemented lockdown rules and enacted social distancing norms from March 24, 2020, and it is further continued up to May 31, 2020, to manage the rapid outbreak of COVID-19 pandemic during global emergency.", [["COVID", "DISEASE", 196, 201], ["COVID", "TEST", 196, 201]]], ["Among the highly COVID-19 affected states in India, West Bengal stands at a vulnerable situation with 2461 confirmed cases till May 15, 2020, and Kolkata (the capital of West Bengal) is severely affected due to COVID-19 pandemic and is the epicentre of the state (Health and Family Welfare Department, Govt. of West Bengal 2020).", [["severely affected", "PROBLEM", 186, 203], ["COVID", "TEST", 211, 216]]], ["Here, the basic problem is that the COVID-19 infection rate and numbers of deaths are frequently increasing day by day in Kolkata City due to co-morbidity of the people such as respiratory disease and chronic obstructive pulmonary disease.", [["respiratory", "ANATOMY", 177, 188], ["pulmonary", "ANATOMY", 221, 230], ["infection", "DISEASE", 45, 54], ["deaths", "DISEASE", 75, 81], ["respiratory disease", "DISEASE", 177, 196], ["chronic obstructive pulmonary disease", "DISEASE", 201, 238], ["people", "ORGANISM", 162, 168], ["pulmonary", "ORGAN", 221, 230], ["people", "SPECIES", 162, 168], ["the COVID", "TEST", 32, 41], ["infection rate", "PROBLEM", 45, 59], ["respiratory disease", "PROBLEM", 177, 196], ["chronic obstructive pulmonary disease", "PROBLEM", 201, 238], ["respiratory disease", "OBSERVATION", 177, 196], ["chronic", "OBSERVATION_MODIFIER", 201, 208], ["obstructive", "OBSERVATION_MODIFIER", 209, 220], ["pulmonary", "ANATOMY", 221, 230], ["disease", "OBSERVATION", 231, 238]]], ["World Health Organization (WHO 2020a, b, c, d, e) also gave clear assertion that the major diseases like respiratory disease (26%), chronic obstructive pulmonary disease (25%) and stroke and ischaemic heart (17%) occurred due to severe air pollution.", [["respiratory", "ANATOMY", 105, 116], ["pulmonary", "ANATOMY", 152, 161], ["heart", "ANATOMY", 201, 206], ["respiratory disease", "DISEASE", 105, 124], ["chronic obstructive pulmonary disease", "DISEASE", 132, 169], ["stroke", "DISEASE", 180, 186], ["pulmonary", "ORGAN", 152, 161], ["heart", "ORGAN", 201, 206], ["the major diseases", "PROBLEM", 81, 99], ["respiratory disease", "PROBLEM", 105, 124], ["chronic obstructive pulmonary disease", "PROBLEM", 132, 169], ["stroke", "PROBLEM", 180, 186], ["ischaemic heart", "PROBLEM", 191, 206], ["severe air pollution", "PROBLEM", 229, 249], ["respiratory disease", "OBSERVATION", 105, 124], ["chronic", "OBSERVATION_MODIFIER", 132, 139], ["obstructive", "OBSERVATION_MODIFIER", 140, 151], ["pulmonary", "ANATOMY", 152, 161], ["disease", "OBSERVATION", 162, 169], ["stroke", "OBSERVATION", 180, 186], ["ischaemic", "OBSERVATION_MODIFIER", 191, 200], ["heart", "ANATOMY", 201, 206], ["severe", "OBSERVATION_MODIFIER", 229, 235], ["air pollution", "OBSERVATION", 236, 249]]], ["Kolkata, the third densely populated region of India, is the home of 4.5 million populations (Census of India 2011).", [["third", "OBSERVATION_MODIFIER", 13, 18], ["densely", "OBSERVATION_MODIFIER", 19, 26], ["populated", "OBSERVATION", 27, 36]]], ["In terms of urban air pollution, Kolkata is designated as dusty city (Kumar and Singh 2003) and it is enlisted in the World's 25 most polluted cities along with 10 worse polluted cities in India (WHO 2011).", [["urban", "OBSERVATION_MODIFIER", 12, 17], ["air pollution", "OBSERVATION", 18, 31]]], ["The Central Pollution Control Board of India (2012) had reported that the Eastern economic pivot (Kolkata) of India is registered as worse polluted city with respect to air pollution and the city is almost equivalent to Delhi (Das et al. 2015) in comparison with another major metropolitan cities like Mumbai, Bengaluru, Chennai, Hyderabad, etc. It must be estimated that the quantity of respiratory and allergic illness would be increased because of the rapid alteration of air quality in Kolkata City.", [["respiratory and allergic illness", "DISEASE", 388, 420], ["respiratory and allergic illness", "PROBLEM", 388, 420], ["the rapid alteration of air quality", "PROBLEM", 451, 486], ["Central", "OBSERVATION_MODIFIER", 4, 11], ["Pollution", "OBSERVATION_MODIFIER", 12, 21], ["air pollution", "OBSERVATION", 169, 182], ["quantity", "OBSERVATION_MODIFIER", 376, 384], ["respiratory", "ANATOMY", 388, 399], ["allergic", "OBSERVATION", 404, 412], ["rapid", "OBSERVATION_MODIFIER", 455, 460], ["air quality", "OBSERVATION", 475, 486]]], ["So, the main objective of this study is to evaluate the status of air quality standard during and pre-COVID-19 lockdown phase in Kolkata City of India and to recommend long-term sustainable environmental management plan.", [["this study", "TEST", 26, 36], ["long-term sustainable environmental management", "TREATMENT", 168, 214]]], ["Although, most of the people of the world have not previously experienced long-term lockdown system but at the same time due to close-down of transport, constructional works and industrial activities, the health of the total environment including humans have been slightly improved.", [["people", "ORGANISM", 22, 28], ["humans", "ORGANISM", 247, 253], ["people", "SPECIES", 22, 28], ["humans", "SPECIES", 247, 253], ["humans", "SPECIES", 247, 253], ["slightly", "OBSERVATION_MODIFIER", 264, 272], ["improved", "OBSERVATION_MODIFIER", 273, 281]]], ["The study has great significance in this present-day context that during lockdown phase how much air pollution is reduced and this scientific study has also been identified the specific sources of air pollution.", [["The study", "TEST", 0, 9], ["this scientific study", "TEST", 126, 147], ["air pollution", "PROBLEM", 197, 210], ["air pollution", "OBSERVATION", 97, 110], ["reduced", "OBSERVATION_MODIFIER", 114, 121], ["air pollution", "OBSERVATION", 197, 210]]], ["The uniqueness of the study reflects actual ground truth regarding air quality standards and public health conditions during and pre-lockdown phase.", [["the study", "TEST", 18, 27]]], ["The policymakers can implement the sustainable environmental management plan which has been prescribed through this study and such type of scientific fundamental research work will definitely help to build simulation model for improving environmental sustainability.", [["this study", "TEST", 111, 121]]], ["Most of the recent studies have been nicely articulated on assessment of air quality standard, status of total environment and reasons behind fluctuations of particular pollution parameter with relation to COVID-19 during and pre-lockdown phase, while this study has tried to examine not only status of air quality but also long-term sustainable environmental management plan.", [["the recent studies", "TEST", 8, 26], ["assessment", "TEST", 59, 69], ["COVID", "TEST", 206, 211], ["this study", "TEST", 252, 262]]], ["Similarly, the strength of the study has also been amplified because it has been validated through the concentration maps of NO 2 and aerosol over Indian subcontinent depicted by European Space Agency (ESA) and National Aeronautics and Space Administration (NASA) during and pre-lockdown phase.", [["NO", "CHEMICAL", 125, 127], ["NO 2", "CHEMICAL", 125, 129], ["NO 2", "SIMPLE_CHEMICAL", 125, 129], ["the study", "TEST", 27, 36], ["the concentration maps", "TEST", 99, 121], ["National Aeronautics and Space Administration", "TREATMENT", 211, 256]]], ["Meanwhile, the study has been effectively completed considering some limitations like inadequate automatic air quality measurement stations, non-working manual stations and limited interaction with experts and laboratory assistance during COVID-19 pandemic situation.Air quality scenarios of Europe and Asian countries during COVID-19 pandemicAs the industrial activities, manufacturing, power and transport sectors are almost stopped during lockdown period, the environment is stressed out from the burden of alarming anthropogenic nuisance.", [["the study", "TEST", 11, 20], ["COVID", "TEST", 239, 244], ["COVID", "TEST", 326, 331]]], ["It must be an inevitable fact that the global economy and health safety of mankind fight against dreadful impact of coronavirus, while restricted economic activities and human actions remarkably reduce the pollution level (Dutheil et al. 2020) .Air quality scenarios of Europe and Asian countries during COVID-19 pandemicDuring the lockdown period, the release of NO 2 , SO 2 and PM 2.5 has been dwindled than the high emission rate of 2019 at Yangtze river delta region in China .", [["coronavirus", "DISEASE", 116, 127], ["NO", "CHEMICAL", 364, 366], ["NO 2", "CHEMICAL", 364, 368], ["SO 2", "CHEMICAL", 371, 375], ["coronavirus", "ORGANISM", 116, 127], ["human", "ORGANISM", 170, 175], ["NO 2", "SIMPLE_CHEMICAL", 364, 368], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 170, 175], ["coronavirus", "PROBLEM", 116, 127], ["human actions", "TREATMENT", 170, 183], ["COVID", "TEST", 304, 309]]], ["Similarly, the significant reduction of CO, NO 2 and PM 2.5 level (by 49%, 35% and 21%) has been recorded in the quarantine session across Almaty, Kazakhstan with respect to the previous year (Kerimray et al. 2020 ).", [["NO", "CHEMICAL", 44, 46], ["CO", "CHEMICAL", 40, 42], ["NO 2", "CHEMICAL", 44, 48], ["CO", "SIMPLE_CHEMICAL", 40, 42], ["NO 2", "GENE_OR_GENE_PRODUCT", 44, 48], ["CO", "TEST", 40, 42], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["reduction", "OBSERVATION_MODIFIER", 27, 36]]], ["It has been reported that the concentration level of NO 2 and PM 2.5 was very low in the lower atmosphere of major cities of China (during lockdown) due to partially shut down of different industries (ESA 2020c; CAMS 2020).", [["NO", "CHEMICAL", 53, 55], ["NO 2", "CHEMICAL", 53, 57], ["NO 2", "GENE_OR_GENE_PRODUCT", 53, 57], ["the concentration level", "TEST", 26, 49], ["low", "OBSERVATION_MODIFIER", 78, 81], ["lower", "ANATOMY_MODIFIER", 89, 94]]], ["Beside this, the air quality of the European countries is amazingly upgraded due to limited anthropogenic activities during the prevalence of COVID-19 global pandemic (Zambrano-Monserrate et al. 2020).", [["limited anthropogenic activities", "PROBLEM", 84, 116], ["COVID", "TEST", 142, 147], ["air", "OBSERVATION", 17, 20]]], ["The global air quality standard and health of total environment are recovered to some extent for controlled vehicles movement, limited usage of fuel energy and partially closed industrial sectors, etc. (Muhammad et al. 2020) .", [["global", "OBSERVATION_MODIFIER", 4, 10], ["air quality", "OBSERVATION", 11, 22], ["some extent", "OBSERVATION_MODIFIER", 81, 92], ["industrial sectors", "OBSERVATION", 177, 195]]], ["A study is focussed that the concentration of NO 2 is vibrantly reduced by 20-30% in France, Spain, Italy and Germany during lockdown phase (ESA 2020b).", [["NO", "CHEMICAL", 46, 48], ["NO 2", "CHEMICAL", 46, 50], ["NO 2", "SIMPLE_CHEMICAL", 46, 50], ["A study", "TEST", 0, 7]]], ["A comparative study (year 2019 and 2020) shows that the NO 2 emission rate is dramatically fallen (30% reduction) in the year 2020 compared with 2019 at Wuhan City in China (NASA 2020a).", [["NO", "CHEMICAL", 56, 58], ["NO 2", "CHEMICAL", 56, 60], ["NO 2", "SIMPLE_CHEMICAL", 56, 60], ["A comparative study", "TEST", 0, 19], ["dramatically", "OBSERVATION_MODIFIER", 78, 90]]], ["In this context, it is noteworthy that the reduction of emissions of different pollutants from industrial and transport sector is not prolific to avert acute air pollution level in China due to the worse meteorological conditions .", [["acute air pollution level", "PROBLEM", 152, 177], ["the worse meteorological conditions", "PROBLEM", 194, 229], ["reduction", "OBSERVATION_MODIFIER", 43, 52], ["acute", "OBSERVATION_MODIFIER", 152, 157], ["air pollution", "OBSERVATION", 158, 171]]], ["In this context, the discharge of manufacturing waste, emission of greenhouse gasses, release of poisonous particulates and combustion of coal and petroleum have been curtailed due to the pausing of industrial production, vehicles movement and power generation during lockdown period which promote pollution free sky in city areas, revitalization of ozone layer, declining of pollution status in different tourist spots as well as the restoration of entire ecosystem enormously (Chakraborty and Maity 2020) .", [["petroleum", "CHEMICAL", 147, 156], ["ozone", "CHEMICAL", 350, 355], ["coal", "CHEMICAL", 138, 142], ["petroleum", "CHEMICAL", 147, 156], ["ozone", "CHEMICAL", 350, 355], ["petroleum", "SIMPLE_CHEMICAL", 147, 156], ["manufacturing waste", "TREATMENT", 34, 53], ["poisonous particulates", "PROBLEM", 97, 119], ["coal and petroleum", "TREATMENT", 138, 156], ["industrial production", "PROBLEM", 199, 220], ["ozone layer", "TREATMENT", 350, 361], ["greenhouse gasses", "OBSERVATION", 67, 84], ["poisonous particulates", "OBSERVATION", 97, 119], ["industrial production", "OBSERVATION", 199, 220], ["pollution", "OBSERVATION_MODIFIER", 298, 307], ["free", "OBSERVATION_MODIFIER", 308, 312], ["ozone layer", "OBSERVATION", 350, 361], ["tourist spots", "OBSERVATION", 406, 419]]], ["Gautam (2020a) has assessed the modifications of No 2 concentration over the different Asian countries during COVID-19 emergency condition where NO 2 level is lowered by 20-30% in China and 70% in India.", [["NO", "CHEMICAL", 145, 147], ["NO 2", "CHEMICAL", 145, 149], ["NO 2", "GENE_OR_GENE_PRODUCT", 145, 149]]], ["Furthermore, the various countries of Europe experience a sharp dissimilarity in terms of NO 2 emission during pre-and post-COVID-19 disaster.", [["NO", "CHEMICAL", 90, 92], ["NO 2", "CHEMICAL", 90, 94], ["NO 2", "SIMPLE_CHEMICAL", 90, 94], ["a sharp dissimilarity", "PROBLEM", 56, 77]]], ["It must be stated that the efficacy of lockdown is more vibrant in Asian states compared with European nations on the basis of the drop of NO 2 during lockdown period (Gautam 2020a) .", [["NO", "CHEMICAL", 139, 141], ["NO 2", "CHEMICAL", 139, 143], ["NO 2", "GENE_OR_GENE_PRODUCT", 139, 143]]], ["The share of SO 2 , NO 2 , CO 2 , O 3 , PM 10 and PM 2.5 during the month of March and April 2020 across the 22 cities in India has been compared with the concentration level of these parameters during the same time period in 2017 and the study reflects the positive modifications of air quality during March and April in 2020 (Sharma et al. 2020) .", [["NO", "CHEMICAL", 20, 22], ["SO 2", "CHEMICAL", 13, 17], ["NO 2", "CHEMICAL", 20, 24], ["CO 2", "CHEMICAL", 27, 31], ["O 3", "CHEMICAL", 34, 37], ["NO 2", "SIMPLE_CHEMICAL", 20, 24], ["CO 2", "SIMPLE_CHEMICAL", 27, 31], ["O 3", "SIMPLE_CHEMICAL", 34, 37], ["CO", "TEST", 27, 29], ["the concentration level", "TEST", 151, 174], ["the study", "TEST", 235, 244], ["positive modifications", "OBSERVATION", 258, 280], ["air quality", "OBSERVATION", 284, 295]]], ["It is evident that various preventive measures with social distancing norms have been taken to regulate the transmission of COVID-19 pandemic, whereas these preventive measures directly affect the growth of global economy, human health and environment (Sarkodie and Owusu 2020) .", [["COVID-19", "ORGANISM", 124, 132], ["human", "ORGANISM", 223, 228], ["human", "SPECIES", 223, 228], ["human", "SPECIES", 223, 228], ["COVID", "TEST", 124, 129]]], ["Similarly, another study established that social distancing rule is the most effective way for administration to regulate the contagious nature of COVID-19 pandemic in India (Bherwani et al. 2020) .", [["another study", "TEST", 11, 24], ["COVID", "TEST", 147, 152]]], ["It is undoubtedly observed that the per day emission rate from road traffic sector was the lowermost on the day of national Janta Curfew in India (CPCB 2009 (CPCB , 2020 .", [["lowermost", "OBSERVATION_MODIFIER", 91, 100]]], ["After the initiation of lockdown, the average concentration of PM 2.5 was decreased up to 26 \u03bcg/ m 3 on March 27, 2020, from 91 \u03bcg/m 3 on March 20, 2020, in New Delhi and it is indicating that around 71% reduction of this particulate matter in the atmosphere (CPCB 2020; Mate et al. 2020; Mitra et al. 2020) .", [["PM 2.5", "CHEMICAL", 63, 69], ["lockdown", "TREATMENT", 24, 32], ["the average concentration of PM", "TREATMENT", 34, 65]]], ["The long-term lockdown system becomes effective to diminish the materialistic consumption and energy usage (Jribi et al. 2020 ).", [["The long-term lockdown system", "TREATMENT", 0, 29], ["long-term", "OBSERVATION_MODIFIER", 4, 13]]], ["There is a prominent decline in utilization of renewable energy source, i.e. coal consumption during the first half of 2020 in comparison with the preceding years (Eroglu 2020 ).", [["coal", "CHEMICAL", 77, 81], ["a prominent decline", "PROBLEM", 9, 28], ["prominent", "OBSERVATION_MODIFIER", 11, 20], ["decline", "OBSERVATION_MODIFIER", 21, 28], ["renewable energy source", "OBSERVATION", 47, 70], ["coal consumption", "OBSERVATION", 77, 93]]], ["Subsequently, it has been recorded that the pollutants in the major metropolitan cities of India (namely Mumbai, Kolkata, Bengaluru and Chennai) have been tremendously decreased during the lockdown phase (CPCB 2020; Sharma et al. 2020; Lau et al. 2020) .", [["pollutants", "OBSERVATION_MODIFIER", 44, 54], ["major", "OBSERVATION_MODIFIER", 62, 67], ["tremendously", "OBSERVATION_MODIFIER", 155, 167], ["decreased", "OBSERVATION_MODIFIER", 168, 177]]], ["It is evident that there is an inter-relation between the ambient air quality indicators and different meteorological factors, e.g. temperature (Bashir et al. 2020 ).", [["an inter-relation between the ambient air quality indicators", "PROBLEM", 28, 88], ["different meteorological factors", "PROBLEM", 93, 125], ["ambient", "OBSERVATION_MODIFIER", 58, 65], ["air quality", "OBSERVATION", 66, 77], ["different", "OBSERVATION_MODIFIER", 93, 102], ["meteorological factors", "OBSERVATION", 103, 125]]], ["The contemporary research on bio-aerosol reflects the hazardous impact on human health in international and regional level (Humbal et al. 2020 (Humbal et al. , 2018 .", [["bio-aerosol", "SIMPLE_CHEMICAL", 29, 40], ["human", "ORGANISM", 74, 79], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 74, 79]]], ["It must be mentioned that the share of earlier fatality caused by life-threatening air pollution is substantially decreased in India due to enormous depletion of aerosol accumulation during lockdown phase (Gautam 2020b) .", [["fatality", "DISEASE", 47, 55], ["aerosol accumulation", "PROBLEM", 162, 182], ["air pollution", "OBSERVATION", 83, 96], ["substantially", "OBSERVATION_MODIFIER", 100, 113], ["decreased", "OBSERVATION_MODIFIER", 114, 123], ["enormous", "OBSERVATION_MODIFIER", 140, 148], ["depletion", "OBSERVATION", 149, 158], ["aerosol accumulation", "OBSERVATION", 162, 182]]], ["The excessive concentration of greenhouse gasses controls the temperature variation in the lower atmosphere, whereas lower accumulation of CO, NO 2 , SO 2 , PM 10 and PM 2.5 may modify the intensity of surface air temperature.", [["surface", "ANATOMY", 202, 209], ["NO", "CHEMICAL", 143, 145], ["CO", "CHEMICAL", 139, 141], ["NO 2", "CHEMICAL", 143, 147], ["SO 2", "CHEMICAL", 150, 154], ["CO", "SIMPLE_CHEMICAL", 139, 141], ["NO 2", "SIMPLE_CHEMICAL", 143, 147], ["SO 2", "SIMPLE_CHEMICAL", 150, 154], ["PM 10", "SIMPLE_CHEMICAL", 157, 162], ["The excessive concentration of greenhouse gasses", "PROBLEM", 0, 48], ["the temperature variation", "PROBLEM", 58, 83], ["lower accumulation of CO", "PROBLEM", 117, 141], ["surface air temperature", "PROBLEM", 202, 225], ["excessive", "OBSERVATION_MODIFIER", 4, 13], ["concentration", "OBSERVATION_MODIFIER", 14, 27], ["greenhouse gasses", "OBSERVATION", 31, 48], ["lower", "ANATOMY_MODIFIER", 91, 96], ["lower", "OBSERVATION_MODIFIER", 117, 122], ["accumulation", "OBSERVATION_MODIFIER", 123, 135], ["air temperature", "OBSERVATION", 210, 225]]], ["The Meteorologists have explained that high emission rate of greenhouse gases has been significantly controlled due to global lockdown which seems to be an unusual phenomenon after World War II (Global Carbon Project 2020).Data sources and data acquisitionIn this study, six parameters like CO, NO 2 , SO 2 , O 3 , PM 10 and PM 2.5 have been considered to evaluate the deviation of air quality during lockdown and pre-lockdown period.", [["NO", "CHEMICAL", 295, 297], ["Carbon", "CHEMICAL", 202, 208], ["CO", "CHEMICAL", 291, 293], ["NO 2", "CHEMICAL", 295, 299], ["SO 2", "CHEMICAL", 302, 306], ["O 3", "CHEMICAL", 309, 312], ["CO", "SIMPLE_CHEMICAL", 291, 293], ["NO 2", "SIMPLE_CHEMICAL", 295, 299], ["O 3", "SIMPLE_CHEMICAL", 309, 312], ["high emission rate of greenhouse gases", "PROBLEM", 39, 77], ["global lockdown", "PROBLEM", 119, 134], ["an unusual phenomenon", "PROBLEM", 153, 174], ["this study", "TEST", 259, 269], ["six parameters", "TEST", 271, 285], ["CO", "TEST", 291, 293], ["the deviation of air quality", "PROBLEM", 365, 393], ["air quality", "OBSERVATION", 382, 393]]], ["Hourly emission levels of above-mentioned selected pollution parameters have been obtained on daily basis from the State Pollution Control Board under Govt. of West Bengal.", [["Hourly emission levels", "TEST", 0, 22]]], ["Moreover, LANDSAT 8 OLI and LANDSAT 7 ETM + images (path 138, row 44 and resolution 30 m) of the United States Geological Survey (USGS) have been used to prepare land surface temperature mapping for analysing the temperature variation before and after lockdown.", [["surface", "ANATOMY", 167, 174], ["LANDSAT 8 OLI", "DNA", 10, 23], ["LANDSAT", "TEST", 10, 17], ["LANDSAT", "TEST", 28, 35], ["images (path", "TEST", 44, 56], ["land surface temperature mapping", "TREATMENT", 162, 194], ["the temperature variation", "TEST", 209, 234]]], ["The maps regarding variation of NO 2 and aerosol concentration over India during lockdown and pre-lockdown phase have been obtained from European space agency (ESA) and the National aeronautics and Space Administration (NASA) individually (ESA 2020a; NASA 2020b).", [["NO", "CHEMICAL", 32, 34], ["NO 2", "CHEMICAL", 32, 36], ["NO 2", "GENE_OR_GENE_PRODUCT", 32, 36], ["The maps", "TEST", 0, 8], ["aerosol concentration", "TREATMENT", 41, 62], ["Space Administration (NASA)", "TREATMENT", 198, 225]]], ["Here, ESA has captured the data of NO 2 concentration using Copernicus Sentinel-5 Precursor Tropospheric Monitoring Instrument (S5P/TROPOMI).", [["NO", "CHEMICAL", 35, 37], ["NO 2", "CHEMICAL", 35, 39], ["ESA", "SIMPLE_CHEMICAL", 6, 9], ["NO 2", "SIMPLE_CHEMICAL", 35, 39], ["Instrument (S5P/TROPOMI)", "TREATMENT", 116, 140]]], ["During lockdown phase, some technical limitations have been faced like limited automatic data collection stations and laboratory-based analysis.", [["laboratory-based analysis", "TEST", 118, 143]]], ["With the advancement of science and technology, there are various simulation models and modern devices which have been designed to quantify area-time-specific pollutants concentration and magnitude of dispersal.", [["modern devices", "TREATMENT", 88, 102]]], ["Despite the fact, the merit of this scientific study is to determine the short-term impacts of COVID-19 on urban air pollution in Kolkata City and long-term sustainable management plan using ground automatic stations data, satellite imageries, RS&GIS and descriptive statistical techniques.", [["COVID-19", "CHEMICAL", 95, 103], ["this scientific study", "TEST", 31, 52], ["COVID", "TEST", 95, 100], ["long-term sustainable management", "TREATMENT", 147, 179]]], ["The study of significant impacts (of COVID-19 lockdown) on urban air pollution has been authenticated through the maps of concentration of NO 2 and aerosol over Indian subcontinent prepared by European space agency (ESA) and National aeronautics and Space Administration (NASA).Application of RS & GIS techniquesThe diurnal and monthly average of selected parameters at every station has been calculated of all over Kolkata City during (in 2020) and pre-lockdown years 2017, 2018 and 2019.", [["NO", "CHEMICAL", 139, 141], ["NO 2", "CHEMICAL", 139, 143], ["NO 2", "SIMPLE_CHEMICAL", 139, 143], ["The study", "TEST", 0, 9], ["COVID", "TEST", 37, 42], ["urban air pollution", "TREATMENT", 59, 78], ["National aeronautics and Space Administration", "TREATMENT", 225, 270], ["GIS techniques", "TEST", 298, 312], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["diurnal", "OBSERVATION_MODIFIER", 316, 323]]], ["The spatio-temporal variation of different components and their percentages has been calculated to understand the changing nature of the air quality.", [["temporal", "OBSERVATION_MODIFIER", 11, 19], ["variation", "OBSERVATION_MODIFIER", 20, 29], ["different", "OBSERVATION_MODIFIER", 33, 42], ["components", "OBSERVATION_MODIFIER", 43, 53], ["percentages", "OBSERVATION_MODIFIER", 64, 75], ["air quality", "OBSERVATION", 137, 148]]], ["The different digital thematic maps have been prepared on Arc GIS 10.3 platform.Statistical analysisThe diverse multivariate statistical methods such as hierarchical cluster analysis (HCA) and principal component analysis (PCA) have been employed using IBM SPSS (16.0) statistical software to examine the significance of the selective air pollution parameters of Kolkata City.", [["Arc GIS", "TEST", 58, 65], ["Statistical analysis", "TEST", 80, 100], ["hierarchical cluster analysis", "TEST", 153, 182], ["principal component analysis", "TEST", 193, 221], ["IBM SPSS", "TEST", 253, 261], ["statistical software", "TEST", 269, 289]]], ["In hierarchical cluster analysis, the similarity is drawn by various proper metrics with linkage principle.", [["hierarchical cluster analysis", "TEST", 3, 32]]], ["A few common metrics have been applied (between a & b variables) in HCA system.", [["a & b variables", "TREATMENT", 48, 63], ["few", "OBSERVATION_MODIFIER", 2, 5]]], ["PCA has been performed considering six different parameters of air quality standard in pre-and during lockdown and PCA mainly represents the dataset more reliable.", [["PCA", "TREATMENT", 0, 3], ["lockdown and PCA", "TREATMENT", 102, 118]]], ["The PCA is done through some mathematical algorithms.", [["The PCA", "TREATMENT", 0, 7], ["some mathematical algorithms", "TEST", 24, 52], ["PCA", "ANATOMY", 4, 7]]], ["These are as follows:Statistical analysis\u2022 Standardization \u2022 Covariance matrix \u2022 Computation of eigenvector and value.Statistical analysiswhere X is the initial, whereas \u00b5 and represent mean and SD.Statistical analysisFor population For SampleDetection of land surface temperature variationWhen the temperature of the earth surface features is higher than the absolute zero (\u2212273\u00b0C/0 K), then each object radiates thermal electromagnetic energy and in addition to LST of different objects has been determined.", [["surface", "ANATOMY", 324, 331], ["Statistical analysis", "TEST", 21, 41], ["Statistical analysis", "TEST", 198, 218], ["SampleDetection", "TEST", 237, 252], ["land surface temperature", "TEST", 256, 280], ["higher", "OBSERVATION_MODIFIER", 344, 350], ["electromagnetic energy", "OBSERVATION", 422, 444], ["objects", "OBSERVATION", 481, 488]]], ["The different methods are available for the extraction of accurate LST, whereas these methods are invented by Landsat Project Science Office (LPSO 2002) .", [["the extraction", "TREATMENT", 40, 54]]], ["The transformation of DN values into reflectance values has been accomplished through the application of radiometric correction.", [["reflectance values", "TEST", 37, 55], ["radiometric correction", "TREATMENT", 105, 127]]], ["For the extraction of the Top of Atmospheric Radiance (TAR), the LANDSAT 8 OLI and LANDSAT 7 ETM + band data have been converted using the following formula:Detection of land surface temperature variationwhere L\u03bb = Top of Atmospheric Radiance, M L = band-specific multiplicative rescaling factor, Q cal = Band10 image, AL = band-specific additive rescaling factor and Oi = correction for Band10.Detection of land surface temperature variationThen, the brightness temperature has been measured using the thermal constant extracted from metadata file for conversion of radiance to at-sensor temperature.", [["surface", "ANATOMY", 175, 182], ["surface", "ANATOMY", 413, 420], ["multiplicative rescaling factor", "PROTEIN", 264, 295], ["additive rescaling factor", "PROTEIN", 338, 363], ["Band10", "PROTEIN", 388, 394], ["Atmospheric Radiance (TAR", "TREATMENT", 33, 58], ["the LANDSAT", "TEST", 61, 72], ["LANDSAT", "TEST", 83, 90], ["band data", "TEST", 99, 108], ["land surface temperature", "TEST", 170, 194], ["variationwhere", "TEST", 195, 209], ["L\u03bb", "TEST", 210, 212], ["Atmospheric Radiance", "TEST", 222, 242], ["band", "TEST", 250, 254], ["multiplicative rescaling factor", "TEST", 264, 295], ["Band10 image", "TEST", 305, 317], ["AL = band", "TEST", 319, 328], ["Band10", "TEST", 388, 394], ["land surface temperature variation", "PROBLEM", 408, 442], ["the brightness temperature", "TEST", 448, 474]]], ["The following equation has been applied (1)Detection of land surface temperature variationwhere BT = brightness temperature.", [["surface", "ANATOMY", 61, 68], ["land surface temperature", "TEST", 56, 80], ["brightness temperature", "TEST", 101, 123]]], ["K 1 and K 2 = band-specific thermal conversion constants from the metadata file of the downloaded image.Detection of land surface temperature variationNDVI is regarded as an imperative tool for LST calculation because the proportion of vegetation (PV) is interrelated with NDVI.", [["surface", "ANATOMY", 122, 129], ["K", "CHEMICAL", 0, 1], ["K", "CHEMICAL", 8, 9], ["K 1", "GENE_OR_GENE_PRODUCT", 0, 3], ["K", "TEST", 0, 1], ["K", "TEST", 8, 9], ["band", "TEST", 14, 18], ["land surface temperature variationNDVI", "TEST", 117, 155], ["LST calculation", "TEST", 194, 209], ["vegetation (PV)", "PROBLEM", 236, 251], ["vegetation", "OBSERVATION", 236, 246]]], ["The calculation has been done with the help of following equationDetection of land surface temperature variationwhere NIR = near-infrared band (Band5) and R = red band (Band4).Detection of land surface temperature variationThe following formula has been used to calculate the proportion of vegetation (PV)Detection of land surface temperature variationThe emissivity of every pixel has been measured from the PV value.", [["surface", "ANATOMY", 194, 201], ["surface", "ANATOMY", 323, 330], ["Band5", "PROTEIN", 144, 149], ["red band", "PROTEIN", 159, 167], ["Band4", "PROTEIN", 169, 174], ["The calculation", "TEST", 0, 15], ["land surface temperature", "TEST", 78, 102], ["NIR", "TEST", 118, 121], ["infrared band", "TEST", 129, 142], ["Band5", "TEST", 144, 149], ["red band (Band4", "TEST", 159, 174], ["land surface temperature variation", "PROBLEM", 189, 223], ["vegetation", "PROBLEM", 290, 300], ["land surface temperature variation", "PROBLEM", 318, 352], ["the PV value", "TEST", 405, 417], ["vegetation", "OBSERVATION", 290, 300], ["emissivity", "OBSERVATION_MODIFIER", 356, 366], ["PV", "ANATOMY", 409, 411]]], ["The land surface emissivity has been derived using the following formula where \u03b5 \u03bb= Land surface Emissivity, \u03b5 V= vegetation emissivity, \u03b5 s = soil emissivity, C = surface roughness (C = 0 for homogenous and flat surfaces) considered as a constant value of 0.005 (Sobrino and Raissouni 2000) .Detection of land surface temperature variationFinally, the extraction of LST has been executed using the following equationDetection of land surface temperature variationwhere T s = LST in Celsius (\u00b0C), BT = brightness temperature, \u03bb = wavelength of emitted radiance (\u03bb = 10.895), \u03b5 \u03bb = calculated emissivity.", [["surface", "ANATOMY", 9, 16], ["surface", "ANATOMY", 164, 171], ["surface", "ANATOMY", 311, 318], ["surface", "ANATOMY", 435, 442], ["The land surface emissivity", "TREATMENT", 0, 27], ["Land surface Emissivity", "TEST", 84, 107], ["vegetation emissivity", "TEST", 114, 135], ["\u03b5 s", "TEST", 137, 140], ["soil emissivity", "TEST", 143, 158], ["C = surface roughness", "TEST", 160, 181], ["C", "TEST", 183, 184], ["homogenous and flat surfaces", "PROBLEM", 193, 221], ["a constant value", "TEST", 237, 253], ["land surface temperature variation", "PROBLEM", 306, 340], ["land surface temperature", "TEST", 430, 454], ["T s", "TEST", 470, 473], ["LST in Celsius", "TEST", 476, 490], ["BT", "TEST", 497, 499], ["brightness temperature", "TEST", 502, 524], ["emitted radiance", "TEST", 544, 560]]], ["After the computation of LST during the sampling time period, LST mapping has been performed on the platform of Arc GIS 10.3 to compare the modification of land surface temperature between lockdown phase and pre-lockdown.", [["surface", "ANATOMY", 161, 168], ["LST", "DNA", 25, 28], ["LST", "DNA", 62, 65], ["LST mapping", "TEST", 62, 73], ["Arc GIS", "TEST", 112, 119]]], ["Furthermore, the range of temperature variability has been depicted by the graphical representation using MS Excel 2016.Changing trend of CO, NO 2 , SO 2 and O 3 during and pre-lockdown phase over Kolkata CityThe qualitative aspect of air is recognized as an indispensable criterion for the health-related issues of human being, while 91% population of the world survives in the areas where the inferior air quality surpasses the desirable limit (WHO 2016).", [["NO", "CHEMICAL", 142, 144], ["CO", "CHEMICAL", 138, 140], ["NO 2", "CHEMICAL", 142, 146], ["SO 2", "CHEMICAL", 149, 153], ["O 3", "CHEMICAL", 158, 161], ["CO", "SIMPLE_CHEMICAL", 138, 140], ["NO 2", "SIMPLE_CHEMICAL", 142, 146], ["SO 2", "GENE_OR_GENE_PRODUCT", 149, 153], ["O 3", "GENE_OR_GENE_PRODUCT", 158, 161], ["human", "ORGANISM", 316, 321], ["human", "SPECIES", 316, 321], ["human", "SPECIES", 316, 321], ["air", "OBSERVATION", 235, 238], ["inferior", "ANATOMY_MODIFIER", 395, 403]]], ["The concentration of NO 2 and aerosol has been massively reduced over India in the lockdown period compared with the prior years (Figs.", [["NO", "CHEMICAL", 21, 23], ["NO 2", "CHEMICAL", 21, 25], ["NO 2", "SIMPLE_CHEMICAL", 21, 25], ["aerosol", "TREATMENT", 30, 37], ["massively", "OBSERVATION_MODIFIER", 47, 56], ["reduced", "OBSERVATION_MODIFIER", 57, 64]]], ["The average level of CO, NO 2 and SO 2 is significantly decreased in the year 2020 during the lockdown phase (March 25 to May15) compared with the identical time period from 2017 to 2019 (Table 1) (Table 1 ; Fig. 4 ; Supplemental Materials S1, S2, S3 and S4).", [["NO", "CHEMICAL", 25, 27], ["CO", "CHEMICAL", 21, 23], ["NO 2", "CHEMICAL", 25, 29], ["SO 2", "CHEMICAL", 34, 38], ["CO", "SIMPLE_CHEMICAL", 21, 23], ["NO 2", "GENE_OR_GENE_PRODUCT", 25, 29], ["SO 2", "GENE_OR_GENE_PRODUCT", 34, 38], ["S2", "PROTEIN", 244, 246], ["S3", "PROTEIN", 248, 250], ["S4", "PROTEIN", 255, 257], ["The average level of CO", "TEST", 0, 23], ["significantly", "OBSERVATION_MODIFIER", 42, 55], ["decreased", "OBSERVATION", 56, 65], ["S2", "ANATOMY", 244, 246], ["S4", "ANATOMY", 255, 257]]], ["The similarChanging trend of CO, NO 2 , SO 2 and O 3 during and pre-lockdown phase over Kolkata Cityscenario is observed during April and May (up to May 15) of 2020 when the share of CO is radically dropped up to 6.34% and 6.88%, respectively, from April and May (up to May 15) of 2019 (Table 2) .", [["NO", "CHEMICAL", 33, 35], ["CO", "CHEMICAL", 29, 31], ["NO 2", "CHEMICAL", 33, 37], ["SO 2", "CHEMICAL", 40, 44], ["O 3", "CHEMICAL", 49, 52], ["CO", "CHEMICAL", 183, 185], ["CO", "SIMPLE_CHEMICAL", 29, 31], ["NO 2", "SIMPLE_CHEMICAL", 33, 37], ["SO 2", "SIMPLE_CHEMICAL", 40, 44], ["O 3", "SIMPLE_CHEMICAL", 49, 52], ["CO", "SIMPLE_CHEMICAL", 183, 185], ["CO", "TEST", 29, 31], ["CO", "TEST", 183, 185], ["trend", "OBSERVATION_MODIFIER", 20, 25]]], ["It is surprisingly noticed that highest monthly average concentration level of CO was 34.88% in May 2018 during pre-lockdown, while the maximum monthly average decrease in CO (14.99%) has been recorded in May 2020 during lockdown period (Table 2) .", [["CO", "CHEMICAL", 79, 81], ["CO", "CHEMICAL", 172, 174], ["CO", "TEST", 79, 81], ["CO", "TEST", 172, 174], ["decrease", "OBSERVATION_MODIFIER", 160, 168]]], ["On the other hand, the reduction rate of NO 2 is highest (12.98%) in the month of April 2020 throughout the lockdown periods, whereas the maximum amount of NO 2 emission (40.19%) was measured in March 2019 ( Table 2 ).", [["NO", "CHEMICAL", 41, 43], ["NO", "CHEMICAL", 156, 158], ["NO 2", "CHEMICAL", 41, 45], ["NO 2", "CHEMICAL", 156, 160], ["NO 2", "GENE_OR_GENE_PRODUCT", 41, 45], ["NO 2", "SIMPLE_CHEMICAL", 156, 160], ["the reduction rate", "TEST", 19, 37], ["maximum", "OBSERVATION_MODIFIER", 138, 145], ["amount", "OBSERVATION_MODIFIER", 146, 152], ["NO", "UNCERTAINTY", 156, 158]]], ["The month-wise concentration of mean NO 2 has been (Table 1; Fig. 4 ; Supplemental Materials S1, S2, S3 and S4).", [["NO", "CHEMICAL", 37, 39], ["NO 2", "CHEMICAL", 37, 41], ["S2", "PROTEIN", 97, 99], ["S3", "PROTEIN", 101, 103], ["S4", "PROTEIN", 108, 110], ["S2", "ANATOMY", 97, 99], ["S4", "ANATOMY", 108, 110]]], ["It is focused that about 19.46% NO 2 is reduced during the quarantine phase in Kolkata, while emission of NO 2 is dwindled by 22.79% from March 2019 (41.58 \u00b5g/m 3 ) to March 2020 (18.01 \u00b5g/m3) (Tables 1, 2) .", [["NO", "CHEMICAL", 32, 34], ["NO", "CHEMICAL", 106, 108], ["NO 2", "CHEMICAL", 32, 36], ["NO 2", "CHEMICAL", 106, 110], ["NO 2", "GENE_OR_GENE_PRODUCT", 32, 36], ["NO 2", "SIMPLE_CHEMICAL", 106, 110], ["reduced", "OBSERVATION_MODIFIER", 40, 47]]], ["Beside this, the slashing trend of another crucial pollutant (SO 2) has been registered throughout the lockdown period in this overcrowded city of India.", [["crucial", "OBSERVATION_MODIFIER", 43, 50], ["pollutant", "OBSERVATION", 51, 60]]], ["In April of 2018, the accumulation of SO 2 in the lower atmosphere was 9.47 \u00b5g/m3, whereas the quantity has been diminished up to 5.36 \u00b5g/m3 in the same month of 2020 (Table 1; Fig. 4 ; Supplemental Materials S1, S2, S3 and S4).", [["SO 2", "CHEMICAL", 38, 42], ["SO 2", "CHEMICAL", 38, 42], ["SO 2", "GENE_OR_GENE_PRODUCT", 38, 42], ["S2", "PROTEIN", 213, 215], ["S3", "PROTEIN", 217, 219], ["S4", "PROTEIN", 224, 226], ["diminished", "PROBLEM", 113, 123], ["lower", "ANATOMY_MODIFIER", 50, 55], ["quantity", "OBSERVATION_MODIFIER", 95, 103], ["diminished", "OBSERVATION_MODIFIER", 113, 123], ["S2", "ANATOMY", 213, 215], ["S4", "ANATOMY", 224, 226]]], ["Around 13.4% drop of this lethal gaseous substance (SO 2 ) occurred during this critical period.", [["this lethal gaseous substance", "PROBLEM", 21, 50]]], ["In the same way, the extreme concentration of SO 2 (42.92%) had been recorded in May of 2017, while during the lockdown, the highest emission of SO 2 (30.41%) has been found in March of 2020 (Table 2 ).", [["SO 2", "CHEMICAL", 46, 50]]], ["Moreover; it is an exceptional incident that the density of O 3 has been amplified in Kolkata during this ongoing lockdown period.", [["O 3", "CHEMICAL", 60, 63], ["O 3", "GENE_OR_GENE_PRODUCT", 60, 63], ["O 3", "PROTEIN", 60, 63], ["density", "OBSERVATION", 49, 56]]], ["The result shows that the concentration of O 3 is boosted up to 9.73% in April of 2020 and the similar increasing trend has been reported in March and May of 2020 compared with 2019 (Table 2, Fig. 4) .", [["O 3", "CHEMICAL", 43, 46], ["increasing", "OBSERVATION_MODIFIER", 103, 113]]], ["The quantity of O 3 was 28.08 \u00b5g/m3 in April 2019, while it has been increased up to 45.56 \u00b5g/m 3 in this particular month of 2020 (Table 1; Fig. 4 ; Supplemental Materials S1, S2, S3 and S4) and it is representing the rebounding tendency of this significant parameter of air quality in Kolkata.Fluctuation of the concentration of suspended particulate matters (PM 10 and PM 2.5 )The concentration of suspended particulate matters above 100 \u00b5g/m 3 in the lower atmosphere is injurious for the health of human being (WHO 2006) .", [["O 3", "CHEMICAL", 16, 19], ["human", "ORGANISM", 503, 508], ["human", "SPECIES", 503, 508], ["human", "SPECIES", 503, 508], ["The concentration of suspended particulate matters", "TREATMENT", 380, 430], ["quantity", "OBSERVATION_MODIFIER", 4, 12], ["increased", "OBSERVATION_MODIFIER", 69, 78], ["S2", "ANATOMY", 177, 179], ["air quality", "OBSERVATION", 272, 283], ["concentration", "OBSERVATION_MODIFIER", 314, 327], ["injurious", "OBSERVATION", 475, 484]]], ["Just during the initiation of lockdown (in the end of March 2020), PM 10 level is dropped to 8.94% in comparison with 2019 and the magnitude of reducing trend becomes sharply vibrant through the lockdown months (Table 2 ).", [["lockdown", "TREATMENT", 30, 38]]], ["PM 10 is reduced by 11.75% and 20.91% in April and May of 2020, respectively, from same months of the year 2019 (Impact of air quality change on land surface temperatureThe LST records illustrate the distinct variation of surface temperature of Kolkata City between lockdown and pre-lockdown situation.", [["surface", "ANATOMY", 222, 229], ["land surface temperature", "TREATMENT", 145, 169], ["reduced", "OBSERVATION_MODIFIER", 9, 16], ["air quality", "OBSERVATION", 123, 134], ["distinct", "OBSERVATION_MODIFIER", 200, 208], ["variation", "OBSERVATION_MODIFIER", 209, 218], ["surface", "OBSERVATION_MODIFIER", 222, 229]]], ["The study portrays that there is a prominent reduction of surface temperature due to the continuation of lockdowns compared with the previous years (2017-2019).", [["surface", "ANATOMY", 58, 65], ["The study", "TEST", 0, 9], ["a prominent reduction of surface temperature", "PROBLEM", 33, 77], ["prominent", "OBSERVATION_MODIFIER", 35, 44], ["reduction", "OBSERVATION_MODIFIER", 45, 54], ["surface temperature", "OBSERVATION", 58, 77]]], ["The surface temperature varies from 26.39 to 33.34\u00b0C from March 25 to May 15, 2020, during lockdown session (Figs.", [["surface", "ANATOMY", 4, 11], ["The surface temperature", "TEST", 0, 23], ["surface", "OBSERVATION_MODIFIER", 4, 11]]], ["During the prior time period (2017-2019) of lockdown state, the variation of surface temperature had been reflected from 26.62 to 36.54\u00b0C and it must be mentioned that temperature has been reduced by 0.23 to 3.2\u00b0C within the lockdown ambience ( Figs.", [["surface", "ANATOMY", 77, 84], ["C", "GENE_OR_GENE_PRODUCT", 212, 213], ["surface temperature", "TEST", 77, 96], ["temperature", "TEST", 168, 179]]], ["It is found that the average surface temperature during the mentioned time period is 29.98\u00b0C in 2020, while the average value was 31.84\u00b0C during 2017-2019.The lower atmospheric temperature gradually rises due to the higher concentration of suspended particulate matters along with other pollutants.", [["surface", "ANATOMY", 29, 36], ["The lower atmospheric temperature", "PROBLEM", 155, 188], ["average", "OBSERVATION_MODIFIER", 21, 28], ["surface", "OBSERVATION_MODIFIER", 29, 36], ["lower", "OBSERVATION_MODIFIER", 159, 164], ["particulate matters", "OBSERVATION", 250, 269]]], ["So, there is direct relationship between presence of pollutants and increase in lower atmospheric temperature.Evaluation of air quality standard applying statistical techniquesTwo important cluster groups have been created applying hierarchical cluster analysis (HCA) and each cluster has similar air quality standard.", [["pollutants", "PROBLEM", 53, 63], ["lower atmospheric temperature", "PROBLEM", 80, 109], ["Evaluation of air quality", "TEST", 110, 135], ["statistical techniques", "TEST", 154, 176], ["pollutants", "OBSERVATION", 53, 63], ["increase", "OBSERVATION_MODIFIER", 68, 76], ["lower", "OBSERVATION_MODIFIER", 80, 85], ["atmospheric temperature", "OBSERVATION", 86, 109], ["air quality", "OBSERVATION", 124, 135], ["air quality", "OBSERVATION", 297, 308]]], ["The average value of CO in cluster-1 is 3.16, while the value of CO in cluster-2 is 0.77.", [["CO", "CHEMICAL", 21, 23], ["CO", "CHEMICAL", 65, 67], ["CO", "PROTEIN", 21, 23], ["CO in cluster", "TEST", 21, 34], ["CO in cluster", "TEST", 65, 78], ["average", "OBSERVATION_MODIFIER", 4, 11]]], ["It has been also noticed that the average value of NO 2 and SO 2 in cluster-1 is 25.76 and 14.78, respectively, whereas the values of NO 2 and SO 2 in cluster-2 are 13.14 and 5.01, respectively.", [["NO", "CHEMICAL", 51, 53], ["NO", "CHEMICAL", 134, 136], ["NO 2", "CHEMICAL", 51, 55], ["SO 2", "CHEMICAL", 60, 64], ["NO 2", "CHEMICAL", 134, 138], ["SO 2", "CHEMICAL", 143, 147], ["NO 2", "GENE_OR_GENE_PRODUCT", 51, 55], ["SO 2", "GENE_OR_GENE_PRODUCT", 60, 64], ["cluster-1", "GENE_OR_GENE_PRODUCT", 68, 77], ["NO 2", "GENE_OR_GENE_PRODUCT", 134, 138], ["SO 2", "GENE_OR_GENE_PRODUCT", 143, 147], ["the average value", "TEST", 30, 47], ["the values", "TEST", 120, 130], ["average", "OBSERVATION_MODIFIER", 34, 41]]], ["From this overall analysis, it is explained that the air quality is far better in the year 2020 lockdown period with respect to pre-lockdown years (2017, 2018 and 2019) .", [["this overall analysis", "TEST", 5, 26], ["the air quality", "PROBLEM", 49, 64], ["air", "OBSERVATION", 53, 56]]], ["The ordinal plot also reveals that in pre-lockdown phase O 3 , SO 2 and NO 2 have more or less similar pattern, whereas PM 10 , PM 2.5 and CO are distantly correlated.", [["NO", "CHEMICAL", 72, 74], ["O 3", "CHEMICAL", 57, 60], ["SO 2", "CHEMICAL", 63, 67], ["NO 2", "CHEMICAL", 72, 76], ["CO", "CHEMICAL", 139, 141], ["SO 2", "GENE_OR_GENE_PRODUCT", 63, 67], ["NO 2", "GENE_OR_GENE_PRODUCT", 72, 76], ["CO", "SIMPLE_CHEMICAL", 139, 141], ["The ordinal plot", "TEST", 0, 16], ["CO", "TEST", 139, 141]]], ["On the other hand, during lockdown period the first two components of PCA depict about 81.471% of the total variables and the ordinal plot also reveals that SO 2 has a distant correlation with other parameters, while other parameters have a same pattern.DiscussionAs the air quality is deteriorating day by day across the globe, the longevity of human life compels to turn down and annual death toll is ever-increasing throughout the world within the last decade.", [["death", "DISEASE", 389, 394], ["SO 2", "GENE_OR_GENE_PRODUCT", 157, 161], ["human", "ORGANISM", 346, 351], ["human", "SPECIES", 346, 351], ["human", "SPECIES", 346, 351], ["PCA depict", "TEST", 70, 80], ["the total variables", "TEST", 98, 117], ["the ordinal plot", "TEST", 122, 138], ["globe", "ANATOMY", 322, 327]]], ["Around 8% human demise had been caused due to the threat of air pollution mostly in the countries in Asia, Africa and a small portion of Europe (WHO 2016) .", [["human", "ORGANISM", 10, 15], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 10, 15], ["air pollution", "PROBLEM", 60, 73], ["air pollution", "OBSERVATION", 60, 73], ["small", "OBSERVATION_MODIFIER", 120, 125]]], ["The global human deaths are directly linked with respiratory diseases (26%), chronic obstructive pulmonary disease (25%), stroke and ischaemic heart (17%) due to the threat of severe air pollution (WHO 2020b).", [["respiratory", "ANATOMY", 49, 60], ["pulmonary", "ANATOMY", 97, 106], ["heart", "ANATOMY", 143, 148], ["deaths", "DISEASE", 17, 23], ["respiratory diseases", "DISEASE", 49, 69], ["chronic obstructive pulmonary disease", "DISEASE", 77, 114], ["stroke", "DISEASE", 122, 128], ["air pollution", "DISEASE", 183, 196], ["human", "ORGANISM", 11, 16], ["pulmonary", "ORGAN", 97, 106], ["heart", "ORGAN", 143, 148], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["The global human deaths", "PROBLEM", 0, 23], ["respiratory diseases", "PROBLEM", 49, 69], ["chronic obstructive pulmonary disease", "PROBLEM", 77, 114], ["stroke", "PROBLEM", 122, 128], ["ischaemic heart", "PROBLEM", 133, 148], ["severe air pollution", "PROBLEM", 176, 196], ["global", "OBSERVATION_MODIFIER", 4, 10], ["human deaths", "OBSERVATION", 11, 23], ["respiratory diseases", "OBSERVATION", 49, 69], ["chronic", "OBSERVATION_MODIFIER", 77, 84], ["obstructive", "OBSERVATION_MODIFIER", 85, 96], ["pulmonary", "ANATOMY", 97, 106], ["disease", "OBSERVATION", 107, 114], ["stroke", "OBSERVATION", 122, 128], ["ischaemic", "OBSERVATION_MODIFIER", 133, 142], ["heart", "ANATOMY", 143, 148], ["severe", "OBSERVATION_MODIFIER", 176, 182], ["air pollution", "OBSERVATION", 183, 196]]], ["It must be predicted that the proportion of respiratory and allergic illness would be augmented mostly because of the rapid modification of air quality in different corners of the globe (Haque and Singh 2017) .", [["respiratory and allergic illness", "DISEASE", 44, 76], ["respiratory and allergic illness", "PROBLEM", 44, 76], ["the rapid modification of air quality", "PROBLEM", 114, 151], ["respiratory", "ANATOMY", 44, 55], ["allergic", "OBSERVATION", 60, 68], ["rapid", "OBSERVATION_MODIFIER", 118, 123], ["modification", "OBSERVATION", 124, 136], ["air quality", "OBSERVATION", 140, 151], ["different", "ANATOMY_MODIFIER", 155, 164], ["corners", "ANATOMY_MODIFIER", 165, 172], ["globe", "ANATOMY", 180, 185]]], ["In general, lighting, power plants and transport sectors are the principal source areas of NO 2 (He et al. 2020; Sharma et al. 2020) .", [["NO", "CHEMICAL", 91, 93], ["NO 2", "CHEMICAL", 91, 95], ["NO", "SIMPLE_CHEMICAL", 91, 93]]], ["Several studies have pointed out that long-time acquaintance to NO 2 is responsible for various deadly diseases like lung function disorders, stroke, cardiovascular disease, severe asthma, untimely demise, etc. (Saeha et al. 2020; Humbal et al. 2019; Arden Pope et al. 2004) .", [["lung", "ANATOMY", 117, 121], ["cardiovascular", "ANATOMY", 150, 164], ["NO", "CHEMICAL", 64, 66], ["lung function disorders", "DISEASE", 117, 140], ["stroke", "DISEASE", 142, 148], ["cardiovascular disease", "DISEASE", 150, 172], ["asthma", "DISEASE", 181, 187], ["NO 2", "CHEMICAL", 64, 68], ["NO 2", "GENE_OR_GENE_PRODUCT", 64, 68], ["lung", "ORGAN", 117, 121], ["Several studies", "TEST", 0, 15], ["various deadly diseases", "PROBLEM", 88, 111], ["lung function disorders", "PROBLEM", 117, 140], ["stroke", "PROBLEM", 142, 148], ["cardiovascular disease", "PROBLEM", 150, 172], ["severe asthma", "PROBLEM", 174, 187], ["untimely demise", "PROBLEM", 189, 204], ["responsible for", "UNCERTAINTY", 72, 87], ["lung", "ANATOMY", 117, 121], ["cardiovascular", "ANATOMY", 150, 164], ["severe", "OBSERVATION_MODIFIER", 174, 180], ["asthma", "OBSERVATION", 181, 187]]], ["Not only the long-time based contact, short-spell contact with NO 2 can also aggravate the death rate of human being (Faustini et al. 2014 ).The gaseous emissions from the chimneys of power plants and industries, vehicles, burning of biomass, solid waste and dust particles from constructional activities are the principal anthropogenic sources of air pollution including CO, NO 2 , SO 2 , suspended particulate matters (PM 10 , PM 2.5 ) in India.", [["NO", "CHEMICAL", 63, 65], ["death", "DISEASE", 91, 96], ["NO", "CHEMICAL", 376, 378], ["NO 2", "CHEMICAL", 63, 67], ["CO", "CHEMICAL", 372, 374], ["NO 2", "CHEMICAL", 376, 380], ["SO 2", "CHEMICAL", 383, 387], ["NO 2", "GENE_OR_GENE_PRODUCT", 63, 67], ["human", "ORGANISM", 105, 110], ["CO", "SIMPLE_CHEMICAL", 372, 374], ["NO 2", "SIMPLE_CHEMICAL", 376, 380], ["SO 2", "SIMPLE_CHEMICAL", 383, 387], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["The gaseous emissions", "PROBLEM", 141, 162], ["burning of biomass", "PROBLEM", 223, 241], ["solid waste", "PROBLEM", 243, 254], ["dust particles", "PROBLEM", 259, 273], ["air pollution", "PROBLEM", 348, 361], ["gaseous emissions", "OBSERVATION", 145, 162], ["power plants", "OBSERVATION", 184, 196], ["solid waste", "OBSERVATION", 243, 254], ["dust particles", "OBSERVATION", 259, 273], ["principal", "OBSERVATION_MODIFIER", 313, 322], ["anthropogenic sources", "OBSERVATION", 323, 344], ["air pollution", "OBSERVATION", 348, 361]]], ["In the last two decades, the increasing trend of morbidity as well as mortality due to cardiovascular disease, chronic obstructive pulmonary disease, infections, asthma, bronchitis is regarded as the fatal consequences of tremendous air pollution in city and town areas countrywide.", [["cardiovascular", "ANATOMY", 87, 101], ["pulmonary", "ANATOMY", 131, 140], ["cardiovascular disease", "DISEASE", 87, 109], ["chronic obstructive pulmonary disease", "DISEASE", 111, 148], ["infections", "DISEASE", 150, 160], ["asthma", "DISEASE", 162, 168], ["bronchitis", "DISEASE", 170, 180], ["pulmonary", "ORGAN", 131, 140], ["morbidity", "PROBLEM", 49, 58], ["cardiovascular disease", "PROBLEM", 87, 109], ["chronic obstructive pulmonary disease", "PROBLEM", 111, 148], ["infections", "PROBLEM", 150, 160], ["asthma", "PROBLEM", 162, 168], ["bronchitis", "PROBLEM", 170, 180], ["tremendous air pollution", "PROBLEM", 222, 246], ["increasing", "OBSERVATION_MODIFIER", 29, 39], ["trend", "OBSERVATION_MODIFIER", 40, 45], ["morbidity", "OBSERVATION", 49, 58], ["cardiovascular", "ANATOMY", 87, 101], ["disease", "OBSERVATION", 102, 109], ["chronic", "OBSERVATION_MODIFIER", 111, 118], ["obstructive", "OBSERVATION_MODIFIER", 119, 130], ["pulmonary", "ANATOMY", 131, 140], ["disease", "OBSERVATION", 141, 148], ["infections", "OBSERVATION", 150, 160], ["asthma", "OBSERVATION", 162, 168], ["bronchitis", "OBSERVATION", 170, 180], ["tremendous", "OBSERVATION_MODIFIER", 222, 232], ["air pollution", "OBSERVATION", 233, 246]]], ["The previous study highlighted that approximately 70% people of Kolkata have been victimized due to the respiratory illness caused by the lower atmospheric toxic pollutants (Mukhopadhyay 2009 ).", [["respiratory", "ANATOMY", 104, 115], ["respiratory illness", "DISEASE", 104, 123], ["people", "ORGANISM", 54, 60], ["people", "SPECIES", 54, 60], ["The previous study", "TEST", 0, 18], ["the respiratory illness", "PROBLEM", 100, 123], ["the lower atmospheric toxic pollutants", "PROBLEM", 134, 172], ["respiratory illness", "OBSERVATION", 104, 123], ["lower", "OBSERVATION_MODIFIER", 138, 143], ["atmospheric", "OBSERVATION_MODIFIER", 144, 155], ["toxic pollutants", "OBSERVATION", 156, 172]]], ["Here, the study reflects that enormous accumulation of vital air pollutants like CO, NO 2 , SO 2 , PM 10 , PM 2.5 in the lower atmosphere degrades the air quality of Kolkata over the years.", [["NO 2 , SO 2 , PM 10 , PM 2.5", "CHEMICAL", 85, 113], ["CO", "CHEMICAL", 81, 83], ["NO 2", "CHEMICAL", 85, 89], ["SO 2", "CHEMICAL", 92, 96], ["CO", "SIMPLE_CHEMICAL", 81, 83], ["NO 2", "SIMPLE_CHEMICAL", 85, 89], ["SO 2", "SIMPLE_CHEMICAL", 92, 96], ["PM 10", "SIMPLE_CHEMICAL", 99, 104], ["the study", "TEST", 6, 15], ["enormous accumulation of vital air pollutants", "PROBLEM", 30, 75], ["enormous", "OBSERVATION_MODIFIER", 30, 38], ["accumulation", "OBSERVATION_MODIFIER", 39, 51], ["vital air pollutants", "OBSERVATION", 55, 75], ["air quality", "OBSERVATION_MODIFIER", 151, 162]]], ["It must be stated that the gaseous and dust emissions from outdated and unwell-maintained vehicles, numerous industries, activities of eateries and construction works are continuously degrading the air quality standard in and around the city.", [["the gaseous and dust emissions", "PROBLEM", 23, 53], ["unwell", "PROBLEM", 72, 78], ["gaseous", "OBSERVATION_MODIFIER", 27, 34]]], ["Among these sources, transport sector plays a crucial role to excess release of NO 2 , whereas maximum CO and SO 2 have been emitted from different modes of transport and large, medium and small-scale industries in and around the vicinity of Kolkata.", [["NO", "CHEMICAL", 80, 82], ["NO 2", "CHEMICAL", 80, 84], ["CO", "CHEMICAL", 103, 105], ["SO 2", "CHEMICAL", 110, 114], ["NO 2", "SIMPLE_CHEMICAL", 80, 84], ["CO", "SIMPLE_CHEMICAL", 103, 105], ["SO 2", "GENE_OR_GENE_PRODUCT", 110, 114], ["large", "OBSERVATION_MODIFIER", 171, 176]]], ["Moreover, PM 10 and PM 2.5 have been mostly released from road dust, gaseous emission of vehicles, industrial chimneys and combustion of coal and burning of municipal wastes.", [["coal", "CHEMICAL", 137, 141], ["industrial chimneys", "PROBLEM", 99, 118], ["coal and burning of municipal wastes", "PROBLEM", 137, 173], ["gaseous emission", "OBSERVATION", 69, 85], ["industrial chimneys", "OBSERVATION", 99, 118], ["municipal wastes", "OBSERVATION", 157, 173]]], ["Roadways, railways, airways and waterways are mostly stopped during the lockdown period which reduces the concentration of CO and NO 2 in the atmosphere of Kolkata.", [["airways", "ANATOMY", 20, 27], ["NO", "CHEMICAL", 130, 132], ["CO", "CHEMICAL", 123, 125], ["NO 2", "CHEMICAL", 130, 134], ["airways", "MULTI-TISSUE_STRUCTURE", 20, 27], ["CO", "SIMPLE_CHEMICAL", 123, 125], ["NO 2", "SIMPLE_CHEMICAL", 130, 134], ["airways", "ANATOMY", 20, 27]]], ["Moreover, partially shutdown of industrial and transport sectors reduces SO 2 level than the preceding period of lockdown but due to continuous coal combustion in different thermal power stations (Kolaghat, Bandel and Budge-Budge thermal power stations) at the vicinity of Kolkata, SO 2 level has not been significantly declined.", [["coal", "CHEMICAL", 144, 148], ["continuous coal combustion", "PROBLEM", 133, 159], ["Kolaghat", "TREATMENT", 197, 205], ["Bandel", "TREATMENT", 207, 213], ["Budge", "TREATMENT", 218, 223], ["Budge thermal power stations", "TREATMENT", 224, 252], ["coal combustion", "OBSERVATION", 144, 159]]], ["The PM 10 and PM 2.5 have been drastically fallen due to diminution of fossil fuel combustion, transportation and industrial release of dusts along with closed constructional activities in the city.", [["The PM", "TEST", 0, 6], ["fossil fuel combustion", "PROBLEM", 71, 93], ["industrial release of dusts", "TREATMENT", 114, 141], ["fossil", "OBSERVATION", 71, 77], ["fuel combustion", "OBSERVATION", 78, 93]]], ["It is noteworthy in this context that the concentration of O 3 is one of the important parameters for assessing air quality and it is comprehensively improved during lockdown because of the falling of NO 2 accumulation.", [["NO", "CHEMICAL", 201, 203], ["O 3", "CHEMICAL", 59, 62], ["NO 2", "CHEMICAL", 201, 205], ["O 3", "GENE_OR_GENE_PRODUCT", 59, 62], ["NO 2", "GENE_OR_GENE_PRODUCT", 201, 205], ["2 accumulation", "PROBLEM", 204, 218]]], ["During the lockdown phase, the concentration of O 3 amplifies in the lower atmosphere due to low consumption of O 3 and consequently leading to less emission of NO 2 from the anthropogenic sources (Andrade et al. 2017; Tobias et al. 2020) .", [["O 3", "CHEMICAL", 48, 51], ["O 3", "CHEMICAL", 112, 115], ["NO", "CHEMICAL", 161, 163], ["O 3", "CHEMICAL", 48, 51], ["O 3", "CHEMICAL", 112, 115], ["NO 2", "CHEMICAL", 161, 165], ["O 3", "SIMPLE_CHEMICAL", 48, 51], ["NO 2", "SIMPLE_CHEMICAL", 161, 165]]], ["The natural quantity of ozone in the troposphere is normally around 0.04 parts per million (ppm), and that amount is not dangerous to human health.", [["ozone", "CHEMICAL", 24, 29], ["ozone", "CHEMICAL", 24, 29], ["ozone", "SIMPLE_CHEMICAL", 24, 29], ["human", "ORGANISM", 134, 139], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 134, 139], ["natural", "OBSERVATION_MODIFIER", 4, 11], ["quantity", "OBSERVATION_MODIFIER", 12, 20], ["ozone", "OBSERVATION_MODIFIER", 24, 29], ["troposphere", "ANATOMY_MODIFIER", 37, 48]]], ["The concentration of ozone above 200 \u00b5g/m 3 or 0.2 mg/m 3 or o.1 ppm in the lower troposphere is very harmful for the human health or environment but during lockdown phase specially in the months of March (53.48 \u00b5g/m 3 ), April (45.56 \u00b5g/m 3 ) and May (38.68 \u00b5g/m 3 ) the average concentration of ozone is slightly increased compared with the previous year due to less emission of NO 2 from the anthropogenic sources, although the average concentration level of ozone during lockdown phase is not detrimental for environment including human health.DiscussionThe land surface temperature is slightly dropped during the lockdown period (2020) due to short duration lockdown along with controlled economic activities.", [["surface", "ANATOMY", 567, 574], ["ozone", "CHEMICAL", 21, 26], ["ozone", "CHEMICAL", 297, 302], ["NO", "CHEMICAL", 381, 383], ["ozone", "CHEMICAL", 462, 467], ["ozone", "CHEMICAL", 21, 26], ["ozone", "CHEMICAL", 297, 302], ["NO 2", "CHEMICAL", 381, 385], ["ozone", "CHEMICAL", 462, 467], ["ozone", "SIMPLE_CHEMICAL", 21, 26], ["human", "ORGANISM", 118, 123], ["ozone", "SIMPLE_CHEMICAL", 297, 302], ["NO 2", "SIMPLE_CHEMICAL", 381, 385], ["ozone", "SIMPLE_CHEMICAL", 462, 467], ["human", "ORGANISM", 535, 540], ["human", "SPECIES", 118, 123], ["human", "SPECIES", 535, 540], ["human", "SPECIES", 118, 123], ["human", "SPECIES", 535, 540], ["The concentration of ozone above", "TREATMENT", 0, 32], ["The land surface temperature", "TEST", 558, 586], ["slightly dropped", "PROBLEM", 590, 606], ["short duration lockdown", "PROBLEM", 648, 671], ["ozone", "OBSERVATION", 297, 302], ["slightly", "OBSERVATION_MODIFIER", 306, 314], ["increased", "OBSERVATION_MODIFIER", 315, 324], ["anthropogenic sources", "OBSERVATION", 395, 416]]], ["In general, various natural as well as anthropogenic activities regulate land surface temperature on the surface of the earth, whereas long-term sustainable environmental management steps can partially modify the spatio-temporal weather conditions.", [["surface", "ANATOMY", 78, 85], ["surface", "ANATOMY", 105, 112]]], ["In those stations which are located at the vicinity of greeneries, the air pollution rate is comparatively lower with respect to other stations.", [["the air pollution rate", "TEST", 67, 89], ["air pollution", "OBSERVATION", 71, 84]]], ["It is highly significant that the extension of lockdown period due to COVID-19 pandemic incredibly affects the economic supply chain, socio-cultural rhythm of the nations and mental health of the people worldwide.", [["COVID-19", "CHEMICAL", 70, 78], ["people", "ORGANISM", 196, 202], ["people", "SPECIES", 196, 202], ["COVID", "TEST", 70, 75], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["chain", "OBSERVATION_MODIFIER", 127, 132]]], ["The declining trend of air pollution level in Kolkata during lockdown is a momentary phenomenon.", [["air pollution level", "PROBLEM", 23, 42], ["a momentary phenomenon", "PROBLEM", 73, 95], ["declining", "OBSERVATION_MODIFIER", 4, 13], ["trend", "OBSERVATION_MODIFIER", 14, 19], ["air pollution", "OBSERVATION", 23, 36], ["momentary phenomenon", "OBSERVATION", 75, 95]]], ["The enforcement of lockdown system is not a permanent remedial measure to mitigate the menace of pollution.", [["lockdown system", "TREATMENT", 19, 34], ["a permanent remedial measure", "TREATMENT", 42, 70], ["pollution", "OBSERVATION", 97, 106]]], ["So, an alternative sustainable management technique should be implemented to keep the purity of environment.", [["an alternative sustainable management technique", "TREATMENT", 4, 51]]], ["It must be noted that plants are the principal recipient of different types of air pollutants and act as an enormous sink (Kaur and Nagpal 2017; Letter and Jager 2020) .", [["air pollutants", "PROBLEM", 79, 93], ["air pollutants", "OBSERVATION", 79, 93]]], ["A scientific study has been identified some plant species along with high absorption capacity of specific pollutants (Salih et al. 2017 ; Table 3 ).", [["A scientific study", "TEST", 0, 18], ["some plant species", "PROBLEM", 39, 57], ["high absorption capacity", "PROBLEM", 69, 93]]], ["Suspended particulate matters and dust particles are absorbed through the stomatal pores into the leaf or over the surface of the leaf (Farmer 2002) .", [["stomatal pores", "ANATOMY", 74, 88], ["leaf", "ANATOMY", 98, 102], ["surface", "ANATOMY", 115, 122], ["leaf", "ANATOMY", 130, 134], ["stomatal pores", "MULTI-TISSUE_STRUCTURE", 74, 88], ["leaf", "ORGAN", 98, 102], ["surface", "CELLULAR_COMPONENT", 115, 122], ["leaf", "ORGAN", 130, 134], ["Suspended particulate matters", "PROBLEM", 0, 29], ["dust particles", "PROBLEM", 34, 48], ["particulate matters", "OBSERVATION", 10, 29], ["dust particles", "OBSERVATION", 34, 48], ["stomatal pores", "OBSERVATION", 74, 88], ["leaf", "ANATOMY_MODIFIER", 98, 102], ["surface", "ANATOMY_MODIFIER", 115, 122], ["leaf", "ANATOMY", 130, 134]]], ["The air pollution-tolerant species plantation in urban vacant spaces would play an effective role to ameliorate environmental health along with quality of urban life (Bamniya et al. 2011) .", [["The air pollution", "PROBLEM", 0, 17], ["tolerant species plantation", "TREATMENT", 18, 45], ["air pollution", "OBSERVATION", 4, 17]]], ["The air pollution tolerance index (APTI) is applied to assess the susceptibility or resistance level of plant species for air pollutants (Pandey et al. 2015) .", [["The air pollution tolerance index", "TEST", 0, 33], ["the susceptibility", "PROBLEM", 62, 80], ["plant species", "PROBLEM", 104, 117], ["air pollutants", "PROBLEM", 122, 136], ["air pollution", "OBSERVATION", 4, 17], ["plant species", "OBSERVATION", 104, 117]]], ["The improvement of green envelop by plantation of tolerant species can combat air pollution to a certain level.", [["green envelop", "PROBLEM", 19, 32], ["tolerant species", "PROBLEM", 50, 66], ["air pollution", "PROBLEM", 78, 91], ["improvement", "OBSERVATION_MODIFIER", 4, 15], ["green envelop", "OBSERVATION_MODIFIER", 19, 32]]], ["The selection of plant species (based on tolerance level) is a principal factor for the mitigation of urban air pollution.", [["plant species", "PROBLEM", 17, 30], ["urban air pollution", "PROBLEM", 102, 121], ["plant species", "OBSERVATION", 17, 30], ["air pollution", "OBSERVATION", 108, 121]]], ["Subsequently, APTI is used to select tolerant plant species particularly for the reduction of vehicular pollution in urban environment (Kaur and Nagpal 2017 (Acharya et al. 2017) .", [["APTI", "CHEMICAL", 14, 18], ["APTI", "TREATMENT", 14, 18], ["tolerant plant species", "PROBLEM", 37, 59], ["vehicular pollution", "OBSERVATION", 94, 113]]], ["Moreover, a scientific study highlighted that Eucalyptus Globus has the extreme tolerance capacity against air pollution followed by Ficus Religiosa and Mangifera Indica and those species have reduced air pollution across the heavy traffic areas in Dehradun, India (Lohe et al. 2015) .", [["Globus", "CHEMICAL", 57, 63], ["Eucalyptus Globus", "ORGANISM", 46, 63], ["Ficus Religiosa", "ORGANISM", 133, 148], ["Mangifera Indica", "ORGANISM", 153, 169], ["Mangifera Indica", "SPECIES", 153, 169], ["Ficus Religiosa", "SPECIES", 133, 148], ["a scientific study", "TEST", 10, 28], ["Eucalyptus Globus", "PROBLEM", 46, 63], ["the extreme tolerance capacity", "PROBLEM", 68, 98], ["air pollution", "PROBLEM", 107, 120], ["reduced air pollution", "PROBLEM", 193, 214], ["reduced", "OBSERVATION_MODIFIER", 193, 200], ["air pollution", "OBSERVATION", 201, 214], ["heavy", "OBSERVATION_MODIFIER", 226, 231]]], ["It is also proved that Ficus Religiosa has the maximum capacity of tolerance in terms of air pollution (Muhammad et al. 2016) .", [["Religiosa", "CHEMICAL", 29, 38], ["Ficus Religiosa", "ORGANISM", 23, 38], ["maximum", "OBSERVATION_MODIFIER", 47, 54], ["capacity", "OBSERVATION_MODIFIER", 55, 63], ["air pollution", "OBSERVATION", 89, 102]]], ["Another study revealed that Hibiscus rosa-sinensis followed by Psidium guajava, Mangifera indica and Ficus bengalensis have achieved the maximum APTI value in case of industrial area of Rourkela in Odisha, India (Rai et al. 2013) .", [["Hibiscus rosa-sinensis", "ORGANISM", 28, 50], ["Psidium guajava", "ORGANISM", 63, 78], ["Mangifera indica", "ORGANISM", 80, 96], ["Ficus bengalensis", "ORGANISM", 101, 118], ["Hibiscus", "SPECIES", 28, 36], ["rosa-sinensis", "SPECIES", 37, 50], ["Psidium guajava", "SPECIES", 63, 78], ["Mangifera indica", "SPECIES", 80, 96], ["Ficus bengalensis", "SPECIES", 101, 118], ["Hibiscus rosa-sinensis", "SPECIES", 28, 50], ["Psidium guajava", "SPECIES", 63, 78], ["Mangifera indica", "SPECIES", 80, 96], ["Ficus bengalensis", "SPECIES", 101, 118], ["Another study", "TEST", 0, 13], ["the maximum APTI value", "TEST", 133, 155], ["Hibiscus rosa", "OBSERVATION", 28, 41], ["industrial", "OBSERVATION_MODIFIER", 167, 177], ["area", "OBSERVATION_MODIFIER", 178, 182]]], ["The geographical distribution of vegetation cover in the city of Kolkata helps to comprehend the overall spatial association along with the density of plant species (Fig. 9 ).", [["vegetation", "PROBLEM", 33, 43], ["plant species", "PROBLEM", 151, 164], ["geographical", "OBSERVATION_MODIFIER", 4, 16], ["distribution", "OBSERVATION_MODIFIER", 17, 29], ["vegetation", "OBSERVATION", 33, 43], ["plant species", "OBSERVATION", 151, 164]]], ["It must be stated that the physical conditions of Kolkata are exceedingly favourable for the growth of these above-mentioned plants and these plant species can place in the vacant spaces (Fort William, Hastings, Victoria Memorial, Maidan, Vidhan Sabha Area, Eden Garden Surroundings, Governors House, Tollygunge Golf Club Area, Golf Garden Area, Rabindra Sarovar Area, Jodhpur, Park, East Kolkata Wetlands Area, Salt Lake Area, etc.) of the city and road sides.", [["road sides", "MULTI-TISSUE_STRUCTURE", 450, 460], ["these plant species", "TREATMENT", 136, 155], ["Golf Garden Area", "TREATMENT", 328, 344], ["Rabindra Sarovar Area", "TREATMENT", 346, 367], ["plant species", "OBSERVATION", 142, 155]]], ["But the matter of serious concern is that proportion of vacant space is very much limited in this highly populous city and the city is extremely congested with high-rise buildings along with busiest roadways.", [["vacant space", "PROBLEM", 56, 68], ["extremely congested", "PROBLEM", 135, 154], ["vacant space", "OBSERVATION", 56, 68], ["extremely", "OBSERVATION_MODIFIER", 135, 144], ["congested", "OBSERVATION", 145, 154]]], ["In this context, the implementation of sustainable micro-green belt project like roof garden, green frontage or green wall, vertical green zone, roadside garden should be encouraged to re-establish (Pandey et al. 2015) .", [["sustainable micro-green belt", "TREATMENT", 39, 67], ["green wall, vertical green zone", "PROBLEM", 112, 143], ["roof garden", "OBSERVATION", 81, 92], ["green frontage", "OBSERVATION", 94, 108], ["wall", "ANATOMY_MODIFIER", 118, 122], ["vertical", "OBSERVATION_MODIFIER", 124, 132], ["green", "OBSERVATION_MODIFIER", 133, 138], ["zone", "OBSERVATION_MODIFIER", 139, 143]]], ["Kolkata is considered as an ideal habitat for these climber plants also due to its parallel climatic conditions.", [["these climber plants", "TREATMENT", 46, 66], ["its parallel climatic conditions", "PROBLEM", 79, 111]]], ["These species can be kept on the roof top, balcony and wall, grill of every household, industrial and commercial centre, shopping complex, etc. and to restore the natural environmental quality of Kolkata (Table 4) .", [["wall", "ANATOMY", 55, 59], ["wall", "TISSUE", 55, 59], ["wall", "ANATOMY_MODIFIER", 55, 59]]], ["So, the development of green sphere as well as proper execution of reforestation and afforestation scheme throughout the city is utmost important steps to recover the sustainable urban ecological indicators after the temporary lockdown.ConclusionsThe lockdown strategy due to COVID-19 pandemic disaster offers a meaningful message to all the countries worldwide for restoring the environmental quality as well as natural ecosystem stability.", [["green sphere", "PROBLEM", 23, 35], ["afforestation scheme", "TREATMENT", 85, 105], ["the temporary lockdown", "TREATMENT", 213, 235], ["The lockdown strategy", "TREATMENT", 247, 268], ["green sphere", "OBSERVATION", 23, 35], ["reforestation", "OBSERVATION_MODIFIER", 67, 80], ["ecosystem stability", "OBSERVATION", 421, 440]]], ["Apparently, the slaughterer COVID-19 pandemic and constant lockdown becomes a curse towards the millions of people and the world economy confronts a massive disruption due to the unpleasant and unusual incident.", [["people", "ORGANISM", 108, 114], ["people", "SPECIES", 108, 114], ["the slaughterer COVID", "TEST", 12, 33], ["pandemic", "PROBLEM", 37, 45], ["a massive disruption", "PROBLEM", 147, 167], ["massive", "OBSERVATION_MODIFIER", 149, 156], ["disruption", "OBSERVATION", 157, 167]]], ["In the interim, the purification of environment along with air quality modification has become certainly the precious gifts of temporary lockdown system during global emergency.", [["air quality modification", "PROBLEM", 59, 83], ["temporary lockdown system", "TREATMENT", 127, 152], ["air quality", "OBSERVATION", 59, 70]]], ["In Kolkata, the upgrading of air quality standard and declining trend of surface temperature definitely bring the healthy environment during lockdown period.", [["surface", "ANATOMY", 73, 80], ["surface temperature", "PROBLEM", 73, 92]]], ["The severe air pollution is the principal regulating factor for high rate COVID-19 infection and mortality in the City Kolkata.", [["infection", "DISEASE", 83, 92], ["The severe air pollution", "PROBLEM", 0, 24], ["high rate COVID", "PROBLEM", 64, 79], ["19 infection", "PROBLEM", 80, 92], ["severe", "OBSERVATION_MODIFIER", 4, 10], ["air pollution", "OBSERVATION", 11, 24], ["infection", "OBSERVATION", 83, 92]]], ["This study revealed that the concentration of pollutants like NO 2 , CO, PM 10 and PM 2.5 over the City of Kolkata during lockdown phase was significantly low compared with previous years.", [["NO", "CHEMICAL", 62, 64], ["NO 2", "CHEMICAL", 62, 66], ["CO", "CHEMICAL", 69, 71], ["NO 2", "SIMPLE_CHEMICAL", 62, 66], ["CO", "SIMPLE_CHEMICAL", 69, 71], ["This study", "TEST", 0, 10], ["the concentration of pollutants", "PROBLEM", 25, 56], ["CO", "TEST", 69, 71]]], ["This scientific study has tried to give some long-term remedial measures for the improvement of the health of the environment of Kolkata.", [["This scientific study", "TEST", 0, 21], ["some long-term remedial measures", "TREATMENT", 40, 72]]], ["The applied research with instrumental and methodological development is highly required to combat such harmful air pollution in the different polluted cities of India.", [["instrumental and methodological development", "TREATMENT", 26, 69], ["such harmful air pollution", "PROBLEM", 99, 125], ["air pollution", "OBSERVATION", 112, 125]]], ["In spite of few good researches, there is a big gap between scientists and policymakers regarding the implementation of research findings.", [["few", "OBSERVATION_MODIFIER", 12, 15], ["good", "OBSERVATION_MODIFIER", 16, 20], ["researches", "OBSERVATION", 21, 31]]], ["Ultimately, the lockdown system retrieves the sparkle of environment by means of improving air quality standards all over the city where the urban ecological forms and processes have been degraded due to unjustifiable modern livelihood along with fast economic progression.", [["the lockdown system", "TREATMENT", 12, 31], ["fast economic progression", "PROBLEM", 247, 272]]], ["Lockdown system would be the best practice today for all the modern industrial countries in the world and it will be the best therapy to reduce all types of environmental pollution as well as degradation.", [["environmental pollution", "TREATMENT", 157, 180], ["environmental pollution", "OBSERVATION", 157, 180]]], ["Thus, the temporary lockdown mechanism should be treated as the environmental blessings instead of the ruthless curse globally.", [["the temporary lockdown mechanism", "TREATMENT", 6, 38]]]], "293e92b5665741a05091a946224fa2752057e917": [["IntroductionInhibition of Bruton's Tyrosine Kinase (BTK) in the treatment of B-cell malignancies has been an exemplary story of functional understanding of disease pathogenesis translating to superior survival rates (1) (2) (3) (4) .", [["B-cell malignancies", "ANATOMY", 77, 96], ["B-cell malignancies", "DISEASE", 77, 96], ["Tyrosine", "CHEMICAL", 35, 43], ["Bruton's Tyrosine Kinase", "GENE_OR_GENE_PRODUCT", 26, 50], ["BTK", "GENE_OR_GENE_PRODUCT", 52, 55], ["B-cell malignancies", "CANCER", 77, 96], ["Bruton's Tyrosine Kinase", "PROTEIN", 26, 50], ["BTK", "PROTEIN", 52, 55], ["IntroductionInhibition", "TREATMENT", 0, 22], ["Bruton's Tyrosine Kinase (BTK)", "TREATMENT", 26, 56], ["B-cell malignancies", "PROBLEM", 77, 96], ["disease pathogenesis", "PROBLEM", 156, 176], ["cell malignancies", "OBSERVATION", 79, 96], ["disease", "OBSERVATION", 156, 163]]], ["Moreover, inhibition of BTK is currently also being evaluated as a therapeutic strategy for patients with severe COVID-19 disease (5, 6) .", [["COVID-19 disease", "DISEASE", 113, 129], ["BTK", "GENE_OR_GENE_PRODUCT", 24, 27], ["patients", "ORGANISM", 92, 100], ["BTK", "PROTEIN", 24, 27], ["patients", "SPECIES", 92, 100], ["severe COVID-19 disease", "PROBLEM", 106, 129], ["BTK", "OBSERVATION", 24, 27], ["severe", "OBSERVATION_MODIFIER", 106, 112], ["19 disease", "OBSERVATION", 119, 129]]], ["BTK is localized in proximity of the B-cell receptor (BCR), forming a signalosome complex upon BCR activation with other BCR associated kinases (BAK); LYN, SYK, and PI3K (7, 8) .", [["B-cell", "ANATOMY", 37, 43], ["BTK", "GENE_OR_GENE_PRODUCT", 0, 3], ["B-cell receptor", "GENE_OR_GENE_PRODUCT", 37, 52], ["BCR", "GENE_OR_GENE_PRODUCT", 54, 57], ["BCR", "GENE_OR_GENE_PRODUCT", 95, 98], ["BCR associated kinases", "GENE_OR_GENE_PRODUCT", 121, 143], ["BAK", "GENE_OR_GENE_PRODUCT", 145, 148], ["LYN", "GENE_OR_GENE_PRODUCT", 151, 154], ["SYK", "GENE_OR_GENE_PRODUCT", 156, 159], ["PI3K", "GENE_OR_GENE_PRODUCT", 165, 169], ["BTK", "PROTEIN", 0, 3], ["B-cell receptor", "PROTEIN", 37, 52], ["BCR", "PROTEIN", 54, 57], ["signalosome complex", "PROTEIN", 70, 89], ["BCR", "PROTEIN", 95, 98], ["BCR associated kinases", "PROTEIN", 121, 143], ["BAK", "PROTEIN", 145, 148], ["LYN", "PROTEIN", 151, 154], ["SYK", "PROTEIN", 156, 159], ["PI3K (7, 8", "PROTEIN", 165, 175], ["a signalosome complex upon BCR activation", "PROBLEM", 68, 109], ["LYN", "TEST", 151, 154], ["SYK", "TEST", 156, 159], ["PI3K", "TEST", 165, 169], ["B", "ANATOMY", 37, 38], ["-cell receptor", "OBSERVATION", 38, 52], ["signalosome", "OBSERVATION_MODIFIER", 70, 81], ["complex", "OBSERVATION_MODIFIER", 82, 89], ["BCR activation", "OBSERVATION", 95, 109], ["LYN", "ANATOMY", 151, 154], ["SYK", "ANATOMY", 156, 159]]], ["The first generation BTK inhibitor (BTKi) ibrutinib covalently binds its target, which leads to prolonged lymphocytosis via reduced malignant B-cell homing capacity and chemokine signaling (9) .", [["malignant B-cell", "ANATOMY", 132, 148], ["BTKi", "CHEMICAL", 36, 40], ["ibrutinib", "CHEMICAL", 42, 51], ["lymphocytosis", "DISEASE", 106, 119], ["ibrutinib", "CHEMICAL", 42, 51], ["BTK", "GENE_OR_GENE_PRODUCT", 21, 24], ["BTKi", "SIMPLE_CHEMICAL", 36, 40], ["ibrutinib", "SIMPLE_CHEMICAL", 42, 51], ["malignant B-cell", "CELL", 132, 148], ["BTK", "PROTEIN", 21, 24], ["chemokine", "PROTEIN", 169, 178], ["The first generation BTK inhibitor (BTKi) ibrutinib covalently binds", "TREATMENT", 0, 68], ["prolonged lymphocytosis", "PROBLEM", 96, 119], ["reduced malignant B", "PROBLEM", 124, 143], ["chemokine signaling", "TEST", 169, 188], ["prolonged", "OBSERVATION_MODIFIER", 96, 105], ["lymphocytosis", "OBSERVATION", 106, 119], ["reduced", "OBSERVATION_MODIFIER", 124, 131], ["malignant", "OBSERVATION", 132, 141], ["cell", "OBSERVATION", 144, 148]]], ["However, ibrutinib also has high affinity to other Tec kinases, leading to the development of second generation BTKis, such as tirabrutinib and acalabrutinib, which are highly selective for BTK (10, 11) .IntroductionAfter initial success of ibrutinib in early phase clinical trials as a single agent in the relapse/refractory setting, clinical trials were quickly initiated in combination with other frontline agents, namely monoclonal antibodies targeting CD20 (anti-CD20; such as rituximab) (12) (13) (14) (15) .", [["ibrutinib", "CHEMICAL", 9, 18], ["BTKis", "CHEMICAL", 112, 117], ["tirabrutinib", "CHEMICAL", 127, 139], ["acalabrutinib", "CHEMICAL", 144, 157], ["ibrutinib", "CHEMICAL", 241, 250], ["rituximab", "CHEMICAL", 482, 491], ["ibrutinib", "CHEMICAL", 9, 18], ["tirabrutinib", "CHEMICAL", 127, 139], ["acalabrutinib", "CHEMICAL", 144, 157], ["ibrutinib", "CHEMICAL", 241, 250], ["rituximab", "CHEMICAL", 482, 491], ["ibrutinib", "SIMPLE_CHEMICAL", 9, 18], ["Tec", "GENE_OR_GENE_PRODUCT", 51, 54], ["BTKis", "SIMPLE_CHEMICAL", 112, 117], ["tirabrutinib", "SIMPLE_CHEMICAL", 127, 139], ["acalabrutinib", "SIMPLE_CHEMICAL", 144, 157], ["BTK", "GENE_OR_GENE_PRODUCT", 190, 193], ["ibrutinib", "SIMPLE_CHEMICAL", 241, 250], ["CD20", "GENE_OR_GENE_PRODUCT", 457, 461], ["anti-CD20", "GENE_OR_GENE_PRODUCT", 463, 472], ["rituximab) (12) (13) (14)", "SIMPLE_CHEMICAL", 482, 507], ["Tec kinases", "PROTEIN", 51, 62], ["BTK", "PROTEIN", 190, 193], ["monoclonal antibodies", "PROTEIN", 425, 446], ["CD20", "PROTEIN", 457, 461], ["anti", "PROTEIN", 463, 467], ["CD20", "PROTEIN", 468, 472], ["ibrutinib", "PROBLEM", 9, 18], ["high affinity", "PROBLEM", 28, 41], ["second generation BTKis", "PROBLEM", 94, 117], ["tirabrutinib and acalabrutinib", "PROBLEM", 127, 157], ["ibrutinib", "TREATMENT", 241, 250], ["a single agent", "TREATMENT", 285, 299], ["clinical trials", "TREATMENT", 335, 350], ["other frontline agents", "TREATMENT", 394, 416], ["namely monoclonal antibodies", "TREATMENT", 418, 446], ["CD20 (anti-CD20", "TREATMENT", 457, 472], ["rituximab", "TREATMENT", 482, 491], ["ibrutinib", "OBSERVATION", 9, 18], ["high affinity", "OBSERVATION_MODIFIER", 28, 41], ["ibrutinib", "OBSERVATION", 241, 250], ["refractory", "OBSERVATION_MODIFIER", 315, 325]]], ["The most recent phase 3 trial in previously untreated chronic lymphocytic leukemia (CLL) offers superior survival in comparison to the chemo-immunotherapeutic (CIT) regimen fludarabine cyclophosphamide and rituximab (FCR) (12) .", [["chronic lymphocytic leukemia", "ANATOMY", 54, 82], ["CLL", "ANATOMY", 84, 87], ["chronic lymphocytic leukemia", "DISEASE", 54, 82], ["CLL", "DISEASE", 84, 87], ["fludarabine", "CHEMICAL", 173, 184], ["cyclophosphamide", "CHEMICAL", 185, 201], ["rituximab", "CHEMICAL", 206, 215], ["fludarabine cyclophosphamide", "CHEMICAL", 173, 201], ["rituximab", "CHEMICAL", 206, 215], ["chronic lymphocytic leukemia", "CANCER", 54, 82], ["CLL", "CANCER", 84, 87], ["fludarabine", "SIMPLE_CHEMICAL", 173, 184], ["cyclophosphamide", "SIMPLE_CHEMICAL", 185, 201], ["rituximab", "SIMPLE_CHEMICAL", 206, 215], ["FCR", "SIMPLE_CHEMICAL", 217, 220], ["previously untreated chronic lymphocytic leukemia", "PROBLEM", 33, 82], ["CLL", "PROBLEM", 84, 87], ["the chemo-immunotherapeutic (CIT) regimen", "TREATMENT", 131, 172], ["fludarabine cyclophosphamide", "TREATMENT", 173, 201], ["rituximab (FCR", "TREATMENT", 206, 220], ["chronic", "OBSERVATION_MODIFIER", 54, 61], ["lymphocytic leukemia", "OBSERVATION", 62, 82]]], ["Rituximab elicits its therapeutic effect via direct cell killing, complement activation, and Fc-mediated antibody dependent cellular cytotoxicity (ADCC) (16) .", [["cell", "ANATOMY", 52, 56], ["cellular", "ANATOMY", 124, 132], ["Rituximab", "CHEMICAL", 0, 9], ["Rituximab", "SIMPLE_CHEMICAL", 0, 9], ["cell", "CELL", 52, 56], ["Fc-", "SIMPLE_CHEMICAL", 93, 96], ["cellular", "CELL", 124, 132], ["Rituximab", "TREATMENT", 0, 9], ["direct cell killing", "TREATMENT", 45, 64], ["complement activation", "TEST", 66, 87], ["Fc-mediated antibody dependent cellular cytotoxicity", "PROBLEM", 93, 145], ["cellular cytotoxicity", "OBSERVATION", 124, 145]]], ["In addition, CIT has been previously shown to induce an acute secretory phenotype leading to increased macrophage mediated antibody dependent cellular phagocytosis (ADCP), in a humanized mouse model of B-cell lymphoma (17) (18) (19) .", [["macrophage", "ANATOMY", 103, 113], ["cellular", "ANATOMY", 142, 150], ["B-cell lymphoma", "ANATOMY", 202, 217], ["CIT", "CHEMICAL", 13, 16], ["B-cell lymphoma", "DISEASE", 202, 217], ["CIT", "CHEMICAL", 13, 16], ["CIT", "SIMPLE_CHEMICAL", 13, 16], ["macrophage", "CELL", 103, 113], ["cellular", "CELL", 142, 150], ["ADCP", "SIMPLE_CHEMICAL", 165, 169], ["mouse", "ORGANISM", 187, 192], ["B-cell lymphoma", "CANCER", 202, 217], ["CIT", "PROTEIN", 13, 16], ["macrophage mediated antibody", "PROTEIN", 103, 131], ["ADCP", "PROTEIN", 165, 169], ["mouse", "SPECIES", 187, 192], ["mouse", "SPECIES", 187, 192], ["CIT", "TEST", 13, 16], ["an acute secretory phenotype", "PROBLEM", 53, 81], ["increased macrophage mediated antibody dependent cellular phagocytosis", "PROBLEM", 93, 163], ["B-cell lymphoma", "PROBLEM", 202, 217], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["secretory phenotype", "OBSERVATION", 62, 81], ["increased", "OBSERVATION_MODIFIER", 93, 102], ["macrophage", "OBSERVATION", 103, 113], ["cellular phagocytosis", "OBSERVATION", 142, 163], ["B-cell lymphoma", "OBSERVATION", 202, 217]]], ["Therefore, it is important to evaluate the synergistic interaction of BTK inhibition and monoclonal antibody treatment in the context of the tumor microenvironment (TME).", [["tumor", "ANATOMY", 141, 146], ["tumor", "DISEASE", 141, 146], ["BTK", "GENE_OR_GENE_PRODUCT", 70, 73], ["tumor", "CANCER", 141, 146], ["BTK", "PROTEIN", 70, 73], ["monoclonal antibody", "PROTEIN", 89, 108], ["BTK inhibition", "TREATMENT", 70, 84], ["monoclonal antibody treatment", "TREATMENT", 89, 118], ["tumor", "OBSERVATION", 141, 146]]], ["4 Pre-clinical studies assessing the synergistic interaction between ibrutinib and monoclonal antibodies have provided conflicting results, with a number of studies reporting that ibrutinib not only has no impact on antibody-mediated effects, rather a negative effect specifically on NK-cell mediated effects of the antibody (20) (21) (22) (23) .IntroductionDown-regulation of CD20 on CLL cells by ibrutinib has additionally been described in co-culture systems and may be interpreted as a potential antagonistic mechanism (24, 25) .", [["NK-cell", "ANATOMY", 284, 291], ["CLL cells", "ANATOMY", 385, 394], ["ibrutinib", "CHEMICAL", 69, 78], ["ibrutinib", "CHEMICAL", 180, 189], ["CLL", "DISEASE", 385, 388], ["ibrutinib", "CHEMICAL", 398, 407], ["ibrutinib", "CHEMICAL", 69, 78], ["ibrutinib", "CHEMICAL", 180, 189], ["ibrutinib", "CHEMICAL", 398, 407], ["ibrutinib", "SIMPLE_CHEMICAL", 69, 78], ["ibrutinib", "SIMPLE_CHEMICAL", 180, 189], ["NK-cell", "CELL", 284, 291], ["CD20", "GENE_OR_GENE_PRODUCT", 377, 381], ["CLL cells", "CELL", 385, 394], ["ibrutinib", "SIMPLE_CHEMICAL", 398, 407], ["monoclonal antibodies", "PROTEIN", 83, 104], ["CD20", "PROTEIN", 377, 381], ["CLL cells", "CELL_LINE", 385, 394], ["Pre-clinical studies", "TEST", 2, 22], ["the synergistic interaction", "PROBLEM", 33, 60], ["ibrutinib", "TREATMENT", 69, 78], ["monoclonal antibodies", "TEST", 83, 104], ["ibrutinib", "TREATMENT", 180, 189], ["antibody", "TEST", 216, 224], ["NK", "TEST", 284, 286], ["the antibody", "TEST", 312, 324], ["IntroductionDown-regulation of CD20 on CLL cells", "TREATMENT", 346, 394], ["ibrutinib", "TREATMENT", 398, 407], ["co-culture systems", "TEST", 443, 461], ["CLL cells", "OBSERVATION", 385, 394]]], ["However, combination therapy of ibrutinib and anti-CD20 antibody has proven to be clinically highly effective especially for unfit patients with CLL (26, 27) .IntroductionAs the antibody therapy relies on several independent effector mechanisms antibody-dependent cellular phagocytosis has been previously underestimated (28) .IntroductionThe effector function of macrophages is highly dependent on interaction within the tumor microenvironment.", [["CLL", "ANATOMY", 145, 148], ["cellular", "ANATOMY", 264, 272], ["macrophages", "ANATOMY", 364, 375], ["tumor", "ANATOMY", 422, 427], ["ibrutinib", "CHEMICAL", 32, 41], ["CLL", "DISEASE", 145, 148], ["tumor", "DISEASE", 422, 427], ["ibrutinib", "CHEMICAL", 32, 41], ["ibrutinib", "SIMPLE_CHEMICAL", 32, 41], ["anti-CD20 antibody", "GENE_OR_GENE_PRODUCT", 46, 64], ["patients", "ORGANISM", 131, 139], ["CLL", "CANCER", 145, 148], ["cellular", "CELL", 264, 272], ["macrophages", "CELL", 364, 375], ["tumor", "CANCER", 422, 427], ["anti-CD20 antibody", "PROTEIN", 46, 64], ["macrophages", "CELL_TYPE", 364, 375], ["patients", "SPECIES", 131, 139], ["ibrutinib", "TREATMENT", 32, 41], ["anti-CD20 antibody", "TREATMENT", 46, 64], ["CLL", "PROBLEM", 145, 148], ["Introduction", "TREATMENT", 159, 171], ["the antibody therapy", "TREATMENT", 174, 194], ["dependent cellular phagocytosis", "PROBLEM", 254, 285], ["CLL", "OBSERVATION", 145, 148], ["dependent", "OBSERVATION_MODIFIER", 254, 263], ["cellular phagocytosis", "OBSERVATION", 264, 285], ["macrophages", "OBSERVATION", 364, 375], ["tumor", "OBSERVATION", 422, 427]]], ["Therefore, we employed a reliable humanized mouse model of \"Double Hit-Lymphoma\" for functional elucidation of ibrutinib in antibody combination therapy (17) (18) (19) .IntroductionHere, we show that ibrutinib synergizes with multiple monoclonal antibodies in vitro and in vivo via increased macrophage mediated ADCP.", [["Hit-Lymphoma", "ANATOMY", 67, 79], ["macrophage", "ANATOMY", 292, 302], ["Lymphoma", "DISEASE", 71, 79], ["ibrutinib", "CHEMICAL", 111, 120], ["ibrutinib", "CHEMICAL", 200, 209], ["ibrutinib", "CHEMICAL", 111, 120], ["ibrutinib", "CHEMICAL", 200, 209], ["mouse", "ORGANISM", 44, 49], ["Double Hit-Lymphoma", "CANCER", 60, 79], ["ibrutinib", "SIMPLE_CHEMICAL", 111, 120], ["ibrutinib", "SIMPLE_CHEMICAL", 200, 209], ["macrophage", "CELL", 292, 302], ["ADCP", "GENE_OR_GENE_PRODUCT", 312, 316], ["monoclonal antibodies", "PROTEIN", 235, 256], ["ADCP", "PROTEIN", 312, 316], ["mouse", "SPECIES", 44, 49], ["mouse", "SPECIES", 44, 49], ["Double Hit-Lymphoma", "PROBLEM", 60, 79], ["ibrutinib in antibody combination therapy", "TREATMENT", 111, 152], ["ibrutinib synergizes", "TREATMENT", 200, 220], ["multiple monoclonal antibodies", "TREATMENT", 226, 256], ["vitro", "TREATMENT", 260, 265], ["increased macrophage mediated ADCP", "TREATMENT", 282, 316], ["increased macrophage", "OBSERVATION", 282, 302]]], ["We screened the kinase activity of malignant B-cells under ibrutinib, tirabrutinib, and acalabrutinib treatment, identifying Janus Kinase 2 (JAK2) as having significantly reduced activity under ibrutinib, whilst second generation BTKis did not similarly inhibit JAK2 activity.IntroductionFinally, we show using CRISPR/Cas9 knockouts and a kinase inhibitor library that loss of JAK2 as well as inhibition using tofacitinib leads to increased ADCP in vitro, whilst superior survival of JAK2 knockout was observed in combination with monoclonal antibody therapy in vivo.Humanized DHL mouse modelFor in vivo experiments 8-14 weeks old male NOD.Cg-Prkdc scid II2rg tm1Wjl /SzJ (NSG, Jackson Laboratory, USA) immunodeficient mice were injected i.v. with 1x10 6 hMB cells diluted in 100 \u00b5l PBS (19) .", [["malignant B-cells", "ANATOMY", 35, 52], ["hMB cells", "ANATOMY", 755, 764], ["ibrutinib", "CHEMICAL", 59, 68], ["tirabrutinib", "CHEMICAL", 70, 82], ["acalabrutinib", "CHEMICAL", 88, 101], ["ibrutinib", "CHEMICAL", 194, 203], ["BTKis", "CHEMICAL", 230, 235], ["tofacitinib", "CHEMICAL", 410, 421], ["ibrutinib", "CHEMICAL", 59, 68], ["tirabrutinib", "CHEMICAL", 70, 82], ["acalabrutinib", "CHEMICAL", 88, 101], ["ibrutinib", "CHEMICAL", 194, 203], ["BTKis", "CHEMICAL", 230, 235], ["tofacitinib", "CHEMICAL", 410, 421], ["malignant B-cells", "CELL", 35, 52], ["ibrutinib", "SIMPLE_CHEMICAL", 59, 68], ["tirabrutinib", "SIMPLE_CHEMICAL", 70, 82], ["acalabrutinib", "SIMPLE_CHEMICAL", 88, 101], ["Janus Kinase 2", "GENE_OR_GENE_PRODUCT", 125, 139], ["JAK2", "GENE_OR_GENE_PRODUCT", 141, 145], ["ibrutinib", "SIMPLE_CHEMICAL", 194, 203], ["JAK2", "GENE_OR_GENE_PRODUCT", 262, 266], ["Cas9", "GENE_OR_GENE_PRODUCT", 318, 322], ["JAK2", "GENE_OR_GENE_PRODUCT", 377, 381], ["tofacitinib", "SIMPLE_CHEMICAL", 410, 421], ["ADCP", "GENE_OR_GENE_PRODUCT", 441, 445], ["JAK2", "GENE_OR_GENE_PRODUCT", 484, 488], ["mouse", "ORGANISM", 581, 586], ["NOD", "ORGANISM", 636, 639], ["immunodeficient mice", "ORGANISM", 703, 723], ["cells", "CELL", 759, 764], ["malignant B-cells", "CELL_TYPE", 35, 52], ["Janus Kinase 2", "PROTEIN", 125, 139], ["JAK2", "PROTEIN", 141, 145], ["JAK2", "PROTEIN", 262, 266], ["CRISPR", "DNA", 311, 317], ["Cas9", "DNA", 318, 322], ["JAK2", "PROTEIN", 377, 381], ["ADCP", "PROTEIN", 441, 445], ["JAK2", "PROTEIN", 484, 488], ["monoclonal antibody", "PROTEIN", 531, 550], ["Humanized DHL mouse model", "CELL_LINE", 567, 592], ["hMB cells", "CELL_LINE", 755, 764], ["mouse", "SPECIES", 581, 586], ["mice", "SPECIES", 719, 723], ["mouse", "SPECIES", 581, 586], ["mice", "SPECIES", 719, 723], ["malignant B-cells", "PROBLEM", 35, 52], ["ibrutinib", "TREATMENT", 59, 68], ["tirabrutinib", "TREATMENT", 70, 82], ["acalabrutinib treatment", "TREATMENT", 88, 111], ["Janus Kinase", "TREATMENT", 125, 137], ["significantly reduced activity under ibrutinib", "PROBLEM", 157, 203], ["CRISPR/Cas9 knockouts", "TREATMENT", 311, 332], ["a kinase inhibitor library", "TREATMENT", 337, 363], ["loss of JAK2", "PROBLEM", 369, 381], ["tofacitinib", "TREATMENT", 410, 421], ["increased ADCP in vitro", "PROBLEM", 431, 454], ["JAK2 knockout", "PROBLEM", 484, 497], ["monoclonal antibody therapy", "TREATMENT", 531, 558], ["Humanized DHL mouse model", "TREATMENT", 567, 592], ["Cg", "TEST", 640, 642], ["Prkdc", "TEST", 643, 648], ["immunodeficient mice", "TREATMENT", 703, 723], ["reduced", "OBSERVATION_MODIFIER", 171, 178], ["activity", "OBSERVATION_MODIFIER", 179, 187], ["JAK2 knockout", "OBSERVATION", 484, 497]]], ["Ten days after injection mice were treated i.p. on three consecutive days with ibrutinib (30 mg/kg), alemtuzumab (day 1 1 mg/kg, day 2 and day 3 5 mg/kg), tirabrutinib (30 mg/kg), or PBS as control.", [["ibrutinib", "CHEMICAL", 79, 88], ["alemtuzumab", "CHEMICAL", 101, 112], ["tirabrutinib", "CHEMICAL", 155, 167], ["ibrutinib", "CHEMICAL", 79, 88], ["tirabrutinib", "CHEMICAL", 155, 167], ["mice", "ORGANISM", 25, 29], ["ibrutinib", "SIMPLE_CHEMICAL", 79, 88], ["alemtuzumab", "SIMPLE_CHEMICAL", 101, 112], ["tirabrutinib", "SIMPLE_CHEMICAL", 155, 167], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["injection mice", "TREATMENT", 15, 29], ["ibrutinib", "TREATMENT", 79, 88], ["alemtuzumab", "TREATMENT", 101, 112], ["tirabrutinib", "TREATMENT", 155, 167], ["PBS", "TREATMENT", 183, 186]]], ["Disease progression was monitored by weekly blood sampling and daily scoring of the mice.", [["blood", "ANATOMY", 44, 49], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["mice", "ORGANISM", 84, 88], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 84, 88], ["Disease progression", "PROBLEM", 0, 19], ["blood sampling", "TEST", 44, 58]]], ["Spleen and bone marrow were harvested and dissociated by cell strainers with PBS and lysed with 5 ml ACK lysis buffer for 3 min at RT.", [["Spleen", "ANATOMY", 0, 6], ["bone marrow", "ANATOMY", 11, 22], ["cell", "ANATOMY", 57, 61], ["Spleen", "ORGAN", 0, 6], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 11, 22], ["cell", "CELL", 57, 61], ["PBS", "TREATMENT", 77, 80], ["5 ml ACK lysis buffer", "TREATMENT", 96, 117], ["bone marrow", "ANATOMY", 11, 22], ["harvested", "OBSERVATION", 28, 37], ["cell strainers", "OBSERVATION", 57, 71]]], ["For flow cytometry samples were stained with F4-80 APC antibody (BioLegend, San Diego, USA).Cell lines and primary patient materialThe study was approved by the ethical commission of the medical faculty of the University of Cologne (reference no. 13-091) and an informed written consent was obtained from all patients.", [["samples", "ANATOMY", 19, 26], ["Cell lines", "ANATOMY", 92, 102], ["APC", "GENE_OR_GENE_PRODUCT", 51, 54], ["Cell lines", "CELL", 92, 102], ["patient", "ORGANISM", 115, 122], ["patients", "ORGANISM", 309, 317], ["F4", "PROTEIN", 45, 47], ["APC antibody", "PROTEIN", 51, 63], ["BioLegend", "PROTEIN", 65, 74], ["patient", "SPECIES", 115, 122], ["patients", "SPECIES", 309, 317], ["flow cytometry samples", "TEST", 4, 26], ["F4", "TEST", 45, 47], ["APC antibody", "TEST", 51, 63], ["Cell lines", "TREATMENT", 92, 102], ["primary patient material", "TREATMENT", 107, 131], ["The study", "TEST", 131, 140]]], ["Primary CLL patient samples were isolated from peripheral blood as previously described (29) .", [["CLL", "ANATOMY", 8, 11], ["samples", "ANATOMY", 20, 27], ["peripheral blood", "ANATOMY", 47, 63], ["CLL", "DISEASE", 8, 11], ["patient", "ORGANISM", 12, 19], ["peripheral blood", "ORGANISM_SUBSTANCE", 47, 63], ["patient", "SPECIES", 12, 19], ["Primary CLL patient samples", "TEST", 0, 27], ["peripheral blood", "TEST", 47, 63], ["CLL", "OBSERVATION", 8, 11], ["peripheral", "ANATOMY_MODIFIER", 47, 57], ["blood", "ANATOMY", 58, 63]]], ["To isolate peritoneal macrophages, wild type and BTK -/-C57BL/6 mice were injected i.p. with thioglycolate and macrophages obtained via peritoneal lavage after four days (18) .", [["peritoneal macrophages", "ANATOMY", 11, 33], ["macrophages", "ANATOMY", 111, 122], ["peritoneal lavage", "ANATOMY", 136, 153], ["thioglycolate", "CHEMICAL", 93, 106], ["thioglycolate", "CHEMICAL", 93, 106], ["peritoneal macrophages", "CELL", 11, 33], ["BTK", "GENE_OR_GENE_PRODUCT", 49, 52], ["C57BL/6 mice", "ORGANISM", 56, 68], ["thioglycolate", "SIMPLE_CHEMICAL", 93, 106], ["macrophages", "CELL", 111, 122], ["peritoneal lavage", "MULTI-TISSUE_STRUCTURE", 136, 153], ["peritoneal macrophages", "CELL_TYPE", 11, 33], ["BTK", "PROTEIN", 49, 52], ["macrophages", "CELL_TYPE", 111, 122], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 64, 68], ["peritoneal macrophages", "PROBLEM", 11, 33], ["BTK", "TEST", 49, 52], ["C57BL/6 mice", "TREATMENT", 56, 68], ["thioglycolate", "TREATMENT", 93, 106], ["macrophages", "TREATMENT", 111, 122], ["peritoneal lavage", "TREATMENT", 136, 153], ["peritoneal", "ANATOMY", 11, 21], ["macrophages", "OBSERVATION", 22, 33], ["peritoneal", "ANATOMY", 136, 146], ["lavage", "OBSERVATION", 147, 153]]], ["BTK -/-C57BL/6 mice were generated by BTK -/mice backcrossed to C57BL/6J background (30) .Antibody-Dependent Cellular Phagocytosis (ADCP assay)J774A.1 macrophages were cultivated in 96-well plates at 1x10 4 cells per well.", [["Cellular", "ANATOMY", 109, 117], ["J774A.1 macrophages", "ANATOMY", 143, 162], ["1x10 4 cells", "ANATOMY", 200, 212], ["BTK", "GENE_OR_GENE_PRODUCT", 0, 3], ["C57BL/6 mice", "ORGANISM", 7, 19], ["BTK", "GENE_OR_GENE_PRODUCT", 38, 41], ["mice", "ORGANISM", 44, 48], ["C57BL/6J", "ORGANISM", 64, 72], ["J774A.1 macrophages", "CELL", 143, 162], ["1x10 4 cells", "CELL", 200, 212], ["BTK", "PROTEIN", 0, 3], ["BTK", "PROTEIN", 38, 41], ["J774A.1 macrophages", "CELL_LINE", 143, 162], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 44, 48], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 44, 48], ["BTK", "TEST", 0, 3], ["BTK", "TEST", 38, 41], ["Antibody", "TEST", 90, 98], ["Cellular Phagocytosis", "TEST", 109, 130], ["ADCP assay", "TEST", 132, 142], ["macrophages", "TEST", 151, 162], ["Dependent", "OBSERVATION_MODIFIER", 99, 108], ["Cellular Phagocytosis", "OBSERVATION", 109, 130]]], ["After 4 h of incubation at 37\u00b0C, 1.5x10 5 hMB \"double-hit\" lymphoma cells/well were cocultured with respective macrophages.", [["lymphoma cells", "ANATOMY", 59, 73], ["macrophages", "ANATOMY", 111, 122], ["lymphoma", "DISEASE", 59, 67], ["lymphoma cells", "CELL", 59, 73], ["macrophages", "CELL", 111, 122], ["hMB \"double-hit\" lymphoma cells", "CELL_LINE", 42, 73], ["macrophages", "CELL_TYPE", 111, 122], ["incubation", "TREATMENT", 13, 23], ["double-hit\" lymphoma cells", "TREATMENT", 47, 73]]], ["Subsequently, this co-culture was treated for 17 h with tyrosine kinase inhibitors and monoclonal antibodies in combination or as mono treatment.", [["tyrosine", "CHEMICAL", 56, 64], ["tyrosine", "CHEMICAL", 56, 64], ["tyrosine kinase inhibitors", "SIMPLE_CHEMICAL", 56, 82], ["tyrosine kinase", "PROTEIN", 56, 71], ["monoclonal antibodies", "PROTEIN", 87, 108], ["this co-culture", "TEST", 14, 29], ["tyrosine kinase inhibitors", "TREATMENT", 56, 82], ["monoclonal antibodies", "TREATMENT", 87, 108], ["mono treatment", "TREATMENT", 130, 144]]], ["For determination of ADCP GFP + target cells were analyzed using a MACSQuant flow cytometer.", [["ADCP GFP + target cells", "ANATOMY", 21, 44], ["ADCP", "GENE_OR_GENE_PRODUCT", 21, 25], ["GFP", "GENE_OR_GENE_PRODUCT", 26, 29], ["cells", "CELL", 39, 44], ["ADCP GFP + target cells", "CELL_LINE", 21, 44], ["ADCP GFP", "TEST", 21, 29], ["target cells", "PROBLEM", 32, 44], ["a MACSQuant flow cytometer", "TREATMENT", 65, 91]]], ["The percentage of ADCP was calculated as follows:Antibody-Dependent Cellular Phagocytosis (ADCP assay)100 -(100 x (cells/\u00b5L treated / cells/\u00b5L untreated)).Generation of conditioned mediaFor the generation of conditioned media 1.Phagocytosis F4-80 stainingTo determine the amount of phagocyted hMB cells by macrophages, J774A.1 were plated out in a density of 1x10 5 cells in 1ml media 4 h prior to addition of target cells.", [["Cellular", "ANATOMY", 68, 76], ["cells", "ANATOMY", 115, 120], ["cells", "ANATOMY", 134, 139], ["hMB cells", "ANATOMY", 293, 302], ["macrophages", "ANATOMY", 306, 317], ["J774A.1", "ANATOMY", 319, 326], ["1x10 5 cells", "ANATOMY", 359, 371], ["cells", "ANATOMY", 417, 422], ["ADCP", "SIMPLE_CHEMICAL", 18, 22], ["cells", "CELL", 134, 139], ["F4-80", "GENE_OR_GENE_PRODUCT", 241, 246], ["hMB cells", "CELL", 293, 302], ["macrophages", "CELL", 306, 317], ["J774A.1", "CELL", 319, 326], ["1x10 5 cells", "CELL", 359, 371], ["cells", "CELL", 417, 422], ["ADCP", "PROTEIN", 18, 22], ["phagocyted hMB cells", "CELL_LINE", 282, 302], ["macrophages", "CELL_TYPE", 306, 317], ["J774A.1", "CELL_LINE", 319, 326], ["1x10 5 cells", "CELL_LINE", 359, 371], ["target cells", "CELL_TYPE", 410, 422], ["The percentage of ADCP", "TEST", 0, 22], ["Antibody", "TEST", 49, 57], ["Cellular Phagocytosis", "TEST", 68, 89], ["ADCP assay", "TEST", 91, 101], ["cells", "TEST", 115, 120], ["cells", "TEST", 134, 139], ["Phagocytosis F4", "TEST", 228, 243], ["phagocyted hMB cells", "PROBLEM", 282, 302], ["J774A.1", "TEST", 319, 326], ["target cells", "PROBLEM", 410, 422], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["Cellular Phagocytosis", "OBSERVATION", 68, 89], ["macrophages", "ANATOMY", 306, 317], ["target cells", "OBSERVATION", 410, 422]]], ["For data analysis Bio Navigator software (PamGene) was used to calculate the cycle and time dependent signals into a single value for each peptide on the chip (exposure time scaling).", [["data analysis", "TEST", 4, 17], ["the chip", "TREATMENT", 150, 158]]], ["Furthermore, outliers due to saturation or insufficient antibody binding were excluded.", [["saturation", "TEST", 29, 39], ["insufficient antibody binding", "PROBLEM", 43, 72], ["antibody binding", "OBSERVATION", 56, 72]]], ["For analysis, data were log transformed calculating the fold change between treated and untreated, and the p-value was calculated using an unpaired Students' two-tailed t-test.", [["analysis", "TEST", 4, 12], ["the p-value", "TEST", 103, 114]]], ["A p-value of p\u22640.05 was accepted as 8 statistically significant.", [["A p-value", "TEST", 0, 9]]], ["Individual peptides were matched to their representative kinases using a proprietary database (unpublished; PamGene International B. V., Netherlands).", [["kinases", "PROTEIN", 57, 64], ["Individual peptides", "PROBLEM", 0, 19], ["a proprietary database", "TEST", 71, 93]]], ["In brief, this database ranked the likelihood of peptides belonging to kinases using public databases such as; PhosphoNet, Reactome and UniPROT.Kinase activity profiling by PamChip microarrayVolcano plots were produced using the EnhancedVolcano package in RStudio (R version 3.3.1).StatisticsAll data was evaluated and graphs generated using GraphPad Prism 8.", [["Kinase", "GENE_OR_GENE_PRODUCT", 144, 150], ["kinases", "PROTEIN", 71, 78], ["PhosphoNet", "PROTEIN", 111, 121], ["UniPROT", "PROTEIN", 136, 143], ["public databases", "TEST", 85, 101], ["PhosphoNet", "TREATMENT", 111, 121], ["Kinase activity profiling", "TEST", 144, 169], ["Volcano plots", "PROBLEM", 191, 204], ["the EnhancedVolcano package", "TREATMENT", 225, 252], ["StatisticsAll data", "TEST", 282, 300], ["graphs", "TEST", 319, 325]]], ["Unless otherwise stated, bar graphs represent the mean \u00b1 SD of three biological replicates.Ibrutinib enhances macrophage-mediated antibody-dependent cellular phagocytosisIn order to elucidate the potential synergistic interaction between BTKis and monoclonal antibodies on macrophage-mediated ADCP, we utilized multiple monoclonal antibodies (rituximab, obinutuzumab, alemtuzumab), as well as different types of macrophage effector cells in an ADCP co-culture system ex vivo with the hMB humanized mouse model of \"Double-hit\" lymphoma as target cells (17, 31) ( Figure 1A ).Ibrutinib enhances macrophage-mediated antibody-dependent cellular phagocytosisCo-treatment of alemtuzumab with serially diluted concentrations of ibrutinib lead to significantly increased antibody-mediated lymphoma cell depletion in a concentration dependent manner ( Figure 1B ).", [["macrophage", "ANATOMY", 110, 120], ["cellular", "ANATOMY", 149, 157], ["macrophage", "ANATOMY", 273, 283], ["macrophage effector cells", "ANATOMY", 412, 437], ["lymphoma", "ANATOMY", 526, 534], ["cells", "ANATOMY", 545, 550], ["macrophage", "ANATOMY", 593, 603], ["cellular", "ANATOMY", 632, 640], ["lymphoma cell", "ANATOMY", 781, 794], ["Ibrutinib", "CHEMICAL", 91, 100], ["rituximab", "CHEMICAL", 343, 352], ["obinutuzumab", "CHEMICAL", 354, 366], ["alemtuzumab", "CHEMICAL", 368, 379], ["lymphoma", "DISEASE", 526, 534], ["Ibrutinib", "CHEMICAL", 574, 583], ["alemtuzumab", "CHEMICAL", 669, 680], ["ibrutinib", "CHEMICAL", 721, 730], ["lymphoma", "DISEASE", 781, 789], ["Ibrutinib", "CHEMICAL", 91, 100], ["obinutuzumab", "CHEMICAL", 354, 366], ["Ibrutinib", "CHEMICAL", 574, 583], ["ibrutinib", "CHEMICAL", 721, 730], ["Ibrutinib", "SIMPLE_CHEMICAL", 91, 100], ["macrophage", "CELL", 110, 120], ["cellular", "CELL", 149, 157], ["BTKis", "SIMPLE_CHEMICAL", 238, 243], ["macrophage", "CELL", 273, 283], ["ADCP", "SIMPLE_CHEMICAL", 293, 297], ["rituximab", "SIMPLE_CHEMICAL", 343, 352], ["obinutuzumab", "SIMPLE_CHEMICAL", 354, 366], ["alemtuzumab", "SIMPLE_CHEMICAL", 368, 379], ["macrophage effector cells", "CELL", 412, 437], ["ADCP", "CELL", 444, 448], ["mouse", "ORGANISM", 498, 503], ["lymphoma", "CANCER", 526, 534], ["cells", "CELL", 545, 550], ["Ibrutinib", "SIMPLE_CHEMICAL", 574, 583], ["macrophage", "CELL", 593, 603], ["cellular", "CELL", 632, 640], ["alemtuzumab", "SIMPLE_CHEMICAL", 669, 680], ["ibrutinib", "SIMPLE_CHEMICAL", 721, 730], ["lymphoma cell", "CELL", 781, 794], ["BTKis", "PROTEIN", 238, 243], ["monoclonal antibodies", "PROTEIN", 248, 269], ["ADCP", "PROTEIN", 293, 297], ["monoclonal antibodies", "PROTEIN", 320, 341], ["macrophage effector cells", "CELL_TYPE", 412, 437], ["target cells", "CELL_TYPE", 538, 550], ["mouse", "SPECIES", 498, 503], ["mouse", "SPECIES", 498, 503], ["bar graphs", "TEST", 25, 35], ["Ibrutinib enhances macrophage", "TEST", 91, 120], ["mediated antibody", "TEST", 121, 138], ["dependent cellular phagocytosis", "PROBLEM", 139, 170], ["BTKis", "TEST", 238, 243], ["monoclonal antibodies", "TEST", 248, 269], ["multiple monoclonal antibodies", "TREATMENT", 311, 341], ["rituximab", "TREATMENT", 343, 352], ["obinutuzumab", "TREATMENT", 354, 366], ["alemtuzumab", "TREATMENT", 368, 379], ["macrophage effector cells", "TREATMENT", 412, 437], ["an ADCP co-culture system", "TREATMENT", 441, 466], ["Double-hit\" lymphoma", "PROBLEM", 514, 534], ["Ibrutinib enhances macrophage", "PROBLEM", 574, 603], ["mediated antibody", "PROBLEM", 604, 621], ["alemtuzumab", "TREATMENT", 669, 680], ["ibrutinib lead", "PROBLEM", 721, 735], ["significantly increased antibody-mediated lymphoma cell depletion", "PROBLEM", 739, 804], ["macrophage", "OBSERVATION_MODIFIER", 110, 120], ["cellular phagocytosis", "OBSERVATION", 149, 170], ["macrophage effector cells", "OBSERVATION", 412, 437], ["macrophage", "OBSERVATION_MODIFIER", 593, 603], ["antibody", "OBSERVATION_MODIFIER", 613, 621], ["dependent", "OBSERVATION_MODIFIER", 622, 631], ["cellular phagocytosisCo-treatment", "OBSERVATION", 632, 665], ["diluted concentrations", "OBSERVATION_MODIFIER", 695, 717], ["ibrutinib lead", "OBSERVATION", 721, 735], ["significantly", "OBSERVATION_MODIFIER", 739, 752], ["increased", "OBSERVATION_MODIFIER", 753, 762], ["antibody", "OBSERVATION", 763, 771], ["lymphoma cell depletion", "OBSERVATION", 781, 804], ["concentration dependent", "OBSERVATION_MODIFIER", 810, 833]]], ["We did not attribute this significant increase to cell toxicity since at these concentrations the cells retained high cell viability (Supp.", [["cell", "ANATOMY", 50, 54], ["cells", "ANATOMY", 98, 103], ["cell", "ANATOMY", 118, 122], ["toxicity", "DISEASE", 55, 63], ["cell", "CELL", 50, 54], ["cells", "CELL", 98, 103], ["cell", "CELL", 118, 122], ["cell toxicity", "PROBLEM", 50, 63], ["high cell viability", "PROBLEM", 113, 132], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["increase", "OBSERVATION_MODIFIER", 38, 46], ["cell toxicity", "OBSERVATION", 50, 63], ["high cell viability", "OBSERVATION", 113, 132]]], ["Figure S1A and B).", [["B", "GENE_OR_GENE_PRODUCT", 15, 16]]], ["To verify that ibrutinib specifically enhances phagocytosis of antibody-targeted malignant B-cell lymphoma cells we assessed engulfment of GFP + hMB Double-Hit lymphoma cells into F4/80 + J774A.1 macrophages and detected a rising number of F4/80 + /GFP + cells with increasing ibrutinib concentrations ( Figure 1C ).", [["malignant B-cell lymphoma cells", "ANATOMY", 81, 112], ["GFP + hMB Double-Hit lymphoma cells", "ANATOMY", 139, 174], ["F4/80 + J774A", "ANATOMY", 180, 193], ["1 macrophages", "ANATOMY", 194, 207], ["F4/80 + /GFP + cells", "ANATOMY", 240, 260], ["ibrutinib", "CHEMICAL", 15, 24], ["malignant B-cell lymphoma", "DISEASE", 81, 106], ["lymphoma", "DISEASE", 160, 168], ["ibrutinib", "CHEMICAL", 277, 286], ["ibrutinib", "CHEMICAL", 15, 24], ["ibrutinib", "CHEMICAL", 277, 286], ["ibrutinib", "SIMPLE_CHEMICAL", 15, 24], ["malignant B-cell lymphoma cells", "CELL", 81, 112], ["GFP", "GENE_OR_GENE_PRODUCT", 139, 142], ["1 macrophages", "CELL", 194, 207], ["80", "GENE_OR_GENE_PRODUCT", 243, 245], ["GFP", "GENE_OR_GENE_PRODUCT", 249, 252], ["ibrutinib", "SIMPLE_CHEMICAL", 277, 286], ["antibody", "PROTEIN", 63, 71], ["malignant B-cell lymphoma cells", "CELL_TYPE", 81, 112], ["GFP", "PROTEIN", 139, 142], ["hMB Double-Hit lymphoma cells", "CELL_LINE", 145, 174], ["F4/80", "CELL_LINE", 180, 185], ["J774A", "CELL_LINE", 188, 193], ["macrophages", "CELL_TYPE", 196, 207], ["GFP", "PROTEIN", 249, 252], ["phagocytosis", "TEST", 47, 59], ["antibody", "TEST", 63, 71], ["targeted malignant B-cell lymphoma cells", "PROBLEM", 72, 112], ["GFP", "TEST", 139, 142], ["hMB", "TEST", 145, 148], ["F4", "TEST", 240, 242], ["increasing ibrutinib concentrations", "PROBLEM", 266, 301], ["ibrutinib", "OBSERVATION", 15, 24], ["cell lymphoma cells", "OBSERVATION", 93, 112], ["macrophages", "OBSERVATION", 196, 207], ["rising", "OBSERVATION_MODIFIER", 223, 229], ["increasing", "OBSERVATION_MODIFIER", 266, 276], ["ibrutinib concentrations", "OBSERVATION", 277, 301]]], ["Furthermore, this effect was independent of the number of macrophages present under ibrutinib treatment (Supp.", [["macrophages", "ANATOMY", 58, 69], ["ibrutinib", "CHEMICAL", 84, 93], ["ibrutinib", "CHEMICAL", 84, 93], ["macrophages", "CELL", 58, 69], ["ibrutinib", "SIMPLE_CHEMICAL", 84, 93], ["macrophages", "CELL_TYPE", 58, 69], ["ibrutinib treatment", "TREATMENT", 84, 103], ["Supp", "TREATMENT", 105, 109], ["macrophages", "OBSERVATION", 58, 69], ["ibrutinib treatment", "OBSERVATION", 84, 103]]], ["We observed similar significant increases in ADCP performing an independent ex vivo experimental setup using primary murine peritoneal macrophages ( Figure 1D ), whilst also observing concentration dependent antibody-mediated lymphoma cell depletion with the type 1 and 2 anti-CD20 monoclonal antibodies rituximab ( Figure 1E ) and obinutuzumab ( Figure 1F ).", [["peritoneal macrophages", "ANATOMY", 124, 146], ["lymphoma cell", "ANATOMY", 226, 239], ["lymphoma", "DISEASE", 226, 234], ["rituximab", "CHEMICAL", 304, 313], ["obinutuzumab", "CHEMICAL", 332, 344], ["obinutuzumab", "CHEMICAL", 332, 344], ["ADCP", "SIMPLE_CHEMICAL", 45, 49], ["murine", "ORGANISM", 117, 123], ["peritoneal macrophages", "CELL", 124, 146], ["lymphoma cell", "CELL", 226, 239], ["anti-CD20", "GENE_OR_GENE_PRODUCT", 272, 281], ["rituximab", "SIMPLE_CHEMICAL", 304, 313], ["obinutuzumab", "SIMPLE_CHEMICAL", 332, 344], ["primary murine peritoneal macrophages", "CELL_TYPE", 109, 146], ["anti-CD20 monoclonal antibodies", "PROTEIN", 272, 303], ["murine", "SPECIES", 117, 123], ["an independent ex vivo experimental setup", "TREATMENT", 61, 102], ["primary murine peritoneal macrophages", "TREATMENT", 109, 146], ["concentration dependent antibody", "PROBLEM", 184, 216], ["mediated lymphoma cell depletion", "PROBLEM", 217, 249], ["2 anti-CD20 monoclonal antibodies rituximab", "TREATMENT", 270, 313], ["obinutuzumab", "TREATMENT", 332, 344], ["similar", "OBSERVATION_MODIFIER", 12, 19], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["increases", "OBSERVATION_MODIFIER", 32, 41], ["peritoneal", "ANATOMY", 124, 134], ["macrophages", "OBSERVATION", 135, 146], ["concentration dependent", "OBSERVATION_MODIFIER", 184, 207], ["lymphoma cell depletion", "OBSERVATION", 226, 249]]], ["Thereby, ibrutinib treatment of hMB cells in vitro induced a moderate but non-significant increase of CD20 and CD52 expression ( Figure 1G ).", [["hMB cells", "ANATOMY", 32, 41], ["ibrutinib", "CHEMICAL", 9, 18], ["ibrutinib", "CHEMICAL", 9, 18], ["ibrutinib", "SIMPLE_CHEMICAL", 9, 18], ["hMB cells", "CELL", 32, 41], ["CD20", "GENE_OR_GENE_PRODUCT", 102, 106], ["CD52", "GENE_OR_GENE_PRODUCT", 111, 115], ["hMB cells", "CELL_LINE", 32, 41], ["CD20", "PROTEIN", 102, 106], ["CD52", "PROTEIN", 111, 115], ["ibrutinib treatment", "TREATMENT", 9, 28], ["hMB cells", "PROBLEM", 32, 41], ["non-significant increase of CD20", "PROBLEM", 74, 106], ["ibrutinib", "OBSERVATION", 9, 18], ["hMB cells", "OBSERVATION", 32, 41], ["moderate", "OBSERVATION_MODIFIER", 61, 69], ["non-significant", "OBSERVATION_MODIFIER", 74, 89], ["increase", "OBSERVATION_MODIFIER", 90, 98], ["CD20", "OBSERVATION", 102, 106]]], ["We furthermore evaluated the effects of ibrutinib on primary leukemic cells from chronic lymphocytic leukemia (CLL) patients.", [["primary leukemic cells", "ANATOMY", 53, 75], ["chronic lymphocytic leukemia", "ANATOMY", 81, 109], ["CLL", "ANATOMY", 111, 114], ["ibrutinib", "CHEMICAL", 40, 49], ["primary leukemic", "DISEASE", 53, 69], ["chronic lymphocytic leukemia", "DISEASE", 81, 109], ["CLL", "DISEASE", 111, 114], ["ibrutinib", "CHEMICAL", 40, 49], ["ibrutinib", "SIMPLE_CHEMICAL", 40, 49], ["primary leukemic cells", "CELL", 53, 75], ["chronic lymphocytic leukemia", "CANCER", 81, 109], ["CLL", "CANCER", 111, 114], ["patients", "ORGANISM", 116, 124], ["primary leukemic cells", "CELL_TYPE", 53, 75], ["patients", "SPECIES", 116, 124], ["ibrutinib", "PROBLEM", 40, 49], ["primary leukemic cells", "PROBLEM", 53, 75], ["chronic lymphocytic leukemia", "PROBLEM", 81, 109], ["ibrutinib", "OBSERVATION", 40, 49], ["primary leukemic cells", "OBSERVATION", 53, 75], ["chronic", "OBSERVATION_MODIFIER", 81, 88], ["lymphocytic leukemia", "OBSERVATION", 89, 109]]], ["Primary CLL cells pretreated with ibrutinib for 24 h exhibited an increased susceptibility towards alemtuzumab mediated ADCP comparing the ibrutinib treatment with antibody to ibrutinib treatment without antibody therapy ( Figure 1H ).", [["Primary CLL cells", "ANATOMY", 0, 17], ["CLL", "DISEASE", 8, 11], ["ibrutinib", "CHEMICAL", 34, 43], ["alemtuzumab", "CHEMICAL", 99, 110], ["ADCP", "CHEMICAL", 120, 124], ["ibrutinib", "CHEMICAL", 139, 148], ["ibrutinib", "CHEMICAL", 176, 185], ["ibrutinib", "CHEMICAL", 34, 43], ["ibrutinib", "CHEMICAL", 139, 148], ["ibrutinib", "CHEMICAL", 176, 185], ["Primary CLL cells", "CELL", 0, 17], ["ibrutinib", "SIMPLE_CHEMICAL", 34, 43], ["alemtuzumab", "SIMPLE_CHEMICAL", 99, 110], ["ADCP", "SIMPLE_CHEMICAL", 120, 124], ["ibrutinib", "SIMPLE_CHEMICAL", 139, 148], ["ibrutinib", "SIMPLE_CHEMICAL", 176, 185], ["CLL cells", "CELL_LINE", 8, 17], ["Primary CLL cells", "PROBLEM", 0, 17], ["ibrutinib", "TREATMENT", 34, 43], ["an increased susceptibility", "PROBLEM", 63, 90], ["alemtuzumab mediated ADCP", "TREATMENT", 99, 124], ["the ibrutinib treatment", "TREATMENT", 135, 158], ["antibody", "TREATMENT", 164, 172], ["ibrutinib treatment", "TREATMENT", 176, 195], ["antibody therapy", "TREATMENT", 204, 220], ["CLL cells", "OBSERVATION", 8, 17], ["increased", "OBSERVATION_MODIFIER", 66, 75]]], ["Importantly, here we observe an increase of ADCP using a low ibrutinib concentrations of 0.01 \u00b5M.", [["ADCP", "CHEMICAL", 44, 48], ["ibrutinib", "CHEMICAL", 61, 70], ["ibrutinib", "CHEMICAL", 61, 70], ["ADCP", "SIMPLE_CHEMICAL", 44, 48], ["ibrutinib", "SIMPLE_CHEMICAL", 61, 70], ["ADCP", "PROTEIN", 44, 48], ["an increase of ADCP", "PROBLEM", 29, 48], ["a low ibrutinib concentrations", "TREATMENT", 55, 85], ["increase", "OBSERVATION_MODIFIER", 32, 40]]], ["This corresponds to concentrations achieved with oral formulation of 420 mg ibrutinib daily (32) .Ibrutinib elicits increased ADCP independent of BTK inhibitionPreviously we have shown that chemotherapy in combination with monoclonal antibody treatment induces an ASAP1 leading to increased macrophage-mediated lymphoma cell depletion in vivo (31) .", [["oral", "ANATOMY", 49, 53], ["macrophage", "ANATOMY", 291, 301], ["lymphoma cell", "ANATOMY", 311, 324], ["ibrutinib", "CHEMICAL", 76, 85], ["Ibrutinib", "CHEMICAL", 98, 107], ["lymphoma", "DISEASE", 311, 319], ["ibrutinib", "CHEMICAL", 76, 85], ["Ibrutinib", "CHEMICAL", 98, 107], ["oral", "ORGANISM_SUBDIVISION", 49, 53], ["ibrutinib", "SIMPLE_CHEMICAL", 76, 85], ["Ibrutinib", "SIMPLE_CHEMICAL", 98, 107], ["ADCP", "SIMPLE_CHEMICAL", 126, 130], ["BTK", "GENE_OR_GENE_PRODUCT", 146, 149], ["ASAP1", "GENE_OR_GENE_PRODUCT", 264, 269], ["macrophage", "CELL", 291, 301], ["lymphoma cell", "CELL", 311, 324], ["ADCP", "PROTEIN", 126, 130], ["BTK", "PROTEIN", 146, 149], ["monoclonal antibody", "PROTEIN", 223, 242], ["ASAP1", "PROTEIN", 264, 269], ["oral formulation", "TREATMENT", 49, 65], ["Ibrutinib elicits", "PROBLEM", 98, 115], ["BTK inhibition", "TREATMENT", 146, 160], ["chemotherapy", "TREATMENT", 190, 202], ["monoclonal antibody treatment", "TREATMENT", 223, 252], ["an ASAP1", "PROBLEM", 261, 269], ["increased macrophage", "PROBLEM", 281, 301], ["mediated lymphoma cell depletion", "PROBLEM", 302, 334], ["increased", "OBSERVATION_MODIFIER", 281, 290], ["macrophage", "OBSERVATION_MODIFIER", 291, 301], ["lymphoma cell depletion", "OBSERVATION", 311, 334]]], ["Along these lines, we hypothesized that ibrutinib could be eliciting a similar effect.", [["ibrutinib", "CHEMICAL", 40, 49], ["ibrutinib", "CHEMICAL", 40, 49], ["lines", "CELL", 12, 17], ["ibrutinib", "SIMPLE_CHEMICAL", 40, 49], ["ibrutinib", "PROBLEM", 40, 49], ["lines", "OBSERVATION", 12, 17], ["ibrutinib", "OBSERVATION", 40, 49], ["similar", "OBSERVATION_MODIFIER", 71, 78], ["effect", "OBSERVATION_MODIFIER", 79, 85]]], ["To analyze the impact of soluble factors released by malignant B-cells, conditioned media from ibrutinib pretreated hMB cells was generated and applied to ADCP co-culture of treatment na\u00efve effector and target cells.", [["malignant B-cells", "ANATOMY", 53, 70], ["hMB cells", "ANATOMY", 116, 125], ["cells", "ANATOMY", 210, 215], ["ibrutinib", "CHEMICAL", 95, 104], ["ibrutinib", "CHEMICAL", 95, 104], ["malignant B-cells", "CELL", 53, 70], ["ibrutinib", "SIMPLE_CHEMICAL", 95, 104], ["hMB cells", "CELL", 116, 125], ["cells", "CELL", 210, 215], ["soluble factors", "PROTEIN", 25, 40], ["malignant B-cells", "CELL_TYPE", 53, 70], ["ibrutinib pretreated hMB cells", "CELL_LINE", 95, 125], ["na\u00efve effector and target cells", "CELL_TYPE", 184, 215], ["soluble factors", "TREATMENT", 25, 40], ["conditioned media", "TREATMENT", 72, 89], ["ibrutinib pretreated hMB cells", "TREATMENT", 95, 125], ["treatment na\u00efve effector", "TREATMENT", 174, 198], ["hMB cells", "OBSERVATION", 116, 125], ["target cells", "OBSERVATION", 203, 215]]], ["Here, we observed a significant increase of ADCP induced by conditioned media obtained from ibrutinib pretreated hMB cells (Figure 2A ).", [["hMB cells", "ANATOMY", 113, 122], ["ibrutinib", "CHEMICAL", 92, 101], ["ibrutinib", "CHEMICAL", 92, 101], ["ADCP", "GENE_OR_GENE_PRODUCT", 44, 48], ["ibrutinib", "SIMPLE_CHEMICAL", 92, 101], ["hMB cells", "CELL", 113, 122], ["ADCP", "PROTEIN", 44, 48], ["ibrutinib pretreated hMB cells", "CELL_LINE", 92, 122], ["a significant increase of ADCP", "PROBLEM", 18, 48], ["ibrutinib pretreated hMB cells", "PROBLEM", 92, 122], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["increase", "OBSERVATION_MODIFIER", 32, 40]]], ["To validate whether ibrutinib was eliciting its action via the effector or target cells, we conducted pretreatment in both J774A.1 and hMB cells, followed by co-culture with treatment na\u00efve cells in the ADCP assay.", [["cells", "ANATOMY", 82, 87], ["J774A.1", "ANATOMY", 123, 130], ["hMB cells", "ANATOMY", 135, 144], ["cells", "ANATOMY", 190, 195], ["ibrutinib", "CHEMICAL", 20, 29], ["ibrutinib", "CHEMICAL", 20, 29], ["ibrutinib", "SIMPLE_CHEMICAL", 20, 29], ["cells", "CELL", 82, 87], ["J774A.1", "CELL", 123, 130], ["hMB cells", "CELL", 135, 144], ["cells", "CELL", 190, 195], ["target cells", "CELL_TYPE", 75, 87], ["J774A.1", "CELL_LINE", 123, 130], ["hMB cells", "CELL_LINE", 135, 144], ["na\u00efve cells", "CELL_LINE", 184, 195], ["ibrutinib", "TREATMENT", 20, 29], ["target cells", "PROBLEM", 75, 87], ["hMB cells", "PROBLEM", 135, 144], ["co-culture", "TEST", 158, 168], ["treatment na\u00efve cells", "TREATMENT", 174, 195], ["the ADCP assay", "TEST", 199, 213]]], ["When we pretreated macrophages with ibrutinib and subsequently added treatment na\u00efve hMB target cells to the ADCP assay we did not detect any significant change in phagocytosis ( Figure 2B ).", [["macrophages", "ANATOMY", 19, 30], ["cells", "ANATOMY", 96, 101], ["ibrutinib", "CHEMICAL", 36, 45], ["ibrutinib", "CHEMICAL", 36, 45], ["macrophages", "CELL", 19, 30], ["ibrutinib", "SIMPLE_CHEMICAL", 36, 45], ["hMB target cells", "CELL", 85, 101], ["macrophages", "CELL_TYPE", 19, 30], ["na\u00efve hMB target cells", "CELL_LINE", 79, 101], ["ibrutinib", "TREATMENT", 36, 45], ["treatment na\u00efve hMB", "TREATMENT", 69, 88], ["the ADCP assay", "TEST", 105, 119], ["any significant change in phagocytosis", "PROBLEM", 138, 176], ["significant", "OBSERVATION_MODIFIER", 142, 153], ["change", "OBSERVATION", 154, 160]]], ["In contrast, when we applied ibrutinib pretreated hMB cells to treatment na\u00efve macrophages in co-culture, we observed a significant increase in ADCP ( Figure 2C ).", [["hMB cells", "ANATOMY", 50, 59], ["macrophages", "ANATOMY", 79, 90], ["ibrutinib", "CHEMICAL", 29, 38], ["ibrutinib", "CHEMICAL", 29, 38], ["ibrutinib", "SIMPLE_CHEMICAL", 29, 38], ["hMB cells", "CELL", 50, 59], ["macrophages", "CELL", 79, 90], ["ADCP", "SIMPLE_CHEMICAL", 144, 148], ["ibrutinib pretreated hMB cells", "CELL_LINE", 29, 59], ["na\u00efve macrophages", "CELL_TYPE", 73, 90], ["ADCP", "PROTEIN", 144, 148], ["ibrutinib pretreated hMB cells", "TREATMENT", 29, 59], ["na\u00efve macrophages in co-culture", "PROBLEM", 73, 104], ["a significant increase in ADCP", "PROBLEM", 118, 148], ["significant", "OBSERVATION_MODIFIER", 120, 131], ["increase", "OBSERVATION_MODIFIER", 132, 140]]], ["This suggests that ibrutinib is eliciting its synergistic interaction with monoclonal antibody mainly in the malignant B-cells.Ibrutinib elicits increased ADCP independent of BTK inhibitionIn comparison to second generation BTKis, ibrutinib is not as highly selective for BTK binding, having affinity for other Tec kinases, such as EGFR and JAK2 (11) .Ibrutinib elicits increased ADCP independent of BTK inhibitionTherefore, we interrogated whether ibrutinib mediated its effect through covalently binding its main target BTK, leveraging primary peritoneal macrophages from BTK -/mice ( Figure 2D ) and knocking down BTK in hMB cells ( Figure 2E , Supp.", [["malignant B-cells", "ANATOMY", 109, 126], ["peritoneal macrophages", "ANATOMY", 546, 568], ["hMB cells", "ANATOMY", 624, 633], ["ibrutinib", "CHEMICAL", 19, 28], ["Ibrutinib", "CHEMICAL", 127, 136], ["BTKis", "CHEMICAL", 224, 229], ["ibrutinib", "CHEMICAL", 231, 240], ["Ibrutinib", "CHEMICAL", 352, 361], ["ibrutinib", "CHEMICAL", 449, 458], ["ibrutinib", "CHEMICAL", 19, 28], ["Ibrutinib", "CHEMICAL", 127, 136], ["ibrutinib", "CHEMICAL", 231, 240], ["Ibrutinib", "CHEMICAL", 352, 361], ["ibrutinib", "CHEMICAL", 449, 458], ["ibrutinib", "SIMPLE_CHEMICAL", 19, 28], ["malignant B-cells", "CELL", 109, 126], ["Ibrutinib", "SIMPLE_CHEMICAL", 127, 136], ["ADCP", "SIMPLE_CHEMICAL", 155, 159], ["BTK", "GENE_OR_GENE_PRODUCT", 175, 178], ["ibrutinib", "SIMPLE_CHEMICAL", 231, 240], ["BTK", "GENE_OR_GENE_PRODUCT", 272, 275], ["Tec", "GENE_OR_GENE_PRODUCT", 311, 314], ["EGFR", "GENE_OR_GENE_PRODUCT", 332, 336], ["JAK2 (11)", "GENE_OR_GENE_PRODUCT", 341, 350], ["Ibrutinib", "SIMPLE_CHEMICAL", 352, 361], ["ADCP", "SIMPLE_CHEMICAL", 380, 384], ["BTK", "GENE_OR_GENE_PRODUCT", 400, 403], ["ibrutinib", "SIMPLE_CHEMICAL", 449, 458], ["BTK", "GENE_OR_GENE_PRODUCT", 522, 525], ["peritoneal macrophages", "CELL", 546, 568], ["BTK", "GENE_OR_GENE_PRODUCT", 574, 577], ["BTK", "GENE_OR_GENE_PRODUCT", 617, 620], ["hMB cells", "CELL", 624, 633], ["monoclonal antibody", "PROTEIN", 75, 94], ["malignant B-cells", "CELL_TYPE", 109, 126], ["ADCP", "PROTEIN", 155, 159], ["BTK", "PROTEIN", 175, 178], ["BTK", "PROTEIN", 272, 275], ["Tec kinases", "PROTEIN", 311, 322], ["EGFR", "PROTEIN", 332, 336], ["JAK2 (11)", "PROTEIN", 341, 350], ["ADCP", "PROTEIN", 380, 384], ["BTK", "PROTEIN", 400, 403], ["BTK", "PROTEIN", 522, 525], ["primary peritoneal macrophages", "CELL_TYPE", 538, 568], ["BTK", "PROTEIN", 574, 577], ["BTK", "PROTEIN", 617, 620], ["hMB cells", "CELL_LINE", 624, 633], ["mice", "SPECIES", 580, 584], ["ibrutinib", "PROBLEM", 19, 28], ["monoclonal antibody", "PROBLEM", 75, 94], ["Ibrutinib elicits", "PROBLEM", 127, 144], ["increased ADCP", "PROBLEM", 145, 159], ["BTK inhibitionIn", "TREATMENT", 175, 191], ["second generation BTKis", "PROBLEM", 206, 229], ["ibrutinib", "PROBLEM", 231, 240], ["BTK binding", "PROBLEM", 272, 283], ["other Tec kinases", "TEST", 305, 322], ["EGFR", "TEST", 332, 336], ["JAK2", "TEST", 341, 345], ["Ibrutinib elicits", "PROBLEM", 352, 369], ["BTK inhibition", "TREATMENT", 400, 414], ["ibrutinib", "TREATMENT", 449, 458], ["leveraging primary peritoneal macrophages", "PROBLEM", 527, 568], ["knocking down BTK in hMB cells", "PROBLEM", 603, 633], ["ibrutinib", "OBSERVATION", 19, 28], ["monoclonal antibody", "OBSERVATION", 75, 94], ["malignant B-cells", "OBSERVATION", 109, 126], ["increased", "OBSERVATION_MODIFIER", 145, 154], ["ibrutinib", "OBSERVATION", 231, 240], ["increased", "OBSERVATION_MODIFIER", 370, 379], ["peritoneal", "ANATOMY", 546, 556]]], ["In these experiments we observed significant increases in ADCP for BTK -/peritoneal macrophages and no significant difference between wt hMB cells and hMB cells with a knock down in BTK treated with alemtuzumab, suggesting that one of ibrutinib's off-target kinases was responsible for the observed effect.", [["peritoneal macrophages", "ANATOMY", 73, 95], ["hMB cells", "ANATOMY", 137, 146], ["hMB cells", "ANATOMY", 151, 160], ["alemtuzumab", "CHEMICAL", 199, 210], ["ibrutinib", "CHEMICAL", 235, 244], ["ibrutinib", "CHEMICAL", 235, 244], ["ADCP", "SIMPLE_CHEMICAL", 58, 62], ["BTK", "GENE_OR_GENE_PRODUCT", 67, 70], ["peritoneal macrophages", "CELL", 73, 95], ["hMB cells", "CELL", 137, 146], ["hMB cells", "CELL", 151, 160], ["BTK", "GENE_OR_GENE_PRODUCT", 182, 185], ["alemtuzumab", "SIMPLE_CHEMICAL", 199, 210], ["ibrutinib", "SIMPLE_CHEMICAL", 235, 244], ["ADCP", "PROTEIN", 58, 62], ["BTK", "PROTEIN", 67, 70], ["peritoneal macrophages", "CELL_TYPE", 73, 95], ["hMB cells", "CELL_LINE", 137, 146], ["hMB cells", "CELL_LINE", 151, 160], ["BTK", "PROTEIN", 182, 185], ["ibrutinib's off-target kinases", "PROTEIN", 235, 265], ["significant increases in ADCP", "PROBLEM", 33, 62], ["BTK -/peritoneal macrophages", "PROBLEM", 67, 95], ["significant difference between wt hMB cells", "PROBLEM", 103, 146], ["hMB cells", "PROBLEM", 151, 160], ["alemtuzumab", "TREATMENT", 199, 210], ["ibrutinib's", "TREATMENT", 235, 246], ["target kinases", "PROBLEM", 251, 265], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["increases", "OBSERVATION_MODIFIER", 45, 54], ["peritoneal", "ANATOMY", 73, 83], ["macrophages", "OBSERVATION", 84, 95], ["no", "UNCERTAINTY", 100, 102], ["significant", "OBSERVATION_MODIFIER", 103, 114], ["BTK", "ANATOMY", 182, 185]]], ["To further confirm that BTK was not responsible for this effect, we conducted ADCP assays in vitro using the second generation BTKis tirabrutinib ( Figure 2F ) and acalabrutinib (Supp.", [["tirabrutinib", "CHEMICAL", 133, 145], ["acalabrutinib", "CHEMICAL", 164, 177], ["Supp", "CHEMICAL", 179, 183], ["tirabrutinib", "CHEMICAL", 133, 145], ["acalabrutinib", "CHEMICAL", 164, 177], ["BTK", "GENE_OR_GENE_PRODUCT", 24, 27], ["tirabrutinib", "SIMPLE_CHEMICAL", 133, 145], ["acalabrutinib", "SIMPLE_CHEMICAL", 164, 177], ["Supp", "SIMPLE_CHEMICAL", 179, 183], ["BTK", "PROTEIN", 24, 27], ["BTK", "PROBLEM", 24, 27], ["the second generation BTKis tirabrutinib ( Figure 2F", "TREATMENT", 105, 157], ["acalabrutinib (Supp", "TREATMENT", 164, 183], ["BTK", "OBSERVATION", 24, 27], ["not responsible for", "UNCERTAINTY", 32, 51]]], ["Figure S2B) both showing similar levels of phagocytosis and no toxicity (Supp.", [["toxicity", "DISEASE", 63, 71], ["Figure S2B", "TEST", 0, 10], ["phagocytosis", "PROBLEM", 43, 55], ["toxicity", "PROBLEM", 63, 71], ["phagocytosis", "OBSERVATION", 43, 55], ["no", "UNCERTAINTY", 60, 62]]], ["Moreover, combination therapy with alemtuzumab and tirabrutinib in vivo ( Figure 2G ) did not increase overall survival and did not reduce hMB cells or macrophages in spleen and bone marrow.", [["hMB cells", "ANATOMY", 139, 148], ["macrophages", "ANATOMY", 152, 163], ["spleen", "ANATOMY", 167, 173], ["bone marrow", "ANATOMY", 178, 189], ["alemtuzumab", "CHEMICAL", 35, 46], ["tirabrutinib", "CHEMICAL", 51, 63], ["tirabrutinib", "CHEMICAL", 51, 63], ["alemtuzumab", "SIMPLE_CHEMICAL", 35, 46], ["tirabrutinib", "SIMPLE_CHEMICAL", 51, 63], ["hMB cells", "CELL", 139, 148], ["macrophages", "CELL", 152, 163], ["spleen", "ORGAN", 167, 173], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 178, 189], ["hMB cells", "CELL_TYPE", 139, 148], ["macrophages", "CELL_TYPE", 152, 163], ["combination therapy", "TREATMENT", 10, 29], ["alemtuzumab", "TREATMENT", 35, 46], ["tirabrutinib", "TREATMENT", 51, 63], ["hMB cells", "PROBLEM", 139, 148], ["macrophages in spleen and bone marrow", "PROBLEM", 152, 189], ["macrophages", "OBSERVATION", 152, 163], ["spleen", "ANATOMY", 167, 173], ["bone marrow", "ANATOMY", 178, 189]]], ["In conclusion, we have identified that the ADCP-enhancing effects of ibrutinib were mediated by targeting the malignant B-cell compartment, which induces a secretory component in the malignant B-cells leading to macrophage activation.", [["malignant B-cell compartment", "ANATOMY", 110, 138], ["malignant B-cells", "ANATOMY", 183, 200], ["macrophage", "ANATOMY", 212, 222], ["ibrutinib", "CHEMICAL", 69, 78], ["ibrutinib", "CHEMICAL", 69, 78], ["ADCP", "GENE_OR_GENE_PRODUCT", 43, 47], ["ibrutinib", "SIMPLE_CHEMICAL", 69, 78], ["malignant B-cell compartment", "CELL", 110, 138], ["malignant B-cells", "CELL", 183, 200], ["macrophage", "CELL", 212, 222], ["malignant B-cell compartment", "CELL_TYPE", 110, 138], ["malignant B-cells", "CELL_TYPE", 183, 200], ["the ADCP", "TEST", 39, 47], ["ibrutinib", "PROBLEM", 69, 78], ["the malignant B-cell compartment", "PROBLEM", 106, 138], ["a secretory component", "PROBLEM", 154, 175], ["the malignant B-cells", "PROBLEM", 179, 200], ["macrophage activation", "PROBLEM", 212, 233], ["enhancing", "OBSERVATION_MODIFIER", 48, 57], ["ibrutinib", "OBSERVATION", 69, 78], ["malignant", "OBSERVATION_MODIFIER", 110, 119], ["cell compartment", "OBSERVATION", 122, 138], ["secretory", "OBSERVATION_MODIFIER", 156, 165], ["component", "OBSERVATION_MODIFIER", 166, 175], ["malignant", "OBSERVATION_MODIFIER", 183, 192], ["macrophage activation", "OBSERVATION", 212, 233]]], ["Furthermore, we have shown that the observed effect is independent of BTK, therefore we hypothesized that the increased ADCP induced by ibrutinib to be associated with its off-target kinases.Kinase activity profiling identifies Janus Kinase 2 & 3 as the main offtargets for ibrutinib vs. second generation BTKisTo identify the off-target effects of ibrutinib that might be responsible for the synergistic interaction observed in Figures 1 and 2 Figure 3A and B).", [["ADCP", "CHEMICAL", 120, 124], ["ibrutinib", "CHEMICAL", 136, 145], ["ibrutinib", "CHEMICAL", 274, 283], ["ibrutinib", "CHEMICAL", 349, 358], ["ibrutinib", "CHEMICAL", 136, 145], ["ibrutinib", "CHEMICAL", 274, 283], ["ibrutinib", "CHEMICAL", 349, 358], ["BTK", "GENE_OR_GENE_PRODUCT", 70, 73], ["ADCP", "GENE_OR_GENE_PRODUCT", 120, 124], ["ibrutinib", "SIMPLE_CHEMICAL", 136, 145], ["Kinase", "GENE_OR_GENE_PRODUCT", 191, 197], ["Janus Kinase 2 & 3", "GENE_OR_GENE_PRODUCT", 228, 246], ["ibrutinib", "SIMPLE_CHEMICAL", 274, 283], ["ibrutinib", "SIMPLE_CHEMICAL", 349, 358], ["B", "GENE_OR_GENE_PRODUCT", 459, 460], ["BTK", "PROTEIN", 70, 73], ["ADCP", "PROTEIN", 120, 124], ["off-target kinases", "PROTEIN", 172, 190], ["Janus Kinase 2 & 3", "PROTEIN", 228, 246], ["the increased ADCP", "PROBLEM", 106, 124], ["ibrutinib", "PROBLEM", 136, 145], ["Kinase activity profiling", "TEST", 191, 216], ["Janus Kinase", "TEST", 228, 240], ["ibrutinib", "TREATMENT", 274, 283], ["second generation BTKisTo", "TREATMENT", 288, 313], ["ibrutinib", "TREATMENT", 349, 358], ["the synergistic interaction", "PROBLEM", 389, 416], ["increased", "OBSERVATION_MODIFIER", 110, 119], ["ibrutinib", "OBSERVATION", 274, 283]]], ["In conclusion, this data suggests that JAK2 and JAK3 could be the off-target kinases of 13 ibrutinib, and therefore potentially the responsible kinases for the increased macrophage-mediated phagocytic capacity.JAK2 inhibition with ruxolitinib and tofacitinib enhances macrophage mediated ADCPTo translate our kinase activity findings back to macrophage mediated ADCP, we generated a modestly sized Tec kinase inhibitor library, conducting concentration dependent ADCP assays in vitro.", [["macrophage", "ANATOMY", 170, 180], ["macrophage", "ANATOMY", 268, 278], ["macrophage", "ANATOMY", 342, 352], ["ibrutinib", "CHEMICAL", 91, 100], ["ruxolitinib", "CHEMICAL", 231, 242], ["tofacitinib", "CHEMICAL", 247, 258], ["ibrutinib", "CHEMICAL", 91, 100], ["ruxolitinib", "CHEMICAL", 231, 242], ["tofacitinib", "CHEMICAL", 247, 258], ["JAK2", "GENE_OR_GENE_PRODUCT", 39, 43], ["JAK3", "GENE_OR_GENE_PRODUCT", 48, 52], ["ibrutinib", "SIMPLE_CHEMICAL", 91, 100], ["macrophage", "CELL", 170, 180], ["JAK2", "GENE_OR_GENE_PRODUCT", 210, 214], ["ruxolitinib", "SIMPLE_CHEMICAL", 231, 242], ["tofacitinib", "SIMPLE_CHEMICAL", 247, 258], ["macrophage", "CELL", 268, 278], ["ADCPTo", "SIMPLE_CHEMICAL", 288, 294], ["macrophage", "CELL", 342, 352], ["ADCP", "GENE_OR_GENE_PRODUCT", 362, 366], ["Tec", "GENE_OR_GENE_PRODUCT", 398, 401], ["JAK2", "PROTEIN", 39, 43], ["JAK3", "PROTEIN", 48, 52], ["JAK2", "PROTEIN", 210, 214], ["ADCPTo", "PROTEIN", 288, 294], ["ADCP", "PROTEIN", 362, 366], ["Tec kinase", "PROTEIN", 398, 408], ["this data", "TEST", 15, 24], ["JAK2", "PROBLEM", 39, 43], ["JAK3", "TEST", 48, 52], ["ibrutinib", "TREATMENT", 91, 100], ["the increased macrophage-mediated phagocytic capacity", "PROBLEM", 156, 209], ["JAK2 inhibition", "PROBLEM", 210, 225], ["ruxolitinib", "TREATMENT", 231, 242], ["tofacitinib enhances macrophage", "TREATMENT", 247, 278], ["our kinase activity", "TEST", 305, 324], ["a modestly sized Tec kinase inhibitor library", "TREATMENT", 381, 426], ["conducting concentration dependent ADCP assays", "PROBLEM", 428, 474], ["JAK2", "OBSERVATION", 39, 43], ["increased", "OBSERVATION_MODIFIER", 160, 169], ["macrophage", "OBSERVATION", 170, 180], ["phagocytic capacity", "OBSERVATION", 190, 209]]], ["As expected, inhibition of EGFR (erlotinib; Figure 4A ), SYK (entospletinib; Figure 4B ), and BMX (CHMFL-BMX-078; Supp.", [["erlotinib", "CHEMICAL", 33, 42], ["SYK", "CHEMICAL", 57, 60], ["BMX", "CHEMICAL", 94, 97], ["CHMFL-BMX-078", "CHEMICAL", 99, 112], ["erlotinib", "CHEMICAL", 33, 42], ["SYK", "CHEMICAL", 57, 60], ["entospletinib", "CHEMICAL", 62, 75], ["BMX", "CHEMICAL", 94, 97], ["CHMFL-BMX-078", "CHEMICAL", 99, 112], ["Supp.", "CHEMICAL", 114, 119], ["EGFR", "GENE_OR_GENE_PRODUCT", 27, 31], ["erlotinib", "SIMPLE_CHEMICAL", 33, 42], ["SYK", "SIMPLE_CHEMICAL", 57, 60], ["entospletinib", "SIMPLE_CHEMICAL", 62, 75], ["BMX", "SIMPLE_CHEMICAL", 94, 97], ["EGFR", "PROTEIN", 27, 31], ["EGFR", "TEST", 27, 31], ["erlotinib", "TEST", 33, 42], ["CHMFL", "TEST", 99, 104]]], ["Figure S4A ), lead to no significant increases in phagocytosis.", [["significant increases in phagocytosis", "PROBLEM", 25, 62], ["no", "UNCERTAINTY", 22, 24], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["increases", "OBSERVATION_MODIFIER", 37, 46], ["phagocytosis", "OBSERVATION", 50, 62]]], ["Importantly, inhibition of JAK1/2 via ruxolitinib ( Figure 4C ), JAK2/3 via tofacitinib ( Figure 4D ) and pan-JAK inhibition via SP600125 (Supp.", [["ruxolitinib", "CHEMICAL", 38, 49], ["tofacitinib", "CHEMICAL", 76, 87], ["SP600125", "CHEMICAL", 129, 137], ["ruxolitinib", "CHEMICAL", 38, 49], ["tofacitinib", "CHEMICAL", 76, 87], ["SP600125", "CHEMICAL", 129, 137], ["JAK1/2", "GENE_OR_GENE_PRODUCT", 27, 33], ["ruxolitinib", "SIMPLE_CHEMICAL", 38, 49], ["JAK2/3", "GENE_OR_GENE_PRODUCT", 65, 71], ["tofacitinib", "SIMPLE_CHEMICAL", 76, 87], ["pan-JAK", "GENE_OR_GENE_PRODUCT", 106, 113], ["SP600125", "SIMPLE_CHEMICAL", 129, 137], ["Supp", "SIMPLE_CHEMICAL", 139, 143], ["JAK1/2", "PROTEIN", 27, 33], ["JAK2/3", "PROTEIN", 65, 71], ["pan-JAK", "PROTEIN", 106, 113], ["inhibition of JAK1", "TREATMENT", 13, 31], ["ruxolitinib ( Figure 4C", "TREATMENT", 38, 61], ["JAK2", "TEST", 65, 69], ["tofacitinib ( Figure 4D )", "TREATMENT", 76, 101], ["pan-JAK inhibition", "TREATMENT", 106, 124]]], ["Figure S4B ) all induced significant increases in macrophage mediated ADCP in a concentration dependent manner.", [["macrophage", "ANATOMY", 50, 60], ["ADCP", "CHEMICAL", 70, 74], ["macrophage", "CELL", 50, 60], ["ADCP", "SIMPLE_CHEMICAL", 70, 74], ["macrophage mediated ADCP", "PROTEIN", 50, 74], ["macrophage mediated ADCP", "TREATMENT", 50, 74], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["increases", "OBSERVATION_MODIFIER", 37, 46], ["macrophage", "OBSERVATION", 50, 60], ["concentration dependent", "OBSERVATION_MODIFIER", 80, 103]]], ["Notably, all inhibitors did not display direct cytotoxicity or apoptosis induction to lymphoma target cells in the concentrations used (Supp.", [["lymphoma", "ANATOMY", 86, 94], ["cells", "ANATOMY", 102, 107], ["lymphoma", "DISEASE", 86, 94], ["lymphoma target cells", "CELL", 86, 107], ["lymphoma target cells", "CELL_TYPE", 86, 107], ["direct cytotoxicity", "PROBLEM", 40, 59], ["apoptosis induction", "TREATMENT", 63, 82], ["lymphoma target cells", "PROBLEM", 86, 107]]], ["Figure S4C -H).JAK2 inhibition with ruxolitinib and tofacitinib enhances macrophage mediated ADCPTo specifically address the functional implications of JAK2 signaling disruption on lymphoma cell susceptibility to ADCP we generated JAK2 deficient lymphoma target cells (Supp.", [["macrophage", "ANATOMY", 73, 83], ["lymphoma cell", "ANATOMY", 181, 194], ["lymphoma target cells", "ANATOMY", 246, 267], ["ruxolitinib", "CHEMICAL", 36, 47], ["tofacitinib", "CHEMICAL", 52, 63], ["lymphoma", "DISEASE", 181, 189], ["lymphoma", "DISEASE", 246, 254], ["ruxolitinib", "CHEMICAL", 36, 47], ["tofacitinib", "CHEMICAL", 52, 63], ["S4C -H", "GENE_OR_GENE_PRODUCT", 7, 13], ["JAK2", "GENE_OR_GENE_PRODUCT", 15, 19], ["ruxolitinib", "SIMPLE_CHEMICAL", 36, 47], ["tofacitinib", "SIMPLE_CHEMICAL", 52, 63], ["macrophage", "CELL", 73, 83], ["ADCPTo", "SIMPLE_CHEMICAL", 93, 99], ["JAK2", "GENE_OR_GENE_PRODUCT", 152, 156], ["lymphoma cell", "CELL", 181, 194], ["ADCP", "SIMPLE_CHEMICAL", 213, 217], ["JAK2", "GENE_OR_GENE_PRODUCT", 231, 235], ["cells", "CELL", 262, 267], ["Supp", "GENE_OR_GENE_PRODUCT", 269, 273], ["JAK2", "PROTEIN", 15, 19], ["JAK2", "PROTEIN", 152, 156], ["JAK2", "PROTEIN", 231, 235], ["lymphoma target cells", "CELL_TYPE", 246, 267], ["Supp", "PROTEIN", 269, 273], ["JAK2 inhibition", "PROBLEM", 15, 30], ["ruxolitinib", "TREATMENT", 36, 47], ["tofacitinib enhances macrophage mediated ADCPTo", "TREATMENT", 52, 99], ["JAK2 signaling disruption", "PROBLEM", 152, 177], ["lymphoma cell susceptibility", "PROBLEM", 181, 209], ["JAK2 deficient lymphoma target cells", "PROBLEM", 231, 267], ["JAK2 signaling disruption", "OBSERVATION", 152, 177], ["lymphoma cell", "OBSERVATION", 181, 194], ["JAK2 deficient lymphoma", "OBSERVATION", 231, 254]]], ["In our ADCP assay JAK2 -/cells showed significantly increased phagocytosis under monoclonal antibody treatment in comparison to JAK2 wildtype cells, which could not be improved by co-treatment with either ibrutinib or tofacitinib ( Figure 4E ).", [["JAK2 -/cells", "ANATOMY", 18, 30], ["JAK2 wildtype cells", "ANATOMY", 128, 147], ["ibrutinib", "CHEMICAL", 205, 214], ["tofacitinib", "CHEMICAL", 218, 229], ["ibrutinib", "CHEMICAL", 205, 214], ["tofacitinib", "CHEMICAL", 218, 229], ["JAK2", "GENE_OR_GENE_PRODUCT", 18, 22], ["JAK2", "GENE_OR_GENE_PRODUCT", 128, 132], ["cells", "CELL", 142, 147], ["ibrutinib", "SIMPLE_CHEMICAL", 205, 214], ["tofacitinib", "SIMPLE_CHEMICAL", 218, 229], ["ADCP assay JAK2 -/cells", "CELL_LINE", 7, 30], ["monoclonal antibody", "PROTEIN", 81, 100], ["JAK2 wildtype cells", "CELL_LINE", 128, 147], ["our ADCP assay JAK2 -/cells", "TEST", 3, 30], ["significantly increased phagocytosis", "PROBLEM", 38, 74], ["monoclonal antibody treatment", "TREATMENT", 81, 110], ["JAK2 wildtype cells", "PROBLEM", 128, 147], ["ibrutinib", "TREATMENT", 205, 214], ["tofacitinib", "TREATMENT", 218, 229], ["significantly", "OBSERVATION_MODIFIER", 38, 51], ["increased", "OBSERVATION_MODIFIER", 52, 61], ["phagocytosis", "OBSERVATION_MODIFIER", 62, 74], ["monoclonal antibody treatment", "OBSERVATION", 81, 110]]], ["In this light, previous reports examining ibrutinib in combination with rituximab that did not reveal synergy were mostly focused on NK-cell ADCC or relied on monocyte derived macrophages (20) (21) (22) (23) 35) .", [["NK-cell", "ANATOMY", 133, 140], ["monocyte", "ANATOMY", 159, 167], ["ibrutinib", "CHEMICAL", 42, 51], ["rituximab", "CHEMICAL", 72, 81], ["ibrutinib", "CHEMICAL", 42, 51], ["ibrutinib", "SIMPLE_CHEMICAL", 42, 51], ["rituximab", "SIMPLE_CHEMICAL", 72, 81], ["NK-cell ADCC", "CELL", 133, 145], ["monocyte", "CELL", 159, 167], ["macrophages", "CELL", 176, 187], ["20) (21) (22) (23) 35", "SIMPLE_CHEMICAL", 189, 210], ["ibrutinib", "TREATMENT", 42, 51], ["rituximab", "TREATMENT", 72, 81], ["synergy", "PROBLEM", 102, 109], ["NK", "TEST", 133, 135], ["monocyte derived macrophages", "TEST", 159, 187]]], ["Exploring effector cell mechanisms is technically challenging since co-culture systems demand high levels of standardization.", [["effector cell", "ANATOMY", 10, 23], ["effector cell", "CELL", 10, 23], ["effector cell mechanisms", "TREATMENT", 10, 34], ["co-culture systems", "TEST", 68, 86], ["effector cell mechanisms", "OBSERVATION", 10, 34]]], ["However, regarding NK-cell dependent ADCC only modest effects of ibrutinib have been observed (20) or even debated to be inhibitory (21) .JAK2 inhibition with ruxolitinib and tofacitinib enhances macrophage mediated ADCPHere we employed two independent macrophage effector cell in vitro models including primary peritoneal macrophages.", [["NK-cell", "ANATOMY", 19, 26], ["macrophage", "ANATOMY", 196, 206], ["macrophage effector cell", "ANATOMY", 253, 277], ["peritoneal macrophages", "ANATOMY", 312, 334], ["ibrutinib", "CHEMICAL", 65, 74], ["ruxolitinib", "CHEMICAL", 159, 170], ["tofacitinib", "CHEMICAL", 175, 186], ["ibrutinib", "CHEMICAL", 65, 74], ["ruxolitinib", "CHEMICAL", 159, 170], ["tofacitinib", "CHEMICAL", 175, 186], ["NK-cell", "CELL", 19, 26], ["ADCC", "CELL", 37, 41], ["ibrutinib", "SIMPLE_CHEMICAL", 65, 74], [".JAK2", "GENE_OR_GENE_PRODUCT", 137, 142], ["ruxolitinib", "SIMPLE_CHEMICAL", 159, 170], ["tofacitinib", "SIMPLE_CHEMICAL", 175, 186], ["macrophage", "CELL", 196, 206], ["ADCPHere", "SIMPLE_CHEMICAL", 216, 224], ["macrophage", "CELL", 253, 263], ["cell", "CELL", 273, 277], ["peritoneal macrophages", "CELL", 312, 334], ["primary peritoneal macrophages", "CELL_TYPE", 304, 334], ["NK", "TEST", 19, 21], ["cell dependent ADCC", "PROBLEM", 22, 41], ["ibrutinib", "TREATMENT", 65, 74], ["ruxolitinib", "TREATMENT", 159, 170], ["tofacitinib enhances macrophage mediated ADCPHere", "TREATMENT", 175, 224], ["primary peritoneal macrophages", "PROBLEM", 304, 334], ["cell dependent", "OBSERVATION_MODIFIER", 22, 36], ["modest", "OBSERVATION_MODIFIER", 47, 53], ["ibrutinib", "OBSERVATION", 65, 74], ["macrophage effector cell", "OBSERVATION", 253, 277], ["peritoneal", "ANATOMY", 312, 322], ["macrophages", "OBSERVATION", 323, 334]]], ["Moreover, our in vitro ADCP findings were underlined by significantly improved survival in vivo by combination treatment of a humanized mouse model of \"Double-Hit\" lymphoma (19) .", [["Double-Hit\" lymphoma", "ANATOMY", 152, 172], ["lymphoma", "DISEASE", 164, 172], ["mouse", "ORGANISM", 136, 141], ["Double-Hit\" lymphoma", "CANCER", 152, 172], ["mouse", "SPECIES", 136, 141], ["mouse", "SPECIES", 136, 141], ["a humanized mouse model", "TREATMENT", 124, 147], ["Hit\" lymphoma", "PROBLEM", 159, 172]]], ["As the used NSG mice 15 are immunodeficient and do not display mature T-cells, B-cells or NK cells, the main effector cells are macrophages which mediate the antitumor effect of alemtuzumab and ibrutinib (36) .JAK2 inhibition with ruxolitinib and tofacitinib enhances macrophage mediated ADCPOff-target effects of ibrutinib have been identified recently by independent methodology (34) , likewise using Kinobeads the inhibition of TEC kinase family members and particularly BLK by ibrutinib could be shown (37).", [["T-cells", "ANATOMY", 70, 77], ["B-cells", "ANATOMY", 79, 86], ["NK cells", "ANATOMY", 90, 98], ["effector cells", "ANATOMY", 109, 123], ["macrophages", "ANATOMY", 128, 139], ["antitumor", "ANATOMY", 158, 167], ["macrophage", "ANATOMY", 268, 278], ["alemtuzumab", "CHEMICAL", 178, 189], ["ibrutinib", "CHEMICAL", 194, 203], ["ruxolitinib", "CHEMICAL", 231, 242], ["tofacitinib", "CHEMICAL", 247, 258], ["ibrutinib", "CHEMICAL", 314, 323], ["Kinobeads", "CHEMICAL", 403, 412], ["ibrutinib", "CHEMICAL", 481, 490], ["ibrutinib", "CHEMICAL", 194, 203], ["ruxolitinib", "CHEMICAL", 231, 242], ["tofacitinib", "CHEMICAL", 247, 258], ["ibrutinib", "CHEMICAL", 314, 323], ["ibrutinib", "CHEMICAL", 481, 490], ["NSG mice", "ORGANISM", 12, 20], ["T-cells", "CELL", 70, 77], ["B-cells", "CELL", 79, 86], ["NK cells", "CELL", 90, 98], ["cells", "CELL", 118, 123], ["macrophages", "CELL", 128, 139], ["antitumor", "CANCER", 158, 167], ["alemtuzumab", "SIMPLE_CHEMICAL", 178, 189], ["ibrutinib", "SIMPLE_CHEMICAL", 194, 203], [".JAK2", "GENE_OR_GENE_PRODUCT", 209, 214], ["ruxolitinib", "SIMPLE_CHEMICAL", 231, 242], ["tofacitinib", "SIMPLE_CHEMICAL", 247, 258], ["macrophage", "CELL", 268, 278], ["ibrutinib", "SIMPLE_CHEMICAL", 314, 323], ["Kinobeads", "SIMPLE_CHEMICAL", 403, 412], ["TEC kinase", "GENE_OR_GENE_PRODUCT", 431, 441], ["BLK", "GENE_OR_GENE_PRODUCT", 474, 477], ["ibrutinib", "SIMPLE_CHEMICAL", 481, 490], ["mature T-cells", "CELL_TYPE", 63, 77], ["B-cells", "CELL_TYPE", 79, 86], ["NK cells", "CELL_TYPE", 90, 98], ["effector cells", "CELL_TYPE", 109, 123], ["macrophages", "CELL_TYPE", 128, 139], ["TEC kinase family members", "PROTEIN", 431, 456], ["BLK", "PROTEIN", 474, 477], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 16, 20], ["immunodeficient", "PROBLEM", 28, 43], ["NK cells", "PROBLEM", 90, 98], ["macrophages", "PROBLEM", 128, 139], ["alemtuzumab and ibrutinib", "TREATMENT", 178, 203], ["ruxolitinib", "TREATMENT", 231, 242], ["tofacitinib enhances macrophage mediated ADCPOff", "TREATMENT", 247, 295], ["ibrutinib", "TREATMENT", 314, 323], ["NK cells", "OBSERVATION", 90, 98], ["main", "OBSERVATION_MODIFIER", 104, 108], ["effector cells", "OBSERVATION", 109, 123]]], ["However, it remains to be clarified which potential additional kinases beyond BTK are relevant for mediating anti-leukemic effects.JAK2 inhibition with ruxolitinib and tofacitinib enhances macrophage mediated ADCPAs for the interpretation of clinical trial data it remains to be clarified if ibrutinib combinations with anti-CD20 antibodies rituximab or obinutuzumab are superior to monotherapy in B-cell lymphoma (38) .", [["anti-leukemic", "ANATOMY", 109, 122], ["macrophage", "ANATOMY", 189, 199], ["B-cell lymphoma", "ANATOMY", 398, 413], ["ruxolitinib", "CHEMICAL", 152, 163], ["tofacitinib", "CHEMICAL", 168, 179], ["ibrutinib", "CHEMICAL", 292, 301], ["rituximab", "CHEMICAL", 341, 350], ["obinutuzumab", "CHEMICAL", 354, 366], ["B-cell lymphoma", "DISEASE", 398, 413], ["ruxolitinib", "CHEMICAL", 152, 163], ["tofacitinib", "CHEMICAL", 168, 179], ["ibrutinib", "CHEMICAL", 292, 301], ["obinutuzumab", "CHEMICAL", 354, 366], ["BTK", "GENE_OR_GENE_PRODUCT", 78, 81], ["anti-leukemic", "CANCER", 109, 122], ["JAK2", "GENE_OR_GENE_PRODUCT", 131, 135], ["ruxolitinib", "SIMPLE_CHEMICAL", 152, 163], ["tofacitinib", "SIMPLE_CHEMICAL", 168, 179], ["macrophage", "CELL", 189, 199], ["ADCPAs", "SIMPLE_CHEMICAL", 209, 215], ["ibrutinib", "SIMPLE_CHEMICAL", 292, 301], ["anti-CD20", "GENE_OR_GENE_PRODUCT", 320, 329], ["rituximab", "SIMPLE_CHEMICAL", 341, 350], ["obinutuzumab", "SIMPLE_CHEMICAL", 354, 366], ["B-cell lymphoma", "CANCER", 398, 413], ["kinases", "PROTEIN", 63, 70], ["BTK", "PROTEIN", 78, 81], ["JAK2", "PROTEIN", 131, 135], ["anti-CD20 antibodies", "PROTEIN", 320, 340], ["mediating anti-leukemic effects", "PROBLEM", 99, 130], ["JAK2 inhibition", "PROBLEM", 131, 146], ["ruxolitinib", "TREATMENT", 152, 163], ["tofacitinib enhances macrophage", "TREATMENT", 168, 199], ["clinical trial data", "TEST", 242, 261], ["ibrutinib combinations", "TREATMENT", 292, 314], ["anti-CD20 antibodies rituximab", "TREATMENT", 320, 350], ["obinutuzumab", "TREATMENT", 354, 366], ["monotherapy", "TREATMENT", 383, 394], ["B-cell lymphoma", "PROBLEM", 398, 413], ["anti-leukemic effects", "OBSERVATION", 109, 130], ["B-cell lymphoma", "OBSERVATION", 398, 413]]], ["Nevertheless ibrutinib/ rituximab combination therapy has superior outcome to FC-R as the previous first-line standard therapy of CLL (12) .JAK2 inhibition with ruxolitinib and tofacitinib enhances macrophage mediated ADCPUsing second generation BTKis we did not observe a synergistic effect, although the combination of acalabrutinib and obinutuzumab was shown to improve progressionfree survival for patients with treatment-naive symptomatic CLL (39) .", [["CLL", "ANATOMY", 130, 133], ["macrophage", "ANATOMY", 198, 208], ["CLL", "ANATOMY", 444, 447], ["ibrutinib", "CHEMICAL", 13, 22], ["rituximab", "CHEMICAL", 24, 33], ["FC-R", "CHEMICAL", 78, 82], ["CLL", "DISEASE", 130, 133], ["ruxolitinib", "CHEMICAL", 161, 172], ["tofacitinib", "CHEMICAL", 177, 188], ["acalabrutinib", "CHEMICAL", 321, 334], ["obinutuzumab", "CHEMICAL", 339, 351], ["CLL", "DISEASE", 444, 447], ["ibrutinib", "CHEMICAL", 13, 22], ["ruxolitinib", "CHEMICAL", 161, 172], ["tofacitinib", "CHEMICAL", 177, 188], ["acalabrutinib", "CHEMICAL", 321, 334], ["obinutuzumab", "CHEMICAL", 339, 351], ["ibrutinib", "SIMPLE_CHEMICAL", 13, 22], ["rituximab", "SIMPLE_CHEMICAL", 24, 33], ["FC-R", "GENE_OR_GENE_PRODUCT", 78, 82], [".JAK2", "GENE_OR_GENE_PRODUCT", 139, 144], ["ruxolitinib", "SIMPLE_CHEMICAL", 161, 172], ["tofacitinib", "SIMPLE_CHEMICAL", 177, 188], ["macrophage", "CELL", 198, 208], ["acalabrutinib", "SIMPLE_CHEMICAL", 321, 334], ["obinutuzumab", "SIMPLE_CHEMICAL", 339, 351], ["patients", "ORGANISM", 402, 410], ["CLL", "CANCER", 444, 447], ["patients", "SPECIES", 402, 410], ["ibrutinib/ rituximab combination therapy", "TREATMENT", 13, 53], ["the previous first-line standard therapy", "TREATMENT", 86, 126], ["CLL", "PROBLEM", 130, 133], ["ruxolitinib", "TREATMENT", 161, 172], ["tofacitinib enhances macrophage", "TREATMENT", 177, 208], ["a synergistic effect", "PROBLEM", 271, 291], ["acalabrutinib", "TREATMENT", 321, 334], ["obinutuzumab", "TREATMENT", 339, 351], ["treatment", "TREATMENT", 416, 425], ["naive symptomatic CLL", "PROBLEM", 426, 447], ["CLL", "OBSERVATION", 130, 133]]], ["Here, the high single-agent activity of each drug or ADCP-independent mechanisms of synergy are probably reflecting the superior clinical response in CLL.", [["CLL", "ANATOMY", 150, 153], ["CLL", "DISEASE", 150, 153], ["ADCP", "SIMPLE_CHEMICAL", 53, 57], ["CLL", "CANCER", 150, 153], ["ADCP", "PROBLEM", 53, 57], ["synergy", "PROBLEM", 84, 91], ["CLL", "PROBLEM", 150, 153], ["probably reflecting", "UNCERTAINTY", 96, 115], ["CLL", "OBSERVATION", 150, 153]]], ["In our work, we primarily address aggressive Double-Hit lymphoma cells with a potentially less prominent dependence of the malignant B-cell towards sustained BTK signaling.JAK2 inhibition with ruxolitinib and tofacitinib enhances macrophage mediated ADCPAs ibrutinib has shown clinical activity in MCL and non-GCB DLBCL, ibrutinib in combination with R-CHOP regimens for treatment of first-line DLBCL revealed a clinical benefit only in younger patients (40) .", [["Double-Hit lymphoma cells", "ANATOMY", 45, 70], ["malignant B-cell", "ANATOMY", 123, 139], ["macrophage", "ANATOMY", 230, 240], ["MCL", "ANATOMY", 298, 301], ["non-GCB DLBCL", "ANATOMY", 306, 319], ["first-line DLBCL", "ANATOMY", 384, 400], ["lymphoma", "DISEASE", 56, 64], ["ruxolitinib", "CHEMICAL", 193, 204], ["tofacitinib", "CHEMICAL", 209, 220], ["ibrutinib", "CHEMICAL", 257, 266], ["DLBCL", "DISEASE", 314, 319], ["ibrutinib", "CHEMICAL", 321, 330], ["R-CHOP", "CHEMICAL", 351, 357], ["DLBCL", "DISEASE", 395, 400], ["ruxolitinib", "CHEMICAL", 193, 204], ["tofacitinib", "CHEMICAL", 209, 220], ["ibrutinib", "CHEMICAL", 257, 266], ["ibrutinib", "CHEMICAL", 321, 330], ["Double-Hit lymphoma cells", "CELL", 45, 70], ["malignant B-cell", "CELL", 123, 139], ["BTK", "GENE_OR_GENE_PRODUCT", 158, 161], ["JAK2", "GENE_OR_GENE_PRODUCT", 172, 176], ["ruxolitinib", "SIMPLE_CHEMICAL", 193, 204], ["tofacitinib", "SIMPLE_CHEMICAL", 209, 220], ["macrophage", "CELL", 230, 240], ["ADCPAs", "SIMPLE_CHEMICAL", 250, 256], ["ibrutinib", "SIMPLE_CHEMICAL", 257, 266], ["MCL", "CANCER", 298, 301], ["non-GCB DLBCL", "CANCER", 306, 319], ["ibrutinib", "SIMPLE_CHEMICAL", 321, 330], ["R-CHOP", "SIMPLE_CHEMICAL", 351, 357], ["first-line DLBCL", "CANCER", 384, 400], ["patients", "ORGANISM", 445, 453], ["aggressive Double-Hit lymphoma cells", "CELL_LINE", 34, 70], ["malignant B-cell", "CELL_TYPE", 123, 139], ["BTK", "PROTEIN", 158, 161], ["JAK2", "PROTEIN", 172, 176], ["CHOP", "PROTEIN", 353, 357], ["patients", "SPECIES", 445, 453], ["aggressive Double-Hit lymphoma cells", "TREATMENT", 34, 70], ["the malignant B-cell", "PROBLEM", 119, 139], ["sustained BTK signaling", "PROBLEM", 148, 171], ["JAK2 inhibition", "PROBLEM", 172, 187], ["ruxolitinib", "TREATMENT", 193, 204], ["tofacitinib enhances macrophage", "TREATMENT", 209, 240], ["ADCPAs ibrutinib", "TREATMENT", 250, 266], ["clinical activity in MCL", "PROBLEM", 277, 301], ["DLBCL", "PROBLEM", 314, 319], ["ibrutinib", "TREATMENT", 321, 330], ["R-CHOP regimens", "TREATMENT", 351, 366], ["treatment", "TREATMENT", 371, 380], ["first-line DLBCL", "TREATMENT", 384, 400], ["Hit lymphoma cells", "OBSERVATION", 52, 70], ["less prominent", "OBSERVATION_MODIFIER", 90, 104], ["dependence", "OBSERVATION_MODIFIER", 105, 115], ["malignant", "OBSERVATION", 123, 132], ["cell", "OBSERVATION", 135, 139], ["BTK signaling", "OBSERVATION", 158, 171], ["non-GCB DLBCL", "OBSERVATION", 306, 319], ["line DLBCL", "OBSERVATION", 390, 400]]], ["In Waldenstr\u00f6m\u00b4s Macroglobulinemia (WM) the combination of rituximab and ibrutinib displayed superior progression-free survival and has been FDA-approved (15) .", [["Waldenstr\u00f6m\u00b4s Macroglobulinemia", "DISEASE", 3, 34], ["rituximab", "CHEMICAL", 59, 68], ["ibrutinib", "CHEMICAL", 73, 82], ["ibrutinib", "CHEMICAL", 73, 82], ["Waldenstr\u00f6m\u00b4s Macroglobulinemia", "CANCER", 3, 34], ["rituximab", "SIMPLE_CHEMICAL", 59, 68], ["ibrutinib", "SIMPLE_CHEMICAL", 73, 82], ["Waldenstr\u00f6m\u00b4s Macroglobulinemia", "PROBLEM", 3, 34], ["rituximab", "TREATMENT", 59, 68], ["ibrutinib", "TREATMENT", 73, 82], ["superior progression", "PROBLEM", 93, 113], ["Macroglobulinemia", "OBSERVATION", 17, 34], ["superior", "OBSERVATION_MODIFIER", 93, 101], ["progression", "OBSERVATION_MODIFIER", 102, 113], ["free survival", "OBSERVATION", 114, 127]]], ["In WM a constitutively activated JAK-STAT signaling pathway has been linked to secretion and disease progression (41) .JAK2 inhibition with ruxolitinib and tofacitinib enhances macrophage mediated ADCPAs another B-cell receptor signaling related pathway the impact of JAK2-signaling has also been proposed to be relevant in CLL.", [["macrophage", "ANATOMY", 177, 187], ["B-cell", "ANATOMY", 212, 218], ["CLL", "ANATOMY", 324, 327], ["ruxolitinib", "CHEMICAL", 140, 151], ["tofacitinib", "CHEMICAL", 156, 167], ["CLL", "DISEASE", 324, 327], ["ruxolitinib", "CHEMICAL", 140, 151], ["tofacitinib", "CHEMICAL", 156, 167], ["JAK", "GENE_OR_GENE_PRODUCT", 33, 36], ["STAT", "GENE_OR_GENE_PRODUCT", 37, 41], [".JAK2", "GENE_OR_GENE_PRODUCT", 118, 123], ["ruxolitinib", "SIMPLE_CHEMICAL", 140, 151], ["tofacitinib", "SIMPLE_CHEMICAL", 156, 167], ["macrophage", "CELL", 177, 187], ["ADCPAs", "GENE_OR_GENE_PRODUCT", 197, 203], ["B-cell receptor", "GENE_OR_GENE_PRODUCT", 212, 227], ["JAK2", "GENE_OR_GENE_PRODUCT", 268, 272], ["CLL", "CANCER", 324, 327], ["JAK", "PROTEIN", 33, 36], ["STAT", "PROTEIN", 37, 41], ["ADCPAs", "PROTEIN", 197, 203], ["JAK2", "PROTEIN", 268, 272], ["disease progression", "PROBLEM", 93, 112], ["ruxolitinib", "TREATMENT", 140, 151], ["tofacitinib enhances macrophage", "PROBLEM", 156, 187], ["CLL", "PROBLEM", 324, 327], ["JAK2", "OBSERVATION", 268, 272], ["CLL", "OBSERVATION", 324, 327]]], ["Here it could be shown that anti-IgM 16 mediated BCR stimulation induces STAT3 activation signaling in CLL (42) .", [["CLL", "ANATOMY", 103, 106], ["CLL", "DISEASE", 103, 106], ["anti-IgM 16", "GENE_OR_GENE_PRODUCT", 28, 39], ["BCR", "GENE_OR_GENE_PRODUCT", 49, 52], ["STAT3", "GENE_OR_GENE_PRODUCT", 73, 78], ["CLL", "CANCER", 103, 106], ["anti-IgM 16", "PROTEIN", 28, 39], ["BCR", "PROTEIN", 49, 52], ["STAT3", "PROTEIN", 73, 78], ["anti-IgM 16 mediated BCR stimulation", "TREATMENT", 28, 64], ["STAT3 activation signaling in CLL", "PROBLEM", 73, 106]]], ["In a clinical trial inhibition of JAK2 by ruxolitinib decreases symptoms (43)", [["ruxolitinib", "CHEMICAL", 42, 53], ["ruxolitinib", "CHEMICAL", 42, 53], ["JAK2", "GENE_OR_GENE_PRODUCT", 34, 38], ["ruxolitinib", "SIMPLE_CHEMICAL", 42, 53], ["JAK2", "PROTEIN", 34, 38], ["JAK2", "PROBLEM", 34, 38], ["ruxolitinib decreases symptoms", "PROBLEM", 42, 72]]]], "85d296d5ca6cf4c4201f717183f6d4f6045fdae9": [["UrsachenAm Notfallort muss die kardiopulmonale Wiederbelebung (CPR = cardiopulmonary resuscitation) innerhalb von Sekunden eingeleitet werden, bevor die zugrunde liegenden Ursachen vollst\u00e4ndig erkannt worden sind.", [["cardiopulmonary resuscitation", "TREATMENT", 69, 98]]], ["Allerdings sollte hier -parallel zu den Reanimationsma\u00dfnahmen -umgehend nach den Ursachen gesucht werden, damit eine spezifische Therapie eingeleitet werden kann.Ateminsuffizienz, AtemstillstandEine ungen\u00fcgende Atmung (Ateminsuffizienz) f\u00fchrt zu Hypoxie und Hyperkapnie.", [["Ateminsuffizienz", "CHEMICAL", 162, 178], ["AtemstillstandEine ungen\u00fcgende Atmung (Ateminsuffizienz) f\u00fchrt zu Hypoxie und Hyperkapnie", "SPECIES", 180, 269], ["Ateminsuffizienz", "TREATMENT", 162, 178], ["AtemstillstandEine ungen\u00fcgende Atmung (Ateminsuffizienz)", "TREATMENT", 180, 236]]], ["Bei entsprechender Auspr\u00e4gung k\u00f6nnen hierdurch bereits nach kurzer Zeit irreversible Hirnsch\u00e4den hervorgerufen werden.", [["Bei entsprechender Auspr\u00e4gung k\u00f6nnen hierdurch bereits nach kurzer Zeit irreversible Hirnsch\u00e4den hervorgerufen werden", "SPECIES", 0, 117], ["Bei entsprechender", "TREATMENT", 0, 18], ["irreversible", "OBSERVATION_MODIFIER", 72, 84], ["Hirnsch\u00e4den hervorgerufen", "OBSERVATION", 85, 110]]], ["Ein Atemstillstand f\u00fchrt innerhalb weniger Minuten immer zum Herz-Kreislauf-Stillstand.Ateminsuffizienz, AtemstillstandEin pl\u00f6tzlicher Herzstillstand ist ein Zustand, bei dem keine mechanisch wirksame Herzaktion mehr vorhanden ist und somit auch kein Blut mehr ausgeworfen wird.", [["AtemstillstandEin pl\u00f6tzlicher Herzstillstand ist ein Zustand, bei dem keine mechanisch wirksame Herzaktion mehr vorhanden ist und somit auch kein Blut mehr ausgeworfen wird", "SPECIES", 105, 277], ["Ateminsuffizienz", "TREATMENT", 87, 103], ["AtemstillstandEin pl\u00f6tzlicher", "TREATMENT", 105, 134]]], ["Zwei Arten von Herz-Kreislauf-Stillstand werden unterschieden: Der prim\u00e4re, kardial bedingte und der sekund\u00e4re, nicht kardial bedingte Herzstillstand, meist ausgel\u00f6st durch eine St\u00f6rungen der Atemfunktion.", [["Zwei Arten von Herz-Kreislauf-Stillstand werden unterschieden", "SPECIES", 0, 61]]], ["Am h\u00e4ufigsten besteht bei der Erstableitung eines EKGs ein Kammerflimmern, das mit elektrischer Defibrillation beseitigt werden muss.", [["EKGs", "TEST", 50, 54], ["das mit elektrischer Defibrillation", "TREATMENT", 75, 110]]], ["Ein Kreislaufstillstand -gleich welcher Ursache -muss sofort behandelt werden, um schwerste hypoxische Hirnsch\u00e4den zu verhindern.Formen des HerzstillstandsFolgende Formen des Herzstillstands werden unterschieden:C = Circulation (Kreislauf), KompressionBei Verdacht auf einen Herzstillstand wird innerhalb von h\u00f6chstens 10 s der Karotispuls \u00fcberpr\u00fcft.", [["KompressionBei Verdacht", "TREATMENT", 241, 264], ["Circulation", "ANATOMY", 216, 227]]], ["Ist kein Puls tastbar, wird sofort mit der externen (\"extrathorakalen\") Thoraxkompression (30 initiale KompressiArterielle Punktion oder Kan\u00fclierungDie Kan\u00fclierung einer Arterie wird meist erst nach Wiederherstellung einer ausreichenden spontanen Herzaktion durchgef\u00fchrt.", [["wird sofort mit der externen (\"extrathorakalen\") Thoraxkompression (30 initiale KompressiArterielle Punktion oder Kan\u00fclierungDie Kan\u00fclierung einer Arterie wird meist erst nach Wiederherstellung einer ausreichenden spontanen Herzaktion durchgef\u00fchrt", "SPECIES", 23, 270], ["Ist kein Puls tastbar", "TREATMENT", 0, 21], ["Thoraxkompression", "TEST", 72, 89]]], ["Zur Bestimmung der Blutgase und der S\u00e4ure-Basen-Parameter unter der Reanimation reicht die Punktion der Arterie durch einen 3.", [["Zur Bestimmung der Blutgase und der S\u00e4ure-Basen-Parameter unter der Reanimation reicht die Punktion der Arterie durch einen", "SPECIES", 0, 123]]], ["Helfer aus.Medikamente (D = Drogen)Zur medikament\u00f6sen Behandlung des Herzkreislaufstillstandes werden unterschiedliche Pharmaka eingesetzt.", [["Medikamente (D = Drogen)Zur medikament\u00f6sen Behandlung des", "TREATMENT", 11, 68]]], ["Die wichtigsten sind 5 Adrenalin, 5 Amiodaron, 5 Lidocain, 5 Magnesium, 5 Natriumbikarbonat.", [["Adrenalin", "CHEMICAL", 23, 32], ["Amiodaron", "CHEMICAL", 36, 45], ["Lidocain", "CHEMICAL", 49, 57], ["Magnesium", "CHEMICAL", 61, 70], ["Adrenalin", "CHEMICAL", 23, 32], ["Amiodaron", "CHEMICAL", 36, 45], ["Lidocain", "CHEMICAL", 49, 57], ["Magnesium", "CHEMICAL", 61, 70], ["Magnesium", "SIMPLE_CHEMICAL", 61, 70], ["Natriumbikarbonat", "SIMPLE_CHEMICAL", 74, 91], ["Adrenalin", "TREATMENT", 23, 32], ["Amiodaron", "TREATMENT", 36, 45], ["5 Lidocain", "TREATMENT", 47, 57], ["Magnesium", "TREATMENT", 61, 70], ["5 Natriumbikarbonat", "TREATMENT", 72, 91]]]], "PMC7127244": [["IntroductionRecently, there has been a widespread interest in using evolutionary game theory to study economic system, which remedies some drawbacks of orthodox game theory.", [["widespread", "OBSERVATION_MODIFIER", 39, 49]]], ["There may be multiple solutions of general non-cooperative games.", [["may be", "UNCERTAINTY", 6, 12], ["multiple", "OBSERVATION_MODIFIER", 13, 21]]], ["The selected equilibrium is path-dependent, and the observed equilibrium depends on the initial condition.IntroductionOur study is closely related to the disruption management and evolutionary management of a supply chain, and duopoly competition.", [["IntroductionOur study", "TEST", 106, 127], ["the disruption management", "TREATMENT", 150, 175], ["evolutionary management", "TREATMENT", 180, 203], ["a supply chain", "TREATMENT", 207, 221], ["equilibrium", "OBSERVATION_MODIFIER", 13, 24], ["dependent", "OBSERVATION_MODIFIER", 33, 42]]], ["For the competition of the quantity-setting homogeneous oligopoly, see, for example, Tanaka (1999) studied the stochastically stable output of the asymmetric homogeneous oligopoly with low cost and high cost firms and showed that a stochastically stable output equals the competitive (Walrasian) output.", [["low cost", "PROBLEM", 185, 193], ["a stochastically stable output", "PROBLEM", 230, 260], ["the competitive (Walrasian) output", "PROBLEM", 268, 302], ["stable", "OBSERVATION_MODIFIER", 126, 132], ["output", "OBSERVATION_MODIFIER", 133, 139], ["asymmetric", "OBSERVATION_MODIFIER", 147, 157], ["homogeneous", "OBSERVATION_MODIFIER", 158, 169], ["low cost", "OBSERVATION_MODIFIER", 185, 193], ["stable", "OBSERVATION_MODIFIER", 247, 253], ["output", "OBSERVATION_MODIFIER", 254, 260]]], ["They showed that for the nonlinear model multiple (locally) stable equilibriums may be observed.", [["the nonlinear model multiple (locally) stable equilibriums", "PROBLEM", 21, 79], ["multiple", "OBSERVATION_MODIFIER", 41, 49]]], ["Xiao and Yu (2005) studied the evolutionarily stable marketing strategies of retailers in two vertically integrated channels with differentiated goods.", [["stable", "OBSERVATION_MODIFIER", 46, 52], ["differentiated goods", "OBSERVATION", 130, 150]]], ["In this paper, we consider the two vertically integrated channels with homogeneous goods.", [["homogeneous", "OBSERVATION_MODIFIER", 71, 82], ["goods", "OBSERVATION", 83, 88]]], ["Jin (2001) showed that a simple and optimal price strategy could lead the market to a unique steady state.", [["a simple and optimal price strategy", "TREATMENT", 23, 58]]], ["Xiao and Yu (2005) showed that profit maximization is a unique ESS in the price-setting duopoly situation with differentiated goods and linear inverse demand functions.", [["linear", "OBSERVATION_MODIFIER", 136, 142], ["inverse demand", "OBSERVATION", 143, 157]]]]}